Page last updated: 2024-10-28

ibuprofen and Fever

ibuprofen has been researched along with Fever in 285 studies

Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine

Fever: An abnormal elevation of body temperature, usually as a result of a pathologic process.

Research Excerpts

ExcerptRelevanceReference
"This study aims to evaluate the efficacy and safety of multiple or single-dosage intravenous ibuprofen (IVIB) in managing postoperative pain and fever in adults who are unable to take oral medications."9.41Intravenous ibuprofen in postoperative pain and fever management in adults: A systematic review and meta-analysis of randomized controlled trials. ( Chen, L; He, L; Tian, S; Wang, E; Zhai, S; Zhou, P, 2023)
"Our primary objective was to assess the effectiveness of paracetamol (acetaminophen) or NSAIDs, alone or combined, compared with placebo or no treatment in relieving pain in children with AOM."9.41Paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs, alone or combined, for pain relief in acute otitis media in children. ( Damoiseaux, RA; de Sévaux, JLH; Hay, AD; Little, P; Lutje, V; Schilder, AG; van de Pol, AC; Venekamp, RP, 2023)
"In adult age group patients admitted to the emergency department with high fever, the IV forms of 1000 mg paracetamol and 400 mg ibuprofen effectively and equally reduce complaints, such as fever and accompanying pain."9.41Comparison of intravenous ibuprofen and paracetamol in the treatment of fever: A randomized double-blind study. ( Can, Ö; Kıyan, GS; Yalçınlı, S, 2021)
"the overall result showed that ibuprofen had a better fever reducing effect compared to paracetamol."9.34Ibuprofen versus paracetamol for treating fever in preschool children in Nigeria: a randomized clinical trial of effectiveness and safety. ( Akande, PA; Alaje, EO; Meremikwu, MM; Odey, FA; Udoh, EE, 2020)
"No evidence can be found in the medical literature about the efficacy of alternating acetaminophen and ibuprofen treatment in children with refractory fever."9.24Alternating Acetaminophen and Ibuprofen versus Monotherapies in Improvements of Distress and Reducing Refractory Fever in Febrile Children: A Randomized Controlled Trial. ( Guo, Q; Luo, Q; Luo, S; Ran, M; Shu, M; Wan, C; Xie, X; Zhang, C; Zhu, Y, 2017)
"001); in a greater reduction in change from baseline temperature compared to treatment with acetaminophen, and it reduced fever throughout a 24 h dosing period."9.24A multicenter, randomized, open-label, active-comparator trial to determine the efficacy, safety, and pharmacokinetics of intravenous ibuprofen for treatment of fever in hospitalized pediatric patients. ( Chumpitazi, CE; Hahn, BJ; Kaelin, BA; Khalil, SN; Macias, CG; Rock, AD, 2017)
"To evaluate ibuprofen and acetaminophen in the treatment of infectious fever in children."9.22Comparison between Ibuprofen and Acetaminophen in the Treatment of Infectious Fever in Children: A Meta-Analysis. ( Guo, H; Liu, Y; Yin, F, 2022)
"Studies have suggested an association between frequent acetaminophen use and asthma-related complications among children, leading some physicians to recommend that acetaminophen be avoided in children with asthma; however, appropriately designed trials evaluating this association in children are lacking."9.22Acetaminophen versus Ibuprofen in Young Children with Mild Persistent Asthma. ( Bacharier, LB; Baxi, SN; Beigelman, A; Benson, M; Blake, K; Boehmer, SJ; Cabana, MD; Chmiel, JF; Covar, R; Daines, CL; Daines, MO; Fitzpatrick, AM; Gaffin, JM; Gentile, DA; Gower, WA; Holguin, F; Israel, E; Jackson, DJ; Kumar, HV; Lang, JE; Lazarus, SC; Lemanske, RF; Lima, JJ; Ly, N; Marbin, J; Martinez, FD; Mauger, DT; Morgan, WJ; Moy, JN; Myers, RE; Olin, JT; Paul, IM; Peters, SP; Phipatanakul, W; Pongracic, JA; Raissy, HH; Robison, RG; Ross, K; Sheehan, WJ; Sorkness, CA; Szefler, SJ; Thyne, SM; Wechsler, ME, 2016)
"To establish the relative clinical effectiveness and cost-effectiveness of paracetamol plus ibuprofen compared with paracetamol and ibuprofen separately for time without fever, and the relief of fever-associated discomfort in young children who can be managed at home."9.14Paracetamol and ibuprofen for the treatment of fever in children: the PITCH randomised controlled trial. ( Costelloe, C; Fletcher, M; Hay, AD; Hollinghurst, S; Montgomery, AA; Peters, TJ; Redmond, NM, 2009)
"Hospitalized patients are often unable to ingest or tolerate oral antipyretics and recently an aqueous formulation of intravenous (IV) ibuprofen was approved by the US-FDA for the reduction of fever in adults."9.14A multi-center, randomized, double-blind, parallel, placebo-controlled trial to evaluate the efficacy, safety, and pharmacokinetics of intravenous ibuprofen for the treatment of fever in critically ill and non-critically ill adults. ( Arons, MM; Guntupalli, KK; Morris, PE; Promes, JT; Wright, PE, 2010)
"Because some febrile patients are unable to swallow or retain oral antipyretic drugs, we carried out a double-blind, placebo-controlled trial in which intravenous ibuprofen (IV-ibuprofen) was given to adults hospitalized with fever associated with acute uncomplicated falciparum malaria treated with oral artesunate plus mefloquine."9.14Intravenous ibuprofen (IV-ibuprofen) controls fever effectively in adults with acute uncomplicated Plasmodium falciparum malaria but prolongs parasitemia. ( Duangdee, C; Krudsood, S; Looareesuwan, S; Pothipak, N; Tangpukdee, N; Warrell, DA; Wilairatana, P, 2010)
"To investigate whether paracetamol (acetaminophen) plus ibuprofen are superior to either drug alone for increasing time without fever and the relief of fever associated discomfort in febrile children managed at home."9.13Paracetamol plus ibuprofen for the treatment of fever in children (PITCH): randomised controlled trial. ( Costelloe, C; Fletcher, M; Hay, AD; Hollinghurst, S; Montgomery, AA; Peters, TJ; Redmond, NM, 2008)
"According to this study: In children younger than age two, treatment with ibuprofen was associated with reduced fever and less pain within the first 24 hours compared with acetaminophen."9.12Ibuprofen Better than Acetaminophen for Reducing Fever, Pain in Young Children. ( Rosenberg, K, 2021)
"5 mg/kg per dose) and ibuprofen (5 mg/kg per dose) every 4 hours for 3 days, regardless of the initial loading medication, is more effective than monotherapy in lowering fever in infants and children."9.12Antipyretic treatment in young children with fever: acetaminophen, ibuprofen, or both alternating in a randomized, double-blind study. ( Cohen, HA; Sarrell, EM; Wielunsky, E, 2006)
"A randomised open label study of the combined use of paracetamol and ibuprofen to rapidly reduce fever is reported."9.12Randomised controlled trial of combined paracetamol and ibuprofen for fever. ( Benger, JR; Chinnick, PJ; Coppens, K; Davies, P; Erlewyn-Lajeunesse, MD; Higginson, IM; Hunt, LP, 2006)
"Children from the age of 3 months to 12 years with a fever of non-serious origin were randomized to receive either ibuprofen or paracetamol."9.12Ibuprofen versus paracetamol in pediatric fever: objective and subjective findings from a randomized, blinded study. ( Autret-Leca, E; Gibb, IA; Goulder, MA, 2007)
" In a previous randomized trial we observed that treatment with high-dose acetaminophen (paracetamol) led to a reduction of body temperature in patients with acute ischemic stroke, even when they had no fever."9.10Effect of paracetamol (acetaminophen) and ibuprofen on body temperature in acute ischemic stroke PISA, a phase II double-blind, randomized, placebo-controlled trial [ISRCTN98608690]. ( Dippel, DW; Kappelle, LJ; Koudstaal, PJ; Meijer, RJ; van Breda, EJ; van der Worp, HB; van Gemert, HM, 2003)
"Rather than supporting the hypothesis that ibuprofen increases asthma morbidity among children who are not known to be sensitive to aspirin or other nonsteroidal antiinflammatory drugs, these data suggest that compared with acetaminophen, ibuprofen may reduce such risks."9.10Asthma morbidity after the short-term use of ibuprofen in children. ( Lesko, SM; Louik, C; Mitchell, AA; Vezina, RM, 2002)
" Most importantly, we wanted to report the effect of ibuprofen treatment on vital signs, organ failure, and mortality in hypothermic sepsis."9.09Effects of ibuprofen on the physiology and survival of hypothermic sepsis. Ibuprofen in Sepsis Study Group. ( Arons, MM; Bernard, GR; Christman, BW; Dupont, WD; Fulkerson, W; Russell, JA; Schein, R; Steinberg, KP; Summer, WR; Swindell, BB; Wheeler, AP; Wright, P, 1999)
" The role of COX-2 in the genesis of fever in monkeys and humans was examined with use of the specific COX-2 inhibitor rofecoxib."9.09Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans. ( Adcock, S; Bachmann, KA; Chan, CC; Cohen, RA; Davidson, MH; Dobratz, D; Gertz, BJ; Grasing, K; Hedges, J; Jones, TM; McBride, KJ; Moritz, C; Mukhopadhyay, S; Schwartz, JI, 1999)
"The aim of this study was to assess and compare the efficacy and tolerability of paracetamol, ibuprofen and nimesulide in children with upper respiratory tract infections (URTIs)."9.09Assessment of the efficacy and safety of paracetamol, ibuprofen and nimesulide in children with upper respiratory tract infections. ( Cin, S; Köksal, Y; Ulukol, B, 1999)
"5 mg/kg per dose), aspirin (10 mg/kg/dose) and paracetamol (10 mg/kg per dose) on children with fever aged 6-24 months in an open, randomised study with three parallel groups."9.08Evaluation of ibuprofen versus aspirin and paracetamol on efficacy and comfort in children with fever. ( Autret, E; Courcier, S; Goehrs, JM; Henry-Launois, B; Laborde, C; Languillat, G; Launois, R; Reboul-Marty, J, 1997)
"In the ibuprofen group, but not the placebo group, there were significant declines in urinary levels of prostacyclin and thromboxane, temperature, heart rate, oxygen consumption, and lactic acidosis."9.08The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. ( Bernard, GR; Christman, BW; Dupont, WD; Fulkerson, WJ; Higgins, SB; Russell, JA; Schein, R; Steinberg, KP; Summer, WR; Swindell, BB; Wheeler, AP; Wright, PE, 1997)
"kg-1 acetaminophen syrup (n = 77) in 154 children (6 months to 5 years) with fever (> or = 38 degrees C) associated with infectious diseases and treated with antibiotic therapy."9.07Comparative efficacy and tolerance of ibuprofen syrup and acetaminophen syrup in children with pyrexia associated with infectious diseases and treated with antibiotics. ( Autret, E; Breart, G; Courcier, S; Goehrs, JM; Jonville, AP; Lassale, C, 1994)
"Amphotericin B produces chills and fever in a significant proportion of patients who receive this drug."9.06Induction of prostaglandin synthesis as the mechanism responsible for the chills and fever produced by infusing amphotericin B. ( Gigliotti, F; Lott, L; Shenep, JL; Thornton, D, 1987)
"Acetaminophen (paracetamol) and ibuprofen are the most widely prescribed and available over-the-counter medications for management of fever and pain in children."9.05Comparison of Acetaminophen (Paracetamol) With Ibuprofen for Treatment of Fever or Pain in Children Younger Than 2 Years: A Systematic Review and Meta-analysis. ( Braithwaite, I; Dalziel, SR; McKinlay, CJD; Tan, E, 2020)
"The antipyretic activity of ibuprofen and aspirin was compared in sixteen children with pyrexia due to upper respiratory tract infection and in twelve with fever due to other causes."9.05Comparative evaluation of antipyretic activity of ibuprofen and aspirin in children with pyrexia of varied aetiology. ( Joshi, MK; Joshi, VR; Kandoth, PW; Satoskar, RS, 1984)
"In a study of the antipyretic effect of two dosage levels of ibuprofen syrup in children with fever due to a variety of causes, forty-four out of the fifty children admitted completed the 24-hour trial period, twenty-three receiving 20 mg ibuprofen/kg body-weight, twenty-one receiving 30 mg/kg ibuprofen."9.05A comparative study of two dosage levels of ibuprofen syrup in children with pyrexia. ( Kotob, A, 1985)
"Our primary objective was to assess the effectiveness of paracetamol (acetaminophen) or NSAIDs, alone or combined, compared with placebo or no treatment in relieving pain in children with AOM."8.93Paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs, alone or combined, for pain relief in acute otitis media in children. ( Damoiseaux, RA; Hay, AD; Little, P; Schilder, AG; Sjoukes, A; van de Pol, AC; Venekamp, RP, 2016)
"Combination treatment with ibuprofen and acetaminophen is beneficial over either agent alone for sustained fever reduction in children older than 6 months."8.89Does combination treatment with ibuprofen and acetaminophen improve fever control? ( Malya, RR, 2013)
" For many years, ketorolac was the only intravenous NSAID available in the US, but in 2009 intravenous ibuprofen was approved by the US FDA for the treatment of pain and fever in adults."8.88Pharmacokinetics of intravenous ibuprofen: implications of time of infusion in the treatment of pain and fever. ( Smith, HS; Voss, B, 2012)
"To analyse major sources of evidence-based information on the efficacy and gastrointestinal tolerability of aspirin, used short-term, in over-the-counter (OTC) doses, to relieve acute pain and cold symptoms, including associated feverishness."8.88Efficacy and gastrointestinal risk of aspirin used for the treatment of pain and cold. ( McCarthy, DM, 2012)
"Acetylsalicylic acid (ASA [aspirin]) is a commonly used over-the-counter drug for the treatment of pain, fever, or colds, but data on the safety of this use are very limited."8.87Short-term acetylsalicylic acid (aspirin) use for pain, fever, or colds - gastrointestinal adverse effects: a meta-analysis of randomized clinical trials. ( Baron, JA; Brueckner, A; Lanas, A; McCarthy, D; Senn, S; Voelker, M, 2011)
"Paracetamol and ibuprofen are safe and effective medications for reducing a fever in children and young people and they are often administered together with a view to reducing a temperature quickly."8.86Fever management: evaluating the use of ibuprofen and paracetamol. ( Crook, J, 2010)
"Although many studies have investigated the safety and tolerability of ibuprofen or acetaminophen (paracetamol) use in children, few have specifically examined the association of ibuprofen or acetaminophen and the occurrence of asthma in pediatric populations."8.84A review of ibuprofen and acetaminophen use in febrile children and the occurrence of asthma-related symptoms. ( Dale, S; Kanabar, D; Rawat, M, 2007)
"To summarize studies testing the efficacy and safety of single-dose acetaminophen and ibuprofen for treating children's pain or fever."8.82Efficacy and safety of acetaminophen vs ibuprofen for treating children's pain or fever: a meta-analysis. ( Champion, GD; Goodenough, B; Perrott, DA; Piira, T, 2004)
"to compare the antipyretic effects of ibuprofen in febrile children with serious bacterial infections (SBI), and children with a presumed viral infection."8.02Fever response to ibuprofen in viral and bacterial childhood infections. ( Barkan Perl, S; Breitbart, R; Gamsu, S; Gelernter, R; Goldman, M; Kozer, E; Lazarovitch, Z; Ophir, N; Oren-Amit, A; Youngster, I, 2021)
"A healthy 15-year-old boy presented to the emergency department with headache, nausea, dizziness, fever, conjunctival hyperemia and blurred vision 30 minutes after ibuprofen-intake."7.91IBUPROFEN-INDUCED ASEPTIC MENINGITIS: A CASE REPORT. ( Agro, JPSEABD; Lemos, AP; Maia, PADSV; Pereira, EPMN; Pires, SAP, 2019)
" Drug lymphocyte stimulation tests implicated ibuprofen, a main component of the OTC drugs, which has the potential to induce this pathology, and a diagnosis of drug-induced liver injury with multiform exudative erythema was made."7.81Drug-induced liver injury with serious multiform exudative erythema following the use of an over-the-counter medication containing ibuprofen. ( Abe, M; Aritomo, K; Hiasa, Y; Hirooka, M; Ikeda, Y; Koizumi, Y; Kumagi, T; Matsuura, B; Ochi, H; Tada, F; Tokumoto, Y; Watanabe, T, 2015)
"Children who have unresolved pain despite the use of either ibuprofen or acetaminophen should have their medication regimen reviewed to ensure they are receiving the medication at an adequate dose and interval."7.78Alternating acetaminophen and ibuprofen for pain in children. ( Goldman, RD; Smith, C, 2012)
"Seventy-five (3 x 25) patients with acute ischaemic stroke confined to the anterior circulation will be randomised to treatment with either: 400 mg ibuprofen, 1000 mg acetaminophen, or with placebo 6 times daily during 5 days."7.71PISA. The effect of paracetamol (acetaminophen) and ibuprofen on body temperature in acute stroke: protocol for a phase II double-blind randomised placebo-controlled trial [ISRCTN98608690]. ( Dippel, DW; Kappelle, J; Koudstaal, PJ; Meijer, R; van Breda, EJ; van der Worp, B; van Gemert, M, 2002)
"Fever is a common symptom in children and one of the major concerns of parents of younger and preschool-age children."6.75Ketoprofen versus paracetamol (acetaminophen) or ibuprofen in the management of fever: results of two randomized, double-blind, double-dummy, parallel-group, repeated-dose, multicentre, phase III studies in children. ( Kokki, H; Kokki, M, 2010)
"At physician-directed dosing (acetaminophen 15 mg/kg vs ibuprofen 10 mg/kg), no significant differences in antipyretic effects from 0‒6 h and between 0‒6, ‒12, ‒24, or ‒48 h, with single or multiple-doses, respectively, were observed."6.72Acetaminophen and ibuprofen in the treatment of pediatric fever: a narrative review. ( Paul, IM; Walson, PD, 2021)
"Ibuprofen liquid was given as a single dose, 5 mg/kg to 18 patients (group I) and 10 mg/kg to 18 patients (group II); placebo was administered to 20 patients (group III)."6.67Efficacy of ibuprofen in pediatric patients with fever. ( Durrell, DE; Gupta, N; Miller, MA; Nahata, MC; Powell, DA, 1992)
"Ibuprofen, paracetamol and placebo have similar tolerability and safety profiles in terms of gastrointestinal symptoms, asthma and renal adverse effects."6.45Systematic review and meta-analysis of the clinical safety and tolerability of ibuprofen compared with paracetamol in paediatric pain and fever. ( Kleijnen, J; Soares-Weiser, K; Southey, ER, 2009)
"Fever has been reported as a common symptom occurring in COVID-19 illness."5.56The use of ibuprofen to treat fever in COVID-19: A possible indirect association with worse outcome? ( Haryadi, TH; Jamerson, BD, 2020)
" The Paracetamol and Ibuprofen in the Primary Prevention of Asthma in Tamariki (PIPPA Tamariki) trial is an open-label, randomised controlled trial aiming to determine whether paracetamol treatment, compared with ibuprofen treatment, as required for fever and pain in the first year of life, increases the risk of asthma at age six years."5.51Panic or peace - prioritising infant welfare when medicating feverish infants: a grounded theory study of adherence in a paediatric clinical trial. ( Braithwaite, I; Dalziel, SR; Fernando, K; Haskell, L; Hoare, K; McKinlay, CJ; Riley, J; Tan, E, 2022)
" Eligible children will receive treatment allocation randomization either to standard of care for fever management or to prophylactic, scheduled treatment every 6 hours for 72 hours with dual antipyretic therapies using acetaminophen and ibuprofen."5.51Aggressive antipyretics in central nervous system malaria: Study protocol of a randomized-controlled trial assessing antipyretic efficacy and parasite clearance effects (Malaria FEVER study). ( Birbeck, GL; Chilombe, MB; Mathews, M; McDermott, MP; Mwenechanya, M; Seydel, KB, 2022)
"This study aims to evaluate the efficacy and safety of multiple or single-dosage intravenous ibuprofen (IVIB) in managing postoperative pain and fever in adults who are unable to take oral medications."5.41Intravenous ibuprofen in postoperative pain and fever management in adults: A systematic review and meta-analysis of randomized controlled trials. ( Chen, L; He, L; Tian, S; Wang, E; Zhai, S; Zhou, P, 2023)
"Our primary objective was to assess the effectiveness of paracetamol (acetaminophen) or NSAIDs, alone or combined, compared with placebo or no treatment in relieving pain in children with AOM."5.41Paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs, alone or combined, for pain relief in acute otitis media in children. ( Damoiseaux, RA; de Sévaux, JLH; Hay, AD; Little, P; Lutje, V; Schilder, AG; van de Pol, AC; Venekamp, RP, 2023)
"In adult age group patients admitted to the emergency department with high fever, the IV forms of 1000 mg paracetamol and 400 mg ibuprofen effectively and equally reduce complaints, such as fever and accompanying pain."5.41Comparison of intravenous ibuprofen and paracetamol in the treatment of fever: A randomized double-blind study. ( Can, Ö; Kıyan, GS; Yalçınlı, S, 2021)
"Ibuprofen is a well established analgesic, anti-inflammatory and antipyretic NSAID."5.38Intravenous ibuprofen: in adults for pain and fever. ( Scott, LJ, 2012)
"the overall result showed that ibuprofen had a better fever reducing effect compared to paracetamol."5.34Ibuprofen versus paracetamol for treating fever in preschool children in Nigeria: a randomized clinical trial of effectiveness and safety. ( Akande, PA; Alaje, EO; Meremikwu, MM; Odey, FA; Udoh, EE, 2020)
"He had an upper respiratory tract infection in which a vaso-occlusive crisis was precipitated."5.34Tramadol infusion for the pain management in sickle cell disease: a case report. ( Aydinok, Y; Balkan, C; Erhan, E; Inal, MT; Yegul, I, 2007)
"We here present the case of a patient with severe neutropenia, haemolytic anaemia and thrombocytopenia associated with long-term use of ibuprofen."5.28A case of severe pancytopenia caused by ibuprofen. ( Lindblad, R; Rödjer, S, 1991)
"We aimed to compare the antipyretic efficacy, safety, and tolerability between oral dexibuprofen and intravenous propacetamol in children with upper respiratory tract infection (URTI) presenting with fever."5.27The antipyretic efficacy and safety of propacetamol compared with dexibuprofen in febrile children: a multicenter, randomized, double-blind, comparative, phase 3 clinical trial. ( Choi, SJ; Choi, UY; Chun, YH; Jeong, DC; Kim, HM; Lee, J; Lee, JH; Moon, S; Rhim, JW, 2018)
"A 21-year-old woman with systemic lupus erythematosus (SLE) had meningismus, conjunctivitis, lymphadenopathy, and elevation of liver function values following ibuprofen therapy."5.26Tolmetin-induced aseptic meningitis. ( Barth, WF; Ruppert, GB, 1981)
"No evidence can be found in the medical literature about the efficacy of alternating acetaminophen and ibuprofen treatment in children with refractory fever."5.24Alternating Acetaminophen and Ibuprofen versus Monotherapies in Improvements of Distress and Reducing Refractory Fever in Febrile Children: A Randomized Controlled Trial. ( Guo, Q; Luo, Q; Luo, S; Ran, M; Shu, M; Wan, C; Xie, X; Zhang, C; Zhu, Y, 2017)
"Two blinded single-dose studies randomized children 6 months to 11 years old with fever to receive ibuprofen (IBU) pediatric suspension 7."5.24Antipyretic Efficacy and Safety of Ibuprofen Versus Acetaminophen Suspension in Febrile Children: Results of 2 Randomized, Double-Blind, Single-Dose Studies. ( Jayawardena, S; Kellstein, D, 2017)
"001); in a greater reduction in change from baseline temperature compared to treatment with acetaminophen, and it reduced fever throughout a 24 h dosing period."5.24A multicenter, randomized, open-label, active-comparator trial to determine the efficacy, safety, and pharmacokinetics of intravenous ibuprofen for treatment of fever in hospitalized pediatric patients. ( Chumpitazi, CE; Hahn, BJ; Kaelin, BA; Khalil, SN; Macias, CG; Rock, AD, 2017)
"To evaluate ibuprofen and acetaminophen in the treatment of infectious fever in children."5.22Comparison between Ibuprofen and Acetaminophen in the Treatment of Infectious Fever in Children: A Meta-Analysis. ( Guo, H; Liu, Y; Yin, F, 2022)
"Studies have suggested an association between frequent acetaminophen use and asthma-related complications among children, leading some physicians to recommend that acetaminophen be avoided in children with asthma; however, appropriately designed trials evaluating this association in children are lacking."5.22Acetaminophen versus Ibuprofen in Young Children with Mild Persistent Asthma. ( Bacharier, LB; Baxi, SN; Beigelman, A; Benson, M; Blake, K; Boehmer, SJ; Cabana, MD; Chmiel, JF; Covar, R; Daines, CL; Daines, MO; Fitzpatrick, AM; Gaffin, JM; Gentile, DA; Gower, WA; Holguin, F; Israel, E; Jackson, DJ; Kumar, HV; Lang, JE; Lazarus, SC; Lemanske, RF; Lima, JJ; Ly, N; Marbin, J; Martinez, FD; Mauger, DT; Morgan, WJ; Moy, JN; Myers, RE; Olin, JT; Paul, IM; Peters, SP; Phipatanakul, W; Pongracic, JA; Raissy, HH; Robison, RG; Ross, K; Sheehan, WJ; Sorkness, CA; Szefler, SJ; Thyne, SM; Wechsler, ME, 2016)
"The main purpose of the study was to determine the safety profile and efficacy of intravenous ibuprofen administered over 5 to 10 minutes for the treatment of pain or fever in hospitalized patients."5.20The shortened infusion time of intravenous ibuprofen part 1: a multicenter, open-label, surveillance trial to evaluate safety and efficacy. ( Ayad, SS; Bergese, SD; Candiotti, K; Gan, TJ; Soghomonyan, S, 2015)
"To establish the relative clinical effectiveness and cost-effectiveness of paracetamol plus ibuprofen compared with paracetamol and ibuprofen separately for time without fever, and the relief of fever-associated discomfort in young children who can be managed at home."5.14Paracetamol and ibuprofen for the treatment of fever in children: the PITCH randomised controlled trial. ( Costelloe, C; Fletcher, M; Hay, AD; Hollinghurst, S; Montgomery, AA; Peters, TJ; Redmond, NM, 2009)
"Hospitalized patients are often unable to ingest or tolerate oral antipyretics and recently an aqueous formulation of intravenous (IV) ibuprofen was approved by the US-FDA for the reduction of fever in adults."5.14A multi-center, randomized, double-blind, parallel, placebo-controlled trial to evaluate the efficacy, safety, and pharmacokinetics of intravenous ibuprofen for the treatment of fever in critically ill and non-critically ill adults. ( Arons, MM; Guntupalli, KK; Morris, PE; Promes, JT; Wright, PE, 2010)
"Because some febrile patients are unable to swallow or retain oral antipyretic drugs, we carried out a double-blind, placebo-controlled trial in which intravenous ibuprofen (IV-ibuprofen) was given to adults hospitalized with fever associated with acute uncomplicated falciparum malaria treated with oral artesunate plus mefloquine."5.14Intravenous ibuprofen (IV-ibuprofen) controls fever effectively in adults with acute uncomplicated Plasmodium falciparum malaria but prolongs parasitemia. ( Duangdee, C; Krudsood, S; Looareesuwan, S; Pothipak, N; Tangpukdee, N; Warrell, DA; Wilairatana, P, 2010)
"Many pediatricians recommend, and many parents administer, alternating or combined doses of ibuprofen and acetaminophen for fever."5.14Efficacy of standard doses of Ibuprofen alone, alternating, and combined with acetaminophen for the treatment of febrile children. ( Berlin, CM; Engle, L; Paul, IM; Sturgis, SA; Watts, H; Yang, C, 2010)
"Methods A prospective, randomized double-blind placebo control study comparing the efficacy of acetaminophen to acetaminophen alternated with ibuprofen in 38 healthy outpatient children 6 months to 6 years presenting to the outpatient clinic with fever >38 degrees C was conducted."5.13Alternating antipyretics: antipyretic efficacy of acetaminophen versus acetaminophen alternated with ibuprofen in children. ( Fairchok, MP; Harper, DP; Kramer, LC; Richards, PA; Thompson, AM, 2008)
"To investigate whether paracetamol (acetaminophen) plus ibuprofen are superior to either drug alone for increasing time without fever and the relief of fever associated discomfort in febrile children managed at home."5.13Paracetamol plus ibuprofen for the treatment of fever in children (PITCH): randomised controlled trial. ( Costelloe, C; Fletcher, M; Hay, AD; Hollinghurst, S; Montgomery, AA; Peters, TJ; Redmond, NM, 2008)
"In the clinical trial of the antipyretic action of dexibuprofen in patients with fever caused by URTI, there was no statistically significant difference in maximal decrease of temperature and mean time to become apyrexial among the 5 mg kg(-1) dexibuprofen, 7 mg kg(-1) dexibuprofen and 10 mg kg(-1) ibuprofen groups (P > 0."5.13The effects and safety of dexibuprofen compared with ibuprofen in febrile children caused by upper respiratory tract infection. ( Jeong, DC; Kang, JH; Kim, JT; Koh, YY; Lee, HS; Lee, JS; Lee, KY; Oh, JW; Yoon, JS, 2008)
"According to this study: In children younger than age two, treatment with ibuprofen was associated with reduced fever and less pain within the first 24 hours compared with acetaminophen."5.12Ibuprofen Better than Acetaminophen for Reducing Fever, Pain in Young Children. ( Rosenberg, K, 2021)
"5 mg/kg per dose) and ibuprofen (5 mg/kg per dose) every 4 hours for 3 days, regardless of the initial loading medication, is more effective than monotherapy in lowering fever in infants and children."5.12Antipyretic treatment in young children with fever: acetaminophen, ibuprofen, or both alternating in a randomized, double-blind study. ( Cohen, HA; Sarrell, EM; Wielunsky, E, 2006)
"A randomised open label study of the combined use of paracetamol and ibuprofen to rapidly reduce fever is reported."5.12Randomised controlled trial of combined paracetamol and ibuprofen for fever. ( Benger, JR; Chinnick, PJ; Coppens, K; Davies, P; Erlewyn-Lajeunesse, MD; Higginson, IM; Hunt, LP, 2006)
"Children from the age of 3 months to 12 years with a fever of non-serious origin were randomized to receive either ibuprofen or paracetamol."5.12Ibuprofen versus paracetamol in pediatric fever: objective and subjective findings from a randomized, blinded study. ( Autret-Leca, E; Gibb, IA; Goulder, MA, 2007)
"To determine whether evidence in the medical literature supports ibuprofen or acetaminophen for reducing fever in children."5.11The antipyretic effect of ibuprofen and acetaminophen in children. ( Wahba, H, 2004)
"One hundred and three cases of postopterative pain and 60 cases of fever, altogether 163 patients were randomly divided into 2 groups: S (+) -ismer of ibuprofen supporsitory treatment group (one supporsitory per day for 3 days) and ibuprofen supporsitory treatment group (one supporsitory per day for 3 days)."5.11[Randomized controlled study of S (+) -ismer of ibuprofen supporsitory]. ( Gao, JS; Huang, AL; Luo, H; Wu, CL; You, YH, 2004)
" In a previous randomized trial we observed that treatment with high-dose acetaminophen (paracetamol) led to a reduction of body temperature in patients with acute ischemic stroke, even when they had no fever."5.10Effect of paracetamol (acetaminophen) and ibuprofen on body temperature in acute ischemic stroke PISA, a phase II double-blind, randomized, placebo-controlled trial [ISRCTN98608690]. ( Dippel, DW; Kappelle, LJ; Koudstaal, PJ; Meijer, RJ; van Breda, EJ; van der Worp, HB; van Gemert, HM, 2003)
"Rather than supporting the hypothesis that ibuprofen increases asthma morbidity among children who are not known to be sensitive to aspirin or other nonsteroidal antiinflammatory drugs, these data suggest that compared with acetaminophen, ibuprofen may reduce such risks."5.10Asthma morbidity after the short-term use of ibuprofen in children. ( Lesko, SM; Louik, C; Mitchell, AA; Vezina, RM, 2002)
" Most importantly, we wanted to report the effect of ibuprofen treatment on vital signs, organ failure, and mortality in hypothermic sepsis."5.09Effects of ibuprofen on the physiology and survival of hypothermic sepsis. Ibuprofen in Sepsis Study Group. ( Arons, MM; Bernard, GR; Christman, BW; Dupont, WD; Fulkerson, W; Russell, JA; Schein, R; Steinberg, KP; Summer, WR; Swindell, BB; Wheeler, AP; Wright, P, 1999)
" The role of COX-2 in the genesis of fever in monkeys and humans was examined with use of the specific COX-2 inhibitor rofecoxib."5.09Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans. ( Adcock, S; Bachmann, KA; Chan, CC; Cohen, RA; Davidson, MH; Dobratz, D; Gertz, BJ; Grasing, K; Hedges, J; Jones, TM; McBride, KJ; Moritz, C; Mukhopadhyay, S; Schwartz, JI, 1999)
"To compare the incidence of serious adverse clinical events among children <2 years old given ibuprofen and acetaminophen to control fever."5.09The safety of acetaminophen and ibuprofen among children younger than two years old. ( Lesko, SM; Mitchell, AA, 1999)
"The aim of this study was to assess and compare the efficacy and tolerability of paracetamol, ibuprofen and nimesulide in children with upper respiratory tract infections (URTIs)."5.09Assessment of the efficacy and safety of paracetamol, ibuprofen and nimesulide in children with upper respiratory tract infections. ( Cin, S; Köksal, Y; Ulukol, B, 1999)
"Both ibuprofen formulations were effective in reducing fever and may be considered clinically bioequivalent."5.09[Evaluation of the antipyretic safety and accuracy of two pediatric ibuprofen formulations]. ( Antelo Cortizas , J; Armenteros González , S; Díez Domingo , J; Domínguez Granados , R; Molina Carballo , A; Moreno Carretero , E; Moreno Madrid , F; Moreno Martín , J; Planelles Cantarino , MV; Uberos Fernández , J, 2000)
"To evaluate the effects of endotoxemia on respiratory controller function, 12 subjects were randomized to receive endotoxin or saline; six also received ibuprofen, a cyclooxygenase inhibitor, and six received placebo."5.09Effect of endotoxin on ventilation and breath variability: role of cyclooxygenase pathway. ( Banks, SM; Godin, PJ; Jubran, A; Preas, HL; Reda, D; Suffredini, AF; Tobin, MJ; Vandivier, RW, 2001)
"This study compared the antipyretic effectiveness of acetaminophen, ibuprofen, and dipyrone in young children with fever."5.09Antipyretic effects of dipyrone versus ibuprofen versus acetaminophen in children: results of a multinational, randomized, modified double-blind study. ( Barragán, S; Campos, S; De León González, M; Escobar, AM; Ferrero, F; Kesselring, GL; Plager, M; Santolaya, ME; Sibbald, A; Wong, A, 2001)
"5 mg/kg per dose), aspirin (10 mg/kg/dose) and paracetamol (10 mg/kg per dose) on children with fever aged 6-24 months in an open, randomised study with three parallel groups."5.08Evaluation of ibuprofen versus aspirin and paracetamol on efficacy and comfort in children with fever. ( Autret, E; Courcier, S; Goehrs, JM; Henry-Launois, B; Laborde, C; Languillat, G; Launois, R; Reboul-Marty, J, 1997)
"In the ibuprofen group, but not the placebo group, there were significant declines in urinary levels of prostacyclin and thromboxane, temperature, heart rate, oxygen consumption, and lactic acidosis."5.08The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. ( Bernard, GR; Christman, BW; Dupont, WD; Fulkerson, WJ; Higgins, SB; Russell, JA; Schein, R; Steinberg, KP; Summer, WR; Swindell, BB; Wheeler, AP; Wright, PE, 1997)
" Children with a febrile illness were enrolled from outpatient pediatric and family medicine practices and randomly assigned to receive either acetaminophen suspension or one of two dosages of ibuprofen suspension (5 mg/kg or 10 mg/kg) for fever control."5.08Renal function after short-term ibuprofen use in infants and children. ( Lesko, SM; Mitchell, AA, 1997)
"kg-1 acetaminophen syrup (n = 77) in 154 children (6 months to 5 years) with fever (> or = 38 degrees C) associated with infectious diseases and treated with antibiotic therapy."5.07Comparative efficacy and tolerance of ibuprofen syrup and acetaminophen syrup in children with pyrexia associated with infectious diseases and treated with antibiotics. ( Autret, E; Breart, G; Courcier, S; Goehrs, JM; Jonville, AP; Lassale, C, 1994)
"5-, 5-, or 10-mg/kg ibuprofen therapy via a liquid or 15-mg/kg acetaminophen therapy via an elixir every 6 hours for 24 to 48 hours show equivalent fever reduction or suffer adverse effects of the drug administered."5.07Comparison of multidose ibuprofen and acetaminophen therapy in febrile children. ( Braden, NJ; Chomilo, F; Galletta, G; Sawyer, LA; Scheinbaum, ML; Walson, PD, 1992)
"A double-blind, parallel-group, triple-dummy-designed, single-oral-dose study compared the efficacy, tolerability, safety, and dose-response of 5 mg/kg (n = 32) and 10 mg/kg (n = 28) ibuprofen suspension, 10 mg/kg acetaminophen elixir (n = 33), and placebo liquids (n = 34) in 127 children (2 to 11 years of age) with fever (101 degrees to 104 degrees F)."5.06Ibuprofen, acetaminophen, and placebo treatment of febrile children. ( Alexander, L; Braden, NJ; Galletta, G; Walson, PD, 1989)
"Amphotericin B produces chills and fever in a significant proportion of patients who receive this drug."5.06Induction of prostaglandin synthesis as the mechanism responsible for the chills and fever produced by infusing amphotericin B. ( Gigliotti, F; Lott, L; Shenep, JL; Thornton, D, 1987)
"Acetaminophen (paracetamol) and ibuprofen are the most widely prescribed and available over-the-counter medications for management of fever and pain in children."5.05Comparison of Acetaminophen (Paracetamol) With Ibuprofen for Treatment of Fever or Pain in Children Younger Than 2 Years: A Systematic Review and Meta-analysis. ( Braithwaite, I; Dalziel, SR; McKinlay, CJD; Tan, E, 2020)
"The antipyretic activity of ibuprofen and aspirin was compared in sixteen children with pyrexia due to upper respiratory tract infection and in twelve with fever due to other causes."5.05Comparative evaluation of antipyretic activity of ibuprofen and aspirin in children with pyrexia of varied aetiology. ( Joshi, MK; Joshi, VR; Kandoth, PW; Satoskar, RS, 1984)
"In a study of the antipyretic effect of two dosage levels of ibuprofen syrup in children with fever due to a variety of causes, forty-four out of the fifty children admitted completed the 24-hour trial period, twenty-three receiving 20 mg ibuprofen/kg body-weight, twenty-one receiving 30 mg/kg ibuprofen."5.05A comparative study of two dosage levels of ibuprofen syrup in children with pyrexia. ( Kotob, A, 1985)
"- Paracetamol or ibuprofen should only be given when there is a combination of fever and pain."4.95[Revision of the Dutch College of General Practitioners practice guideline 'Children with fever']. ( Eizenga, WE; Opstelten, W, 2017)
" Paracetamol and ibuprofen are the most commonly used interventions to manage fever in children; however, there have been no comparative analyses."4.95Effectiveness of paracetamol versus ibuprofen administration in febrile children: A systematic literature review. ( Cooper, S; Innes, K; Morphet, J; Narayan, K, 2017)
"Ibuprofen is a non-steroidal anti-inflammatory drug frequently administered to children of various ages for relief of fever and pain and is approved as an over-the-counter medication in many countries worldwide."4.95Efficacy and Safety of Ibuprofen in Infants Aged Between 3 and 6 Months. ( Erb, TO; van den Anker, JN; Ziesenitz, VC; Zutter, A, 2017)
"Ibuprofen is the most widely used non-steroidal anti-inflammatory drug (NSAID) for the treatment of inflammation, mild-to-moderate pain and fever in children, and is the only NSAID approved for use in children aged ≥3 months."4.95Working Towards an Appropriate Use of Ibuprofen in Children: An Evidence-Based Appraisal. ( Boner, A; Chiarugi, A; de Martino, M; De' Angelis, GL; Montini, G, 2017)
" The aim of this review is to determine if there are any clinically relevant differences in safety between ibuprofen and paracetamol that may recommend one agent over the other in the management of fever and discomfort in children older than 3 months of age."4.95A clinical and safety review of paracetamol and ibuprofen in children. ( Kanabar, DJ, 2017)
"Our primary objective was to assess the effectiveness of paracetamol (acetaminophen) or NSAIDs, alone or combined, compared with placebo or no treatment in relieving pain in children with AOM."4.93Paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs, alone or combined, for pain relief in acute otitis media in children. ( Damoiseaux, RA; Hay, AD; Little, P; Schilder, AG; Sjoukes, A; van de Pol, AC; Venekamp, RP, 2016)
"Health professionals frequently recommend fever treatment regimens for children that either combine paracetamol and ibuprofen or alternate them."4.90Combined and alternating paracetamol and ibuprofen therapy for febrile children. ( Ganshorn, H; Hartling, L; Johnson, DW; Maconochie, IK; Stang, AS; Thomsen, AM; Wong, T, 2014)
"Combination treatment with ibuprofen and acetaminophen is beneficial over either agent alone for sustained fever reduction in children older than 6 months."4.89Does combination treatment with ibuprofen and acetaminophen improve fever control? ( Malya, RR, 2013)
"Health professionals frequently recommend fever treatment regimens for children that either combine paracetamol and ibuprofen or alternate them."4.89Combined and alternating paracetamol and ibuprofen therapy for febrile children. ( Ganshorn, H; Hartling, L; Johnson, DW; Maconochie, IK; Stang, AS; Thomsen, AM; Wong, T, 2013)
" In paediatric populations, ibuprofen and paracetamol (acetaminophen) are both commonly used over-the-counter medicines for the management of fever or mild-to-moderate pain associated with sore throat, otitis media, toothache, earache and headache."4.89Optimising the management of fever and pain in children. ( van den Anker, JN, 2013)
" For many years, ketorolac was the only intravenous NSAID available in the US, but in 2009 intravenous ibuprofen was approved by the US FDA for the treatment of pain and fever in adults."4.88Pharmacokinetics of intravenous ibuprofen: implications of time of infusion in the treatment of pain and fever. ( Smith, HS; Voss, B, 2012)
"To analyse major sources of evidence-based information on the efficacy and gastrointestinal tolerability of aspirin, used short-term, in over-the-counter (OTC) doses, to relieve acute pain and cold symptoms, including associated feverishness."4.88Efficacy and gastrointestinal risk of aspirin used for the treatment of pain and cold. ( McCarthy, DM, 2012)
"To evaluate the evidence surrounding the use of combinations of paracetamol and ibuprofen in the treatment of fever."4.87Systematic review of studies comparing combined treatment with paracetamol and ibuprofen, with either drug alone. ( Purssell, E, 2011)
"Acetylsalicylic acid (ASA [aspirin]) is a commonly used over-the-counter drug for the treatment of pain, fever, or colds, but data on the safety of this use are very limited."4.87Short-term acetylsalicylic acid (aspirin) use for pain, fever, or colds - gastrointestinal adverse effects: a meta-analysis of randomized clinical trials. ( Baron, JA; Brueckner, A; Lanas, A; McCarthy, D; Senn, S; Voelker, M, 2011)
"Ibuprofen is as or more efficacious than acetaminophen for the treatment of pain and fever in adult and pediatric populations and is equally safe."4.86Efficacy and safety of ibuprofen and acetaminophen in children and adults: a meta-analysis and qualitative review. ( Pierce, CA; Voss, B, 2010)
"Paracetamol and ibuprofen are safe and effective medications for reducing a fever in children and young people and they are often administered together with a view to reducing a temperature quickly."4.86Fever management: evaluating the use of ibuprofen and paracetamol. ( Crook, J, 2010)
"Although many studies have investigated the safety and tolerability of ibuprofen or acetaminophen (paracetamol) use in children, few have specifically examined the association of ibuprofen or acetaminophen and the occurrence of asthma in pediatric populations."4.84A review of ibuprofen and acetaminophen use in febrile children and the occurrence of asthma-related symptoms. ( Dale, S; Kanabar, D; Rawat, M, 2007)
"Ibuprofen is prescribed for children for the treatment of acute pain and fever, and for juvenile idiopathic arthritis."4.82A general overview of the use of ibuprofen in paediatrics. ( Autret-Leca, E, 2003)
"This paper describes two studies in children with fever in which the safety of ibuprofen was compared with that of paracetamol."4.82The safety of ibuprofen suspension in children. ( Lesko, SM, 2003)
"Ibuprofen was significantly more effective than acetaminophen in reducing fever after a single dose."4.82Antipyretic efficacy and safety of ibuprofen and acetaminophen in children. ( Goldman, RD; Ko, K; Linett, LJ; Scolnik, D, 2004)
"To summarize studies testing the efficacy and safety of single-dose acetaminophen and ibuprofen for treating children's pain or fever."4.82Efficacy and safety of acetaminophen vs ibuprofen for treating children's pain or fever: a meta-analysis. ( Champion, GD; Goodenough, B; Perrott, DA; Piira, T, 2004)
"Paracetamol 1,000 mg represents the first choice for the treatment of fever in the ED, followed by Paracetamol/Ibuprofen 500/150 mg."4.31Treatment of fever and associated symptoms in the emergency department: which drug to choose? ( Candelli, M; Carnicelli, A; Covino, M; Franceschi, F; Lorusso, C; Novelli, A; Ojetti, V; Saviano, A, 2023)
"to compare the antipyretic effects of ibuprofen in febrile children with serious bacterial infections (SBI), and children with a presumed viral infection."4.02Fever response to ibuprofen in viral and bacterial childhood infections. ( Barkan Perl, S; Breitbart, R; Gamsu, S; Gelernter, R; Goldman, M; Kozer, E; Lazarovitch, Z; Ophir, N; Oren-Amit, A; Youngster, I, 2021)
" One hundred and seventy-nine (44%) patients had fever, with 32% using paracetamol and 22% using ibuprofen, for symptom-relief."3.96Ibuprofen use and clinical outcomes in COVID-19 patients. ( Bar-Haim, A; Kozer, E; Rinott, E; Shapira, Y; Youngster, I, 2020)
"A healthy 15-year-old boy presented to the emergency department with headache, nausea, dizziness, fever, conjunctival hyperemia and blurred vision 30 minutes after ibuprofen-intake."3.91IBUPROFEN-INDUCED ASEPTIC MENINGITIS: A CASE REPORT. ( Agro, JPSEABD; Lemos, AP; Maia, PADSV; Pereira, EPMN; Pires, SAP, 2019)
" Drug lymphocyte stimulation tests implicated ibuprofen, a main component of the OTC drugs, which has the potential to induce this pathology, and a diagnosis of drug-induced liver injury with multiform exudative erythema was made."3.81Drug-induced liver injury with serious multiform exudative erythema following the use of an over-the-counter medication containing ibuprofen. ( Abe, M; Aritomo, K; Hiasa, Y; Hirooka, M; Ikeda, Y; Koizumi, Y; Kumagi, T; Matsuura, B; Ochi, H; Tada, F; Tokumoto, Y; Watanabe, T, 2015)
"The primary objective was to assess whether patients with a fever are treated with acetaminophen or ibuprofen more promptly than they are treated for pain."3.80Is fever treated more promptly than pain in the pediatric emergency department? ( Bair, J; Dvorkin, R; Glantz, S; Marguilies, J; Patel, H; Rosalia, A; Yens, DP, 2014)
"Treatment of pediatric fever is based on two main molecules, paracetamol and ibuprofen."3.80[How to treat pediatric fever in 2013 with little evidence-based?]. ( Gehri, M; Pauchard, JY, 2014)
"Health-care professionals frequently recommend fever treatment regimens for children who either combine paracetamol and ibuprofen or alternate them."3.80Cochrane in context: Combined and alternating paracetamol and ibuprofen therapy for febrile children. ( Ganshorn, H; Hartling, L; Johnson, DW; Maconochie, IK; Stang, AS; Thomsen, AM; Wong, T, 2014)
"Children who have unresolved pain despite the use of either ibuprofen or acetaminophen should have their medication regimen reviewed to ensure they are receiving the medication at an adequate dose and interval."3.78Alternating acetaminophen and ibuprofen for pain in children. ( Goldman, RD; Smith, C, 2012)
"This study compared the antipyretic effects of ibuprofen and indomethacin regarding the efficacy in blocking fevers induced by lipopolysaccharide (LPS from E."3.77Cyclooxygenase-independent mechanism of ibuprofen-induced antipyresis: the role of central vasopressin V₁ receptors. ( Cristofoletti, R; Fabricio, AS; Lindsey, CJ; Melo, MC; Soares, DM; Souza, GE; Veiga-Souza, FH, 2011)
"Ibuprofen was the first of a new breed of NSAIDs originally introduced into the United Kingdom in 1969."3.76Update on ibuprofen: review article. ( Busson, M, 1986)
" IBU blocked LPS-induced fever but did not block LPS-induced increases in plasma cytokines and corticosterone in the pregnant dam."3.75Effects of prenatal immune activation on hippocampal neurogenesis in the rat. ( Ashdown, H; Boksa, P; Cui, K; Luheshi, GN, 2009)
"To report Australian parents' medication (paracetamol, ibuprofen and homeopathic) use in childhood fever management."3.74Over-the-counter medication use for childhood fever: a cross-sectional study of Australian parents. ( Edwards, H; Fraser, J; Walsh, A, 2007)
" However, due to its side effects, ibuprofen should be used only in high and badly tolerated fever that is not altered by a well conducted acetaminophen monotherapy."3.73[Familial use of ibuprofen in febrile children: a prospective study in the emergency room of an hospital in Lille]. ( Charkaluk, ML; El Kohen, R; Kalach, N; Kremp, O, 2005)
"The results of this survey concerning antipyretic treatment of children by their Jewish and Bedouin Moslem caregivers suggest that lighter body weight and the use of acetaminophen rectal suppositories were associated with the administration of higher-than-recommended doses of acetaminophen."3.73Determinants of antipyretic misuse in children up to 5 years of age: a cross-sectional study. ( Bilenko, N; Gorodischer, R; Okbe, R; Press, J; Tessler, H, 2006)
" Nonetheless, these data suggest that parents use ibuprofen or ibuprofen together with acetaminophen to treat high fever and severe illness, which seems to identify children at high risk for invasive GAS infection."3.71Invasive group A streptococcal infection and nonsteroidal antiinflammatory drug use among children with primary varicella. ( Lesko, SM; Mitchell, AA; O'Brien, KL; Schwartz, B; Vezina, R, 2001)
" Predictive factors of this practice among pediatricians are male sex, having relatively little experience, considering ibuprofen as the drug of choice and recommending the administration of new doses of antipyretic to control mild fever."3.71[Use of alternating antipyretics in the treatment of fever in Spain]. ( Ballester Sanz, A; Burgos Ramírez, A; Díez Domingo, J; Garrido García, J; Moreno Carretero, E, 2001)
"Seventy-five (3 x 25) patients with acute ischaemic stroke confined to the anterior circulation will be randomised to treatment with either: 400 mg ibuprofen, 1000 mg acetaminophen, or with placebo 6 times daily during 5 days."3.71PISA. The effect of paracetamol (acetaminophen) and ibuprofen on body temperature in acute stroke: protocol for a phase II double-blind randomised placebo-controlled trial [ISRCTN98608690]. ( Dippel, DW; Kappelle, J; Koudstaal, PJ; Meijer, R; van Breda, EJ; van der Worp, B; van Gemert, M, 2002)
" To assess the role of MIP-1alpha and MIP-1beta in human inflammation, healthy subjects were studied during experimental endotoxemia with prior administration of ibuprofen, a cyclooxygenase inhibitor, or dimeric p75 tumor necrosis factor (TNF)-alpha receptor, a TNF antagonist; septic patients were also studied."3.70Detection of macrophage inflammatory protein (MIP)-1alpha and MIP-1beta during experimental endotoxemia and human sepsis. ( Banks, SM; O'Grady, NP; Preas, HL; Reda, D; Suffredini, AF; Tropea, M; Vandivier, RW, 1999)
"Ibuprofen is effective in the treatment of fever in children."3.70[Analysis of prognostic factors for the antipyretic response to ibuprofen]. ( , 2000)
" The anti-inflammatory potency of NS-398 in rat carrageenin-induced edema was as potent as that of indomethacin and 8 times more potent than diclofenac."3.68NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions. ( Arai, I; Futaki, N; Hamasaka, Y; Higuchi, S; Iizuka, H; Otomo, S; Yoshikawa, K, 1993)
"Ibuprofen may be an alternative to acetaminophen to control fever in children but little is known about its pharmacokinetics in pediatric patients."3.68Pharmacokinetics of ibuprofen in febrile children. ( Durrell, DE; Gupta, N; Nahata, MC; Powell, DA, 1991)
"Three young women with systemic lupus erythematosus who were given ibuprofen for arthritis voluntarily discontinued taking the drug."3.66Acute adverse reactions to ibuprofen in systemic lupus erythematosus. ( Finch, WR; Strottman, MP, 1979)
"The capacity of ibuprofen to reduce fever in children was compared with that of aspirin, paracetamol, aminophenazone and indomethacin."3.65Oral antipyretic therapy. ( Keinänen, S; Kouvalainen, K; Similä, S, 1976)
" No drug-related adverse events were reported."3.30A Multi-Center Evaluation of the Pharmacokinetics and Safety of Intravenous Ibuprofen in Infants 1-6 Months of Age. ( Berkenbosch, JW; Gibson, BHY; Glover, CD; Kaelin, B; Patel, NV; Taylor, MB; Zhong, J, 2023)
"Fever is the most common reason for children's visits to medical centers."3.11Comparing the effect of body wash with marshmallow plant and lukewarm water on reducing the temperature of febrile children: a randomized clinical trial. ( Delfan, B; Ebrahimzade, F; Ghasemi, F; Goodarzi, H; Seifosadat, SH; Taee, N; Valizadeh, F, 2022)
" Globally, the pharmacologic treatment of pain in pediatric patients is limited largely to nonopioid analgesics, and dosing must account for differences in age, weight, metabolism, and risk of adverse effects."3.01Common Selfcare Indications of Pain Medications in Children. ( Bell, J; Kachroo, P; Mossali, VM; Siddiqui, K; Zempsky, W, 2023)
"Pain, swelling, infection, trismus and temperature were recorded on days 3, 7 and 14 after surgery."2.75Antibiotic prophylaxis in third molar surgery: A randomized double-blind placebo-controlled clinical trial using split-mouth technique. ( Morkel, JA; Siddiqi, A; Zafar, S, 2010)
"Fever is a common symptom in children and one of the major concerns of parents of younger and preschool-age children."2.75Ketoprofen versus paracetamol (acetaminophen) or ibuprofen in the management of fever: results of two randomized, double-blind, double-dummy, parallel-group, repeated-dose, multicentre, phase III studies in children. ( Kokki, H; Kokki, M, 2010)
"Fever was measured with the aid of a tympanic thermometer (Braun Kronberg 6014) and followed for 4-6 hours."2.74Antipyretic effect of ketoprofen. ( Akgoz, S; Arisoy, ES; Aygun, D; Celebi, S; Citak Kurt, AN; Hacimustafaoglu, M; Karali, Y; Seringec, M, 2009)
"At physician-directed dosing (acetaminophen 15 mg/kg vs ibuprofen 10 mg/kg), no significant differences in antipyretic effects from 0‒6 h and between 0‒6, ‒12, ‒24, or ‒48 h, with single or multiple-doses, respectively, were observed."2.72Acetaminophen and ibuprofen in the treatment of pediatric fever: a narrative review. ( Paul, IM; Walson, PD, 2021)
"Diclofenac-K was superior to placebo (P < 0."2.71A multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled, parallel-group comparison of diclofenac-K and ibuprofen for the treatment of adults with influenza-like symptoms. ( Frank, WO; Gold, MS; Grebe, W; Ionescu, E; Liu, JM, 2003)
"During subsequent treatment of the fever episode, parents had to call the investigator at least once each day to notify the investigator in case of febrile seizure recurrence."2.69Randomized, controlled trial of ibuprofen syrup administered during febrile illnesses to prevent febrile seizure recurrences. ( Derksen-Lubsen, G; Habbema, JD; Moll, HA; Steyerberg, EW; van Stuijvenberg, M, 1998)
"To analyse the population pharmacokinetic-pharmacodynamic relationships of racemic ibuprofen administered in suspension or as effervescent granules with the aim of exploring the effect of formulation on the relevant pharmacodynamic parameters."2.69Pharmacokinetic-Pharmacodynamic Modelling of the antipyretic effect of two oral formulations of ibuprofen. ( Armenteros, S; Benítez, J; Calvo, R; Domínguez, R; Planelles, MV; Trocóniz, IF, 2000)
"3 patients in the colorectal cancer group demonstrated objective responses (1 complete remission (CR), 2 partial remission (PR))."2.68Phase II trial of intravenous endotoxin in patients with colorectal and non-small cell lung cancer. ( Braun, M; Engelhardt, R; Galanos, C; Mackensen, A; Mertelsmann, R; Otto, F; Schmid, P; Seiz, A; Wehr, U, 1996)
" The statistical analysis of the results confirmed that ibuprofen and paracetamol are equivalent with respect to the following criteria (1) time elapsed between dosing and the lowest temperature: 3."2.68Equivalent antipyretic activity of ibuprofen and paracetamol in febrile children. ( d'Athis, P; Debregeas, S; Olive, G; Pariente-Khayat, A; Pons, G; Vauzelle-Kervroëdan, F, 1997)
" Pharmacokinetic and pharmacodynamic analyses were performed with temperature as the effect parameter and mean acetaminophen, total ibuprofen, and ibuprofen stereoisomer concentrations over time."2.67Pharmacokinetics and pharmacodynamics of ibuprofen isomers and acetaminophen in febrile children. ( Cox, S; Edge, JH; Kelley, MT; Mortensen, ME; Walson, PD, 1992)
"Ibuprofen liquid was given as a single dose, 5 mg/kg to 18 patients (group I) and 10 mg/kg to 18 patients (group II); placebo was administered to 20 patients (group III)."2.67Efficacy of ibuprofen in pediatric patients with fever. ( Durrell, DE; Gupta, N; Miller, MA; Nahata, MC; Powell, DA, 1992)
"Ibuprofen is a potent antipyretic agent and is a safe alternative for the selected febrile child who may benefit from antipyretic medication but who either cannot take or does not achieve satisfactory antipyresis with acetaminophen."2.67Antipyretic efficacy of ibuprofen vs acetaminophen. ( Kauffman, RE; Sawyer, LA; Scheinbaum, ML, 1992)
"Ibuprofen was evaluated as an antipyretic agent in 178 children (aged 3 months to 12 years) to compare dosage (5 vs 10 mg/kg), establish absolute efficacy (with a placebo control group), determine relative efficacy (ibuprofen vs acetaminophen), evaluate maximum efficacy, and identify potential confounding variables."2.67Single-dose, placebo-controlled comparative study of ibuprofen and acetaminophen antipyresis in children. ( Bertrand, KM; Brown, RD; Eichler, VF; Johnson, VA; Kearns, GL; Lowe, BA; Wilson, JT, 1991)
" Data suggesting that conditions associated with chronic liver damage reduce the dosing threshold for induction of liver failure are of particular concern."2.61Symptomatic treatment of dengue: should the NSAID contraindication be reconsidered? ( Fernandes, L; Kellstein, D, 2019)
"Ibuprofen (IBU) is an efficacious over-the-counter analgesic/antipyretic with adverse event (AE) rates comparable to placebo."2.52Safety of a novel formulation of ibuprofen sodium compared with standard ibuprofen and placebo. ( Jayawardena, S; Kellstein, D; Leyva, R, 2015)
"Fever is a common symptom of childhood infections that in itself does not require treatment."2.50A practical approach to the treatment of low-risk childhood fever. ( Kanabar, D, 2014)
"The selected studies showed great heterogeneity of participants, temperature for fever diagnosis, interventions (dose and dosing intervals) and assessed outcomes."2.48Alternating antipyretics in the treatment of fever in children: a systematic review of randomized clinical trials. ( Dagostini, JM; Pereira, GL; Pizzol, Tda S, 2012)
"Ibuprofen, paracetamol and placebo have similar tolerability and safety profiles in terms of gastrointestinal symptoms, asthma and renal adverse effects."2.45Systematic review and meta-analysis of the clinical safety and tolerability of ibuprofen compared with paracetamol in paediatric pain and fever. ( Kleijnen, J; Soares-Weiser, K; Southey, ER, 2009)
" The evidence for modes of action of ibuprofen are considered in relation to its actions in controlling inflammation, pain and fever, as well as the adverse effects of the drug."2.45Ibuprofen: pharmacology, efficacy and safety. ( Rainsford, KD, 2009)
"Fever is the most common problem in medical situations, but controversy still surrounds its benefit/ risk ratio for human beings."2.44[Using evidence-based nursing to explore the management of child fever]. ( Huang, MC; Wang, YM, 2008)
" The review establishes that aspirin, paracetamol and ibuprofen are safe in OTC doses and that there is no evidence for any difference between the medicines as regards efficacy and safety for treatment of colds and flu (except in certain cases such as the use of aspirin in feverish children)."2.43Efficacy and safety of over-the-counter analgesics in the treatment of common cold and flu. ( Eccles, R, 2006)
"Fever is an important symptom of underlying disease condition and in general is considered harmful in pediatric age group as it may lead to febrile seizures, stupor, dehydration increase work of breathing, discomfort and tachycardia."2.41Antipyretics in children. ( Bhatnagar, SK; Chandra, J, 2002)
"Reasons for treating fever include patient discomfort, the potential for adverse sequelae, the possibility of seizures, and the possibility that fever could affect the pharmacokinetic profiles of drugs."2.38Antipyretic therapy in the febrile child. ( Drwal-Klein, LA; Phelps, SJ, 1992)
"The score was predictive of recurrence among most patient subgroups."1.62A risk score for pericarditis recurrence. ( Antonopoulos, AS; Imazio, M; Karavidas, A; Lazaros, G; Lazarou, E; Tousoulis, D; Toutouzas, K; Tsioufis, C; Vasileiou, P; Vassilopoulos, D; Vlachopoulos, C, 2021)
"Fever has been reported as a common symptom occurring in COVID-19 illness."1.56The use of ibuprofen to treat fever in COVID-19: A possible indirect association with worse outcome? ( Haryadi, TH; Jamerson, BD, 2020)
"Ibuprofen use was significantly lower in children diagnosed with wheezing (n = 22, 52."1.46Association of Acetaminophen and Ibuprofen Use With Wheezing in Children With Acute Febrile Illness. ( Elizur, A; Ganor, S; Kozer, E; Levine, H; Matok, I; Perlman, A, 2017)
"Acetaminophen was administered 2."1.46Parental Approach to the Prevention and Management of Fever and Pain Following Childhood Immunizations: A Survey Study. ( Moody, MA; Saleh, E; Swamy, GK; Walter, EB, 2017)
"Reactive arthritis is defined as arthritis that occurs during or after an extraarticular infection."1.43Hand-Foot and Mouth Dısease and Reactıve Arthritis: An Unusual Paediatric Case. ( A Esra, Y; C Nuket, Y; Neslihan, B; Sancar, E; Tugba, T, 2016)
" This study aimed to assess the health literacy skills of parents and caregivers of preschool-aged children, using a progressive scenario describing a child with fever and presenting tasks relating to selection of a medicine and hypothetical dosing of their child."1.40Management of children's fever by parents and caregivers: Practical measurement of functional health literacy. ( Chaw, XY; Emmerton, L; Kairuz, T; Kelly, F; Marriott, J; Moles, R; Wheeler, A, 2014)
"In Denmark, the traditional choice for treating fever and pain in children is paracetamol."1.38[Ibuprofen is more effective than paracetamol in lowering the temperature in febrile children]. ( Lundstrøm, KE, 2012)
"Ibuprofen is a well established analgesic, anti-inflammatory and antipyretic NSAID."1.38Intravenous ibuprofen: in adults for pain and fever. ( Scott, LJ, 2012)
"Fever is a common occurrence in the intensive care unit, and pharmacologic approaches are limited, particularly in patients unable to tolerate enteral medications."1.36Hot times in the intensive care unit. ( Abraham, E, 2010)
"Ibuprofen plasma concentration reached a Cmax of 74."1.36Ibuprofen transdermal ethosomal gel: characterization and efficiency in animal models. ( Ainbinder, D; Bercovich, R; Duchi, S; Shumilov, M; Touitou, E, 2010)
"We report a case of systemic onset juvenile idiopathic arthritis (SOJIA), the manifestations of which started with fever and skin rash followed by arthritis within neonatal age."1.35Systemic onset juvenile idiopathic arthritis--its unusual presentation. ( Chattopadhyay, N; Ghosh, JB; Gupta, D, 2008)
" Appropriate dosing and managing of these drugs do not likely lead to organ toxicity."1.35Acute non-oliguric kidney failure and cholestatic hepatitis induced by ibuprofen and acetaminophen: a case report. ( Angeli, S; Brugnara, M; Cuzzolin, L; Zaffanello, M, 2009)
"He had an upper respiratory tract infection in which a vaso-occlusive crisis was precipitated."1.34Tramadol infusion for the pain management in sickle cell disease: a case report. ( Aydinok, Y; Balkan, C; Erhan, E; Inal, MT; Yegul, I, 2007)
" There was a wide variability of the dosing interval."1.34Alternating antipyretics for fever reduction in children: an unfounded practice passed down to parents from pediatricians. ( Liebelt, EL; Wright, AD, 2007)
"This study used parental reports of the treatment of fever as an indicator of possible problems that may result from this policy, finding that the use of ineffective treatments and the overuse of drugs were common."1.34Treatment of fever and over-the-counter medicines. ( Purssell, E, 2007)
"However, bacterial infections are important causes of high fever in patients receiving myelosuppressive chemotherapy, and such fevers persist despite the use of COX inhibitors."1.33Endotoxin fever in granulocytopenic rats: evidence that brain cyclooxygenase-2 is more important than circulating prostaglandin E(2). ( Dascombe, MJ; Maldonado, R; Miñano, FJ; Tavares, E, 2006)
" We explore the toxicities of OTC cough and cold medications, discuss mechanisms of dosing errors, and suggest why physicians should be more vigilant in specifically inquiring about OTCs when evaluating an ill child."1.31Toxicity of over-the-counter cough and cold medications. ( Gunn, VL; Liebelt, EL; Serwint, JR; Taha, SH, 2001)
"6 hour-1, corresponding to a half-life of drug in the effect compartment of 1."1.28Effect of age on ibuprofen pharmacokinetics and antipyretic response. ( Kauffman, RE; Nelson, MV, 1992)
"For acetaminophen, the tlag was less than ibuprofen, Ka was more than ibuprofen, and beta was less than ibuprofen."1.28Single-dose pharmacokinetics of ibuprofen and acetaminophen in febrile children. ( Bertrand, KM; Brown, RD; Eichler, VF; Johnson, VA; Kearns, GL; Wilson, JT, 1992)
"We here present the case of a patient with severe neutropenia, haemolytic anaemia and thrombocytopenia associated with long-term use of ibuprofen."1.28A case of severe pancytopenia caused by ibuprofen. ( Lindblad, R; Rödjer, S, 1991)
"Fever is a part of the acute phase response, a generalized reaction to infection or inflammation initiated by interleukin-1 (IL-1)."1.27Fever. What to do and what not to do. ( Rosenthal, TC; Silverstein, DA, 1988)
"A 21-year-old woman with systemic lupus erythematosus (SLE) had meningismus, conjunctivitis, lymphadenopathy, and elevation of liver function values following ibuprofen therapy."1.26Tolmetin-induced aseptic meningitis. ( Barth, WF; Ruppert, GB, 1981)

Research

Studies (285)

TimeframeStudies, this research(%)All Research%
pre-199029 (10.18)18.7374
1990's58 (20.35)18.2507
2000's90 (31.58)29.6817
2010's82 (28.77)24.3611
2020's26 (9.12)2.80

Authors

AuthorsStudies
Terada, A1
Naruto, S1
Wachi, K1
Tanaka, S1
Iizuka, Y1
Misaka, E1
Kazama, I1
Senzaki, M1
Yin, F1
Liu, Y1
Guo, H1
Tan, E2
Hoare, K1
Riley, J1
Fernando, K1
Haskell, L1
McKinlay, CJ1
Dalziel, SR2
Braithwaite, I2
Simon Junior, H1
Pedreira, MC1
Barbosa, SMM1
Fernandes, TF1
Escobar, AMU1
Chilombe, MB1
McDermott, MP1
Seydel, KB1
Mathews, M1
Mwenechanya, M1
Birbeck, GL1
Goodarzi, H1
Valizadeh, F1
Ghasemi, F1
Ebrahimzade, F1
Seifosadat, SH1
Delfan, B1
Taee, N1
Baker, AH2
Monuteaux, MC2
Michelson, KA2
Neuman, MI2
Zempsky, W1
Bell, J1
Mossali, VM1
Kachroo, P1
Siddiqui, K1
Glover, CD1
Berkenbosch, JW1
Taylor, MB1
Patel, NV1
Kaelin, B1
Gibson, BHY1
Zhong, J1
Zhou, P1
Chen, L1
Wang, E1
He, L1
Tian, S1
Zhai, S1
de Sévaux, JLH1
Damoiseaux, RA2
van de Pol, AC2
Lutje, V1
Hay, AD6
Little, P2
Schilder, AG2
Venekamp, RP2
Franceschi, F1
Saviano, A1
Carnicelli, A1
Lorusso, C1
Novelli, A1
Candelli, M1
Ojetti, V1
Covino, M1
Moffett, BS1
Gutierrez, K1
Davis, K1
Sigdel, B1
Strobel, N1
Jamerson, BD1
Haryadi, TH1
Rinott, E1
Kozer, E3
Shapira, Y1
Bar-Haim, A1
Youngster, I3
Joseph, L1
Goldberg, S1
Cohen, S1
Picard, E1
McKinlay, CJD1
Alaje, EO1
Udoh, EE1
Akande, PA1
Odey, FA1
Meremikwu, MM1
Gelernter, R1
Ophir, N1
Goldman, M1
Lazarovitch, Z1
Gamsu, S1
Oren-Amit, A1
Breitbart, R1
Barkan Perl, S1
Rosenberg, K1
Can, Ö1
Kıyan, GS1
Yalçınlı, S1
Long, B1
Gottlieb, M1
Alam, MM1
Emon, NU1
Alam, S1
Rudra, S1
Akhter, N1
Mamun, MMR1
Ganguly, A1
Paul, IM3
Walson, PD6
Kloeden, B1
Tham, D1
Oakley, E1
Cheek, J1
Lazarou, E1
Lazaros, G1
Antonopoulos, AS1
Imazio, M1
Vasileiou, P1
Karavidas, A1
Toutouzas, K1
Vassilopoulos, D1
Tsioufis, C1
Tousoulis, D1
Vlachopoulos, C1
Eizenga, WE1
Opstelten, W1
Hoag, SD1
Chung, K1
Narayan, K1
Cooper, S1
Morphet, J1
Innes, K1
Ziesenitz, VC1
Zutter, A1
Erb, TO1
van den Anker, JN3
Luo, S1
Ran, M1
Luo, Q1
Shu, M1
Guo, Q1
Zhu, Y1
Xie, X1
Zhang, C1
Wan, C1
Osman, WA1
Labib, DA1
Abdelhalim, MO1
Elrokh, EM1
de Martino, M4
Chiarugi, A1
Boner, A1
Montini, G1
De' Angelis, GL1
Rakowsky, S1
Spiller, HA1
Casavant, MJ1
Chounthirath, T1
Hodges, NL1
Kim, EH1
Smith, GA1
Choi, SJ1
Moon, S1
Choi, UY1
Chun, YH1
Lee, JH1
Rhim, JW1
Lee, J1
Kim, HM1
Jeong, DC2
Heinzl, S1
Pigazzani, F1
Mackenzie, I1
MacDonald, TM1
Chaucer, B1
Stone, A1
Whelan, D1
Demanes, A1
Fischer, JL1
Kellstein, D3
Fernandes, L1
Islam, MT1
Pires, SAP1
Lemos, AP1
Pereira, EPMN1
Maia, PADSV1
Agro, JPSEABD1
Jia, LL1
Li, R1
Ma, J1
Fan, Y1
Li, HB1
Malya, RR1
Kim, CK1
Callaway, Z1
Choung, JT1
Yu, JH1
Shim, KS1
Kwon, EM1
Koh, YY2
Emmerton, L1
Chaw, XY1
Kelly, F1
Kairuz, T1
Marriott, J1
Wheeler, A1
Moles, R1
Wong, T3
Stang, AS3
Ganshorn, H3
Hartling, L3
Maconochie, IK3
Thomsen, AM3
Johnson, DW3
Dvorkin, R1
Bair, J1
Patel, H1
Glantz, S1
Yens, DP1
Rosalia, A1
Marguilies, J1
Chiappini, E3
D'Elios, S1
Mazzantini, R1
Becherucci, P3
Pierattelli, M1
Galli, L3
Pauchard, JY1
Gehri, M1
Kanabar, D2
Jayawardena, S2
Leyva, R1
Bergese, SD1
Candiotti, K1
Ayad, SS1
Soghomonyan, S1
Gan, TJ1
Watanabe, T1
Abe, M1
Tada, F1
Aritomo, K1
Ochi, H1
Koizumi, Y1
Tokumoto, Y1
Hirooka, M1
Kumagi, T1
Ikeda, Y1
Matsuura, B1
Hiasa, Y1
Sheehan, WJ2
Mauger, DT1
Moy, JN1
Boehmer, SJ1
Szefler, SJ1
Fitzpatrick, AM1
Jackson, DJ1
Bacharier, LB1
Cabana, MD1
Covar, R1
Holguin, F1
Lemanske, RF1
Martinez, FD1
Pongracic, JA1
Beigelman, A1
Baxi, SN1
Benson, M1
Blake, K1
Chmiel, JF1
Daines, CL1
Daines, MO1
Gaffin, JM1
Gentile, DA1
Gower, WA1
Israel, E1
Kumar, HV1
Lang, JE1
Lazarus, SC1
Lima, JJ1
Ly, N1
Marbin, J1
Morgan, WJ1
Myers, RE1
Olin, JT1
Peters, SP1
Raissy, HH1
Robison, RG1
Ross, K1
Sorkness, CA1
Thyne, SM1
Wechsler, ME1
Phipatanakul, W2
Mayor, S1
Falup-Pecurariu, O1
Man, SC1
Neamtu, ML1
Chicin, G1
Baciu, G1
Pitic, C1
Cara, AC1
Neculau, AE1
Burlea, M1
Brinza, IL1
Schnell, CN1
Sas, V1
Lupu, VV1
François, N1
Swinnen, K1
Borys, D1
Koca, T1
Akcam, M1
Tugba, T1
Neslihan, B1
A Esra, Y1
C Nuket, Y1
Sancar, E1
Lava, SA1
Santi, M1
Milani, GP1
Bianchetti, MG1
Simonetti, GD1
Matok, I1
Elizur, A1
Perlman, A1
Ganor, S1
Levine, H1
Saleh, E1
Swamy, GK1
Moody, MA1
Walter, EB1
Uzoigwe, CE1
Ali, OH1
Sjoukes, A1
Kanabar, DJ1
Khalil, SN1
Hahn, BJ1
Chumpitazi, CE1
Rock, AD1
Kaelin, BA1
Macias, CG1
Wysocki, J1
Center, KJ1
Brzostek, J1
Majda-Stanislawska, E1
Szymanski, H1
Szenborn, L1
Czajka, H1
Hasiec, B1
Dziduch, J1
Jackowska, T1
Witor, A1
Kopińska, E1
Konior, R1
Giardina, PC1
Sundaraiyer, V1
Patterson, S1
Gruber, WC1
Scott, DA1
Gurtman, A1
Ghosh, JB1
Gupta, D1
Chattopadhyay, N1
Kramer, LC1
Richards, PA1
Thompson, AM1
Harper, DP1
Fairchok, MP1
Costelloe, C3
Redmond, NM2
Montgomery, AA2
Fletcher, M4
Hollinghurst, S3
Peters, TJ3
Harnden, A1
Redmond, N2
Montgomery, A1
Purssell, E5
Ospina, CA1
Salcedo, A1
Moore, ND1
Tsuji, T1
Asanuma, M1
Miyazaki, I1
Miyoshi, K1
Ogawa, N1
Yoon, JS1
Oh, JW1
Lee, KY1
Lee, HS1
Kim, JT1
Kang, JH1
Lee, JS1
Guo, SX1
Cheng, Y1
Glatstein, M1
Scolnik, D2
Celebi, S1
Hacimustafaoglu, M1
Aygun, D1
Arisoy, ES1
Karali, Y1
Akgoz, S1
Citak Kurt, AN1
Seringec, M1
Zaffanello, M1
Brugnara, M1
Angeli, S1
Cuzzolin, L1
Kanashiro, A1
Pessini, AC1
Machado, RR1
Malvar, Ddo C1
Aguiar, FA1
Soares, DM2
do Vale, ML1
de Souza, GE1
Bliss-Holtz, J1
Cohee, LM1
Crocetti, MT1
Serwint, JR3
Sabath, B1
Kapoor, S1
Cui, K1
Ashdown, H1
Luheshi, GN1
Boksa, P1
Ni, LJ1
Zhang, LG1
Hou, J1
Shi, WZ1
Guo, ML1
Southey, ER1
Soares-Weiser, K1
Kleijnen, J2
Nabulsi, M1
Principi, N2
Longhi, R2
Tovo, PA2
Bonsignori, F2
Esposito, S2
Festini, F2
Lucchesi, B2
Mugelli, A2
Rainsford, KD1
Siddiqi, A1
Morkel, JA1
Zafar, S1
Pierce, CA1
Voss, B2
Kokki, H1
Kokki, M1
Baer, R1
Crook, J1
Yinh, J1
Pilichowska, M1
Kalish, R1
Miller, RJ1
Bailey, J1
Sullivan, K1
Morris, PE1
Promes, JT1
Guntupalli, KK1
Wright, PE2
Arons, MM2
Krudsood, S1
Tangpukdee, N1
Wilairatana, P1
Pothipak, N1
Duangdee, C1
Warrell, DA1
Looareesuwan, S1
Abraham, E1
Allan, GM1
Ivers, N1
Shevchuk, Y1
Cristofoletti, R1
Melo, MC1
Lindsey, CJ1
Veiga-Souza, FH1
Fabricio, AS1
Souza, GE1
Dixson, M1
Trainor, JL1
Stamos, JK1
Hadas, D1
Cohen, A1
Leibovitch, E1
Shavit, I1
Erez, I1
Uziel, Y1
Berkovitch, M1
Shumilov, M1
Bercovich, R1
Duchi, S1
Ainbinder, D1
Touitou, E1
Wark, JD1
Bensen, W1
Recknor, C1
Ryabitseva, O1
Chiodo, J1
Mesenbrink, P1
de Villiers, TJ1
Sturgis, SA1
Yang, C1
Engle, L1
Watts, H1
Berlin, CM2
Mullins, ME1
Empey, M1
Jaramillo, D1
Sosa, S1
Human, T1
Diringer, MN1
Maesschalck, PJ1
Lanas, A1
McCarthy, D1
Voelker, M1
Brueckner, A1
Senn, S1
Baron, JA1
Eyers, S1
Jefferies, S1
Shirtcliffe, P1
Perrin, K1
Beasley, R1
Badjatia, N1
Smith, HS1
Argentieri, J1
Morrone, K1
Pollack, Y1
Hoover, L1
McCarthy, DM1
Lundstrøm, KE1
Scott, LJ1
Smith, C1
Goldman, RD2
Venturini, E1
Pereira, GL1
Dagostini, JM1
Pizzol, Tda S1
Bardage, C1
Westerlund, T1
Barzi, S1
Bernsten, C1
Dippel, DW2
van Breda, EJ2
van der Worp, HB1
van Gemert, HM1
Meijer, RJ1
Kappelle, LJ1
Koudstaal, PJ2
Autret-Leca, E3
Lesko, SM6
Grebe, W1
Ionescu, E1
Gold, MS1
Liu, JM1
Frank, WO1
Ko, K1
Linett, LJ1
Wahba, H1
Perrott, DA1
Piira, T1
Goodenough, B1
Champion, GD1
Río, J2
Nos, C1
Bonaventura, I1
Arroyo, R1
Genis, D1
Sureda, B1
Ara, JR1
Brieva, L1
Martín, J1
Saiz, A1
Sánchez López, F1
Prieto, JM1
Roquer, J1
Dorado, JF1
Montalban, X2
Kader, A1
Hildebrandt, T1
Powell, C1
Mennick, F1
Body, R1
Potier, K1
Richardson, J1
Sills, J1
Annequin, D1
Carbajal, R1
Carabaño Aguado, I1
Jiménez López, I1
López-Cerón Pinilla, M1
Calvo García, I1
Pello Lázaro, AM1
Balugo Bengoechea, P1
Baro Fernández, M1
Ruiz Contreras, J1
Taéron, C1
Charkaluk, ML1
Kalach, N1
El Kohen, R1
Kremp, O1
You, YH1
Wu, CL1
Gao, JS1
Huang, AL1
Luo, H1
Sarrell, EM1
Wielunsky, E1
Cohen, HA1
Erlewyn-Lajeunesse, MD1
Coppens, K1
Hunt, LP1
Chinnick, PJ1
Davies, P1
Higginson, IM1
Benger, JR1
Nabulsi, MM1
Tamim, H1
Mahfoud, Z1
Itani, M1
Sabra, R1
Chamseddine, F1
Mikati, M1
Rodríguez Serna, A1
Astobiza Beobide, E1
González Balenciaga, M1
Azkunaga Santibáñez, B1
Benito Fernández, J1
Mintegi Raso, S1
Saphyakhajon, P1
Greene, G1
Schmitt, BD1
Bilenko, N1
Tessler, H1
Okbe, R1
Press, J1
Gorodischer, R1
Eccles, R1
Gonzalo-Garijo, MA1
Bobadilla, P1
Tavares, E1
Miñano, FJ1
Maldonado, R1
Dascombe, MJ1
Prado, J1
Daza, R1
Chumbes, O1
Loayza, I1
Huicho, L1
Erhan, E1
Inal, MT1
Aydinok, Y1
Balkan, C1
Yegul, I1
Ambrocio, DU1
John, D1
Wright, AD1
Liebelt, EL2
Deligne, J1
Grimaldi, L1
Jonville-Béra, AP1
Giraudeau, B1
Blum-Boisgard, C1
Walsh, A1
Edwards, H1
Fraser, J1
Gibb, IA1
Goulder, MA1
Miller, AA1
Hu, YJ1
Sun, GM1
Dale, S1
Rawat, M1
Wang, YM1
Huang, MC1
Sobrado, J1
Moldawer, LL1
Bistrian, BR1
Dinarello, CA3
Blackburn, GL1
Marnoy, SO1
Rosenwasser, LJ2
Wilson, G1
Guerra, AJ1
Santos, NT1
Kandoth, PW1
Joshi, MK1
Joshi, VR1
Satoskar, RS1
Lee, RP1
King, EG1
Russell, AS1
Wolff, SM1
Kitamoto, O1
Kobayashi, H1
Kaji, M1
Kashiwagi, S1
Hayashida, K1
Shingu, T1
Hara, K1
Izumikawa, K1
Fukui, M1
Ikebe, A1
Yamaguchi, K1
Suzuyama, Y1
Horiuchi, N1
Komori, M1
Fujimori, I1
Hayakawa, Y1
Katayama, T1
Kohno, M1
Sekita, K1
Tanaka, T1
Keinänen-Kiukaanniemi, S1
Similä, S2
Kouvalainen, K2
Cioli, V1
Putzolu, S1
Rossi, V1
Corradino, C1
Ruppert, GB1
Barth, WF1
Autret, E2
Breart, G1
Jonville, AP1
Courcier, S2
Lassale, C1
Goehrs, JM2
Fujimaki, W1
Griffin, JR1
Kleinerman, ES1
Futaki, N1
Yoshikawa, K1
Hamasaka, Y1
Arai, I1
Higuchi, S1
Iizuka, H1
Otomo, S1
McIntyre, J1
Hull, D2
Khubchandani, RP1
Ghatikar, KN1
Keny, S1
Usgaonkar, NG1
Otto, F1
Schmid, P1
Mackensen, A1
Wehr, U1
Seiz, A1
Braun, M1
Galanos, C1
Mertelsmann, R1
Engelhardt, R1
Reboul-Marty, J1
Henry-Launois, B1
Laborde, C1
Languillat, G1
Launois, R1
Bernard, GR2
Wheeler, AP2
Russell, JA2
Schein, R2
Summer, WR2
Steinberg, KP2
Fulkerson, WJ1
Christman, BW2
Dupont, WD2
Higgins, SB1
Swindell, BB2
Aksoylar, S1
Akşit, S1
Cağlayan, S1
Yaprak, I1
Bakiler, R1
Cetin, F1
Gabriel, CM1
Minor, JR1
Vogel, S1
Piscitelli, SC1
Elliott, MJ1
Woo, P1
Charles, P1
Long-Fox, A1
Woody, JN1
Maini, RN1
St Charles, CS1
Matt, BH1
Hamilton, MM1
Katz, BP1
Melis, R1
Block, S1
Mitchell, AA5
Vauzelle-Kervroëdan, F1
d'Athis, P1
Pariente-Khayat, A1
Debregeas, S1
Olive, G1
Pons, G1
Jensen, W1
van Stuijvenberg, M2
Derksen-Lubsen, G2
Steyerberg, EW2
Habbema, JD1
Moll, HA2
Mofenson, HC1
McFee, R1
Caraccio, T1
Greensher, J1
O'Grady, NP1
Tropea, M1
Preas, HL2
Reda, D2
Vandivier, RW2
Banks, SM2
Suffredini, AF3
Schifter, T1
Lewinski, UH1
Carley, S1
Fletcher, JR1
Fulkerson, W1
Wright, P1
Schwartz, JI1
Chan, CC1
Mukhopadhyay, S1
McBride, KJ1
Jones, TM1
Adcock, S1
Moritz, C1
Hedges, J1
Grasing, K1
Dobratz, D1
Cohen, RA1
Davidson, MH1
Bachmann, KA1
Gertz, BJ1
de Vos, S1
Tjiang, GC1
Stegelman, M1
Ulukol, B1
Köksal, Y1
Cin, S1
Trocóniz, IF1
Armenteros, S1
Planelles, MV1
Benítez, J1
Calvo, R1
Domínguez, R1
Olivencia, G1
Díez Domingo , J1
Planelles Cantarino , MV1
Moreno Madrid , F1
Uberos Fernández , J1
Moreno Martín , J1
Molina Carballo , A1
Antelo Cortizas , J1
Armenteros González , S1
Domínguez Granados , R1
Moreno Carretero , E1
Lal, A1
Gomber, S1
Talukdar, B1
O'Brien, KL1
Schwartz, B1
Vezina, R1
Jubran, A1
Godin, PJ1
Tobin, MJ1
Gunn, VL1
Taha, SH1
Del Vecchio, MT1
Sundel, ER1
Wong, W1
Coward, RJ1
Morris, MC1
Díez Domingo, J1
Burgos Ramírez, A1
Garrido García, J1
Ballester Sanz, A1
Moreno Carretero, E1
Wong, A1
Sibbald, A1
Ferrero, F1
Plager, M1
Santolaya, ME1
Escobar, AM1
Campos, S1
Barragán, S1
De León González, M1
Kesselring, GL1
Louik, C1
Vezina, RM1
Ng, DK1
Lam, JC1
Chow, KW1
Chandra, J1
Bhatnagar, SK1
van der Worp, B1
van Gemert, M1
Meijer, R1
Kappelle, J1
Reess, J1
Haas, J1
Gabriel, K1
Fuhlrott, A1
Fiola, M1
Figueras Nadal, C1
García de Miguel, MJ1
Gómez Campderá, A1
Pou Fernández, J1
Alvarez Calatayud, G1
Sánchez Bayle, M1
Finch, WR1
Strottman, MP1
Keinänen, S1
Mandell, B1
Shen, HS1
Hepburn, B1
Drwal-Klein, LA1
Phelps, SJ1
Choonara, I1
Nunn, AJ1
Barker, C1
Kauffman, RE2
Nelson, MV1
Kelley, MT1
Edge, JH1
Cox, S1
Mortensen, ME1
Nahata, MC2
Powell, DA2
Durrell, DE2
Miller, MA1
Gupta, N2
Casteels-Van Daele, M2
Brown, RD2
Wilson, JT2
Kearns, GL2
Eichler, VF2
Johnson, VA2
Bertrand, KM2
Sawyer, LA2
Scheinbaum, ML2
Galletta, G2
Chomilo, F1
Braden, NJ2
Rosefsky, JB1
Marriott, SC2
Stephenson, TJ2
Pownall, R1
Smith, CM1
Butler, A1
Lowe, BA1
Lorin, MI1
Lindblad, R1
Rödjer, S1
Martich, GD1
Danner, RL1
Ceska, M1
Reekie, RM1
Sidler, J1
Frey, B1
Baerlocher, K1
Graham, NM1
Burrell, CJ1
Douglas, RM1
Debelle, P1
Davies, L1
McGalliard, J1
Bell, AL1
Joshi, YM1
Sovani, VB1
Joshi, VV1
Navrange, JR1
Benakappa, DG1
Shivananda, P1
Sankaranarayanan, VS1
Boal, DK1
Zaino, RJ1
Karl, SR1
Troullos, ES1
Hargreaves, KM1
Butler, DP1
Dionne, RA1
Deeter, LB1
Martin, LW1
Lipton, JM1
Davatelis, G1
Wolpe, SD1
Sherry, B1
Dayer, JM1
Chicheportiche, R1
Cerami, A1
Alexander, L1
Chitty, D1
Heremans, G1
Dehaen, F1
Rom, N1
Ramet, J1
Verboven, M1
Loeb, H1
Rosenthal, TC1
Silverstein, DA1
Gigliotti, F1
Shenep, JL1
Lott, L1
Thornton, D1
Busson, M1
Butterfield, JH1
Schwenk, NM1
Colville, DS1
Kuipers, BJ1
Emau, P1
Giri, SN1
Bruss, ML1
Zia, S1
Gray, JD1
Blaschke, TF1
Kotob, A1
Amdekar, YK1
Desai, RZ1
Gaitonde, BB1
Dattani, K1
Morwani, K1

Clinical Trials (31)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Comparison of the Efficacy of Paracetamol and Ibuprofen in the Management of Fever in Sepsis Patients: A Randomized Double-Blind Controlled Study[NCT06061575]Phase 484 participants (Anticipated)Interventional2023-10-31Not yet recruiting
Prospective Comparative Study of the Efficacy of Common Antipyretic Treatments in Febrile Children[NCT02294071]Phase 4120 participants (Anticipated)Interventional2014-12-31Not yet recruiting
Hypoalgesic Effect of Median Nerve Neural Mobilization in Cervicobrachial Pain Compared to a Controlled Group[NCT02596815]51 participants (Actual)Interventional2015-07-31Completed
Hypoalgesic Effect of Neural Mobilization in Cervicobrachial Pain Compared to a Controlled Group[NCT02595294]52 participants (Actual)Interventional2015-07-31Completed
Hypoalgesic Effect of Median Nerve Neural Mobilization Versus Ibuprofen Pharmacologic Treatment in Patients With Cervicobrachial Pain[NCT02593721]Phase 2/Phase 350 participants (Actual)Interventional2015-07-31Completed
Evaluation Of The Efficacy Of A Novel Ibuprofen Formulation In The Treatment Of Post-Surgical Dental Pain: Study I[NCT01098747]Phase 3335 participants (Actual)Interventional2010-04-30Completed
Evaluation Of The Efficacy Of A Novel Ibuprofen Formulation In The Treatment Of Episodic Tension-Type Headache[NCT01077973]Phase 3200 participants (Actual)Interventional2010-03-31Completed
Evaluation Of The Efficacy Of A Novel Ibuprofen Formulation In The Treatment Of Post-Surgical Dental Pain[NCT01216163]Phase 3218 participants (Actual)Interventional2010-10-31Completed
Ibuprofen Sodium Tension Headache Study[NCT01362491]Phase 3226 participants (Actual)Interventional2011-06-30Completed
Evaluation Of The Antipyretic Efficacy Of Ibuprofen Sodium Tablets In Subjects With An Uncomplicated Acute Infection[NCT01035346]Phase 316 participants (Actual)Interventional2010-01-31Terminated
Acetaminophen vs. Ibuprofen in Children With Asthma[NCT01606319]Phase 3300 participants (Actual)Interventional2013-02-28Completed
Impact of Immediate or Delayed Prophylactic Antipyretic Treatment on the Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline Biologicals' Pneumococcal Vaccine 1024850A and the Co-administered DTPa-combined Vaccines[NCT01235949]Phase 4850 participants (Actual)Interventional2010-11-12Completed
A Multicenter, Randomized, Open-Label, Parallel, Active-Comparator Trial to Determine the Efficacy, Safety, and Pharmacokinetics of Ibuprofen Injection in Pediatric Patients[NCT01002573]Phase 3118 participants (Actual)Interventional2010-07-31Completed
A Phase 4, Randomized, Open-Label Trial To Assess The Impact Of Prophylactic Antipyretic Medication On The Immunogenicity Of 13-Valent Pneumococcal Conjugate Vaccine Given With Routine Pediatric Vaccinations In Healthy Infants[NCT01392378]Phase 4908 participants (Actual)Interventional2011-08-31Completed
Postoperative Ibuprofen Use and Risk of Bleeding in Pediatric Tonsillectomy[NCT03385057]Phase 10 participants (Actual)Interventional2018-09-30Withdrawn (stopped due to Study design flaws; research design needed to be reconfigured)
Assessment of the Analgesic Efficacy of Intravenous Ibuprofen in Biliary Colic[NCT02268955]22 participants (Actual)Interventional2014-09-09Completed
A Prospective, Randomized, Double-blind Study Assessing the Efficacy of Intravenous (IV) Ibuprofen Versus IV Acetaminophen for the Treatment of Pain Following Orthopaedic Low Extremity Surgery[NCT03771755]62 participants (Actual)Interventional2017-07-01Completed
A Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Trial To Evaluate The Efficacy, Safety, and Pharmacokinetics of Ibuprofen Injection in Adult Febrile Patients[NCT01131000]Phase 3123 participants (Actual)Interventional2002-06-30Completed
Ibuprofen Alone and in Combination With Acetaminophen for Treatment of Fever[NCT00267293]Phase 460 participants (Actual)Interventional2006-01-31Completed
Efficacy of Bromocriptine to Reduce Body Temperature in Febrile Critically-ill Adults With Acute Neurologic Disease: an Open-label, Blinded Endpoint, Randomized Controlled Trial[NCT03496545]Phase 1/Phase 247 participants (Actual)Interventional2018-11-30Completed
A Trial of Prednisone and Acetaminophen Versus Acetaminophen Alone in Minimizing Flu-like Symptoms From Pegylated Interferon Beta-1a[NCT03424733]Phase 450 participants (Anticipated)Interventional2017-09-25Recruiting
Feasibility Study of Intra-Tumoral Lipopolysaccharide Immunotherapy for Intra-Abdominal[NCT05751837]Phase 16 participants (Anticipated)Interventional2023-03-16Recruiting
[NCT00000574]Phase 30 participants Interventional1990-09-30Completed
A Phase II Double Blind Randomized Controlled Trial of High Dose Vitamin B12 in Septic Shock[NCT03783091]Phase 220 participants (Anticipated)Interventional2019-08-05Recruiting
Control of Fever in Septic Patients[NCT04227652]140 participants (Actual)Interventional2013-09-03Completed
Phase 2 Single Center, Randomized, Placebo-controlled, Double-blind, Parallel Group Study to Evaluate Efficacy of Para-Tyrosine Supplementation on the Survival and Clinical Outcome in Patients With Sepsis[NCT03278730]Phase 2296 participants (Anticipated)Interventional2025-02-28Not yet recruiting
Postoperative Ibuprofen and the Risk of Bleeding After Tonsillectomy With or Without Adenoidectomy[NCT01605903]Phase 2741 participants (Actual)Interventional2012-05-03Completed
Comparing Narcotics With Non-steroidal Anti-inflammatory Drugs (NSAIDS) Post-operatively in Pediatric Patients Undergoing Adenotonsillectomy[NCT02296840]Phase 445 participants (Actual)Interventional2014-11-30Terminated
Comparison of Supportive Therapies for Symptom Relief From Pediatric Upper Respiratory Infections (URIs)[NCT01814293]0 participants (Actual)Interventional2013-05-31Withdrawn (stopped due to loss of funding. No data was collected.)
Evaluation of Postoperative Edema and Pain Following Third Molar Extraction With Application of Pulsed Electromagnetic Field (PEMF) Therapy[NCT02376946]49 participants (Actual)Interventional2014-01-31Terminated (stopped due to Sponsor decision)
Efficacy of Steroids on Functional Outcomes After Musculoskeletal Injuries of the Hand[NCT05003596]Phase 2/Phase 360 participants (Anticipated)Interventional2021-09-01Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Participant Global Evaluation of Study Medication

Participant global evaluation of study medication was performed at the 8-hour time point or immediately before taking the rescue medication. It was scored on a 6-point categorical scale where 0 = Very poor, 1 = Poor, 2 = Fair, 3 = Good, 4 = Very Good, and 5 = Excellent. (NCT01098747)
Timeframe: 8 hours

InterventionUnits on a scale (Mean)
Placebo1.1
Ibuprofen Sodium3.8
Ibuprofen (Advil + Motrin IB)3.7

Time to Confirmed First Perceptible Relief

Participants evaluated the time to first perceptible relief by stopping a stopwatch labeled 'first perceptible relief' at the moment they first began to experience any relief. Stopwatch was active up to 8 hours after dosing or until stopped by the participant, or rescue medication was administered. The first perceptible relief was considered confirmed if the participant also stopped the second stopwatch indicating meaningful relief. (NCT01098747)
Timeframe: 0 to 8 hours

InterventionMinutes (Median)
PlaceboNA
Ibuprofen Sodium16.4
Ibuprofen (Advil + Motrin IB)25.7

Time to Onset of Meaningful Relief

Participants evaluated the time to meaningful relief by stopping a second stopwatch labeled 'meaningful relief' at the moment they first began to experience meaningful relief. Stopwatch was active up to 8 hours after dosing or until stopped by the participant, or rescue medication was administered. (NCT01098747)
Timeframe: 0 to 8 hours

InterventionMinutes (Median)
PlaceboNA
Ibuprofen Sodium42.4
Ibuprofen (Advil + Motrin IB)55.3

Time to Treatment Failure

Median time of dropping out of the participants from the study due to lack of efficacy or rescue medication, whichever came first. (NCT01098747)
Timeframe: 0 to 8 hours

InterventionHours (Median)
Placebo1.7
Ibuprofen SodiumNA
Ibuprofen (Advil + Motrin IB)NA

Time-weighted Sum of Pain Relief Rating and Pain Intensity Difference From 0-8 Hours (SPRID 0-8)

SPRID: time-weighted sum of pain relief rating combined with pain intensity difference (PRID) over 8 hours. SPRID 0-8 score range: -8 (worst) to 56 (best). PRID: sum of Pain intensity differences (PID) and pain relief rating (PRR) at each time point. PRID score range: -1=worst to 7=best. PID: baseline pain severity score minus pain severity score at a given time point (pain severity score range 0=none to 3=severe; baseline score range 2=moderate to 3=severe). PID score range: -1(worst) to 3 (best). PRR: assessed on 5-point pain relief rating scale (0=No relief to 4=Complete relief). (NCT01098747)
Timeframe: 0 to 8 hours

InterventionUnits on a scale (Mean)
Placebo5.4
Ibuprofen Sodium29.8

Cumulative Percentage of Participants With Complete Relief

Complete relief was defined as a PRR of 4. PRR was assessed on a 5-point categorical pain relief rating scale where 0=No relief to 4=Complete relief. (NCT01098747)
Timeframe: 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8 hours

,,
InterventionPercentage of participants (Number)
0.25 hours0.5 hours1 hour1.5 hours2 hours3 hours4 hours5 hours6 hours7 hours8 hours
Ibuprofen (Advil + Motrin IB)0.03.520.832.443.954.961.863.063.664.264.2
Ibuprofen Sodium0.06.327.441.148.452.654.754.754.754.754.7
Placebo0.00.00.00.00.00.06.36.36.36.36.3

Cumulative Percentage of Participants With Confirmed First Perceptible Relief

Percentage of participants with first perceptible relief was evaluated by stopping a stopwatch labeled 'first perceptible relief' at the moment the participant first began to experience any relief. Stopwatch was active up to 8 hours after dosing or until stopped by the participant, or rescue medication was administered. The first perceptible relief was considered confirmed if the participant also stopped the second stopwatch indicating meaningful relief. (NCT01098747)
Timeframe: 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8 hours

,,
InterventionPercentage of participants (Number)
0.25 hours0.5 hours1 hour1.5 hours2 hours3 hours4 hours5 hours6 hours7 hours8 hours
Ibuprofen (Advil + Motrin IB)12.160.784.487.387.988.488.488.488.488.488.4
Ibuprofen Sodium26.384.294.795.895.895.895.895.895.895.895.8
Placebo6.314.620.822.922.922.922.922.922.922.922.9

Cumulative Percentage of Participants With Meaningful Relief

Percentage of participants with meaningful relief evaluated by stopping the stopwatch labeled 'meaningful relief' at the moment the participant first began to experience meaningful relief. Stopwatch was active up to 8 hours after dosing or until stopped by the participant, or rescue medication was administered. (NCT01098747)
Timeframe: 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8 hours

,,
InterventionPercentage of participants (Number)
0.25 hours0.5 hours1 hour1.5 hours2 hours3 hours4 hours5 hours6 hours7 hours8 hours
Ibuprofen (Advil + Motrin IB)0.616.852.669.979.886.787.987.987.987.988.4
Ibuprofen Sodium1.128.473.787.491.694.794.794.794.795.895.8
Placebo0.04.212.514.618.820.820.820.820.820.822.9

Cumulative Percentage of Participants With Treatment Failure

Percentage of participants who withdrew from the study due to lack of efficacy or received rescue medication. (NCT01098747)
Timeframe: 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8 hours

,,
InterventionPercentage of participants (Number)
0.25 hours0.5 hours1 hour1.5 hours2 hours3 hours4 hours5 hours6 hours7 hours8 hours
Ibuprofen (Advil + Motrin IB)0.00.00.02.35.88.18.110.412.116.220.2
Ibuprofen Sodium0.00.00.01.12.14.29.510.513.720.026.3
Placebo0.00.00.025.054.270.870.870.872.977.179.2

Pain Intensity Difference (PID)

PID was derived by subtracting the pain severity score at a given post-dosing time point (pain severity score range 0 [none] to 3 [severe]) from the baseline score (Baseline pain severity score range 2 [moderate] to 3 [severe]). Total possible score range for PID: -1 (worst) to 3 (best). (NCT01098747)
Timeframe: 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8 hours

,,
InterventionUnits on a scale (Mean)
0.25 hours0.5 hours1 hour1.5 hour2 hours3 hours4 hours5 hours6 hours7 hours8 hours
Ibuprofen (Advil + Motrin IB)0.10.61.31.51.71.71.71.61.51.21.1
Ibuprofen Sodium0.31.01.51.71.81.61.51.41.20.90.8
Placebo0.00.00.00.00.00.00.10.0-0.0-0.0-0.0

Pain Relief Rating (PRR)

PRR was evaluated at different time points during the study up to 8 hours after taking the study medication, and immediately before rescue medication was taken (if necessary). PRR was assessed on a 5-point categorical pain relief rating scale where 0=No relief to 4=Complete relief. (NCT01098747)
Timeframe: 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8 hours

,,
InterventionUnits on a scale (Mean)
0.25 hours0.5 hours1 hour1.5 hours2 hours3 hours4 hours5 hours6 hours7 hours8 hours
Ibuprofen (Advil + Motrin IB)0.51.52.52.83.03.03.02.82.62.32.2
Ibuprofen Sodium0.72.02.93.13.12.92.82.62.31.91.7
Placebo0.40.50.60.70.70.70.80.70.70.50.5

Sum of Pain Relief Rating and Pain Intensity Difference (PRID)

PRID was sum of PID and PRR at each post-dosing time point. The overall possible score range, for PRID was -1 (worst) to 7 (best). PID was derived by subtracting the pain severity score at a given post-dosing time point (pain severity score range 0 [none] to 3 [severe]) from the baseline score (Baseline pain severity score range 2 [moderate] to 3 [severe]). Total possible score range for PID: -1 (worst) to 3 (best). PRR was assessed on 5-point categorical pain relief rating scale (0=No relief to 4=Complete relief). (NCT01098747)
Timeframe: 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8 hours

,,
InterventionUnits on a scale (Mean)
0.25 hours0.5 hours1 hour1.5 hours2 hours3 hours4 hours5 hours6 hours7 hours8 hours
Ibuprofen (Advil + Motrin IB)0.62.13.84.34.74.74.84.44.13.53.2
Ibuprofen Sodium1.13.04.44.84.94.54.34.03.52.92.6
Placebo0.40.60.70.70.80.70.90.80.60.50.5

Time-weighted Sum of Pain Intensity Difference (SPID)

SPID: time-weighted sum of PID over 2, 3, 6 and 8 hours. SPID scores range was -2 (worst) to 6 (best) for SPID 0-2, -3 (worst) to 9 (best) for SPID 0-3, -6 (worst) to 18 (best) for SPID 0-6, -8 (worst) to 24 (best) for SPID 0-8. PID: baseline pain severity score minus pain severity score at a given time point (pain severity score range 0=none to 3=severe; baseline score range 2=moderate to 3=severe). Total score range for PID: -1(worst) to 3 (best). (NCT01098747)
Timeframe: 0-2, 0-3, 0-6, 0-8 hours

,,
InterventionUnits on a scale (Mean)
SPID 0-2SPID 0-3SPID 0-6SPID 0-8
Ibuprofen (Advil + Motrin IB)2.44.18.911.1
Ibuprofen Sodium2.84.48.510.2
Placebo0.10.10.20.1

Time-weighted Sum of Pain Relief Rating (TOTPAR)

TOTPAR: time-weighted sum of PRR scores over 2, 3, 6 and 8 hours. TOTPAR score range was 0 (worst) to 8 (best) for TOTPAR 0-2, 0 (worst) to 12 (best) for TOTPAR 0-3, 0 (worst) to 24 (best) for TOTPAR 0-6, 0 (worst) to 32 (best) for TOTPAR 0-8. PRR was evaluated at different time points during the study up to 8 hours, and immediately after taking rescue medication (if necessary). PRR was assessed on a 5-point categorical pain relief rating scale wherein 0=No relief to 4=Complete relief. (NCT01098747)
Timeframe: 0-2, 0-3, 0-6, 0-8 hours

,,
InterventionUnits on a scale (Mean)
TOTPAR 0-2TOTPAR 0-3TOTPAR 0-6TOTPAR 0-8
Ibuprofen (Advil + Motrin IB)4.67.616.120.6
Ibuprofen Sodium5.28.115.919.5
Placebo1.32.04.25.2

Time-weighted Sum of Pain Relief Rating and Pain Intensity Difference (SPRID)

SPRID: time-weighted sum of PRID over 2, 3, 6 and 8 hours. SPRID score range:-2 (worst) to 14(best) for SPRID 0-2, -3(worst) to 21(best) for SPRID 0-3, -6(worst) to 42(best) for SPRID 0-6, -8(worst) to 56(best) for SPRID 0-8. PRID:sum of PID and PRR at each time point. Total score range for PRID: -1=worst to 7=best. PID:baseline pain severity score minus pain severity score at given time(score range 0=none to 3=severe; baseline score range 2=moderate to 3=severe). Total score range for PID: -1(worst) to 3(best), PRR: scored on 5-point pain relief rating scale(0=No relief to 4=Complete relief). (NCT01098747)
Timeframe: 0-2, 0-3, 0-6, 0-8 hours

,,
InterventionUnits on a scale (Mean)
SPRID 0-2SPRID 0-3SPRID 0-6SPRID 0-8
Ibuprofen (Advil + Motrin IB)7.011.825.031.7
Ibuprofen Sodium8.012.624.329.8
Placebo1.32.14.45.4

Time to Confirmed First Perceptible Relief

"Participants evaluated the time to first perceptible relief by stopping a stopwatch labeled 'first perceptible relief' at the moment the participant first began to experience any relief. Stopwatch was active up to 3 hours after dosing or until stopped by the participant, or rescue medication was administered. First perceptible relief was considered confirmed by meaningful relief if the participant achieved both first perceptible and meaningful relief by either depressing the second stopwatch or by indicating that his/her first perceptible relief was also meaningful." (NCT01077973)
Timeframe: 0 to 3 hours

InterventionMinutes (Median)
Placebo42.3
Ibuprofen Sodium41.7
Ibuprofen (Motrin IB)43.8

Time to Onset of Meaningful Relief for Ibuprofen Sodium Versus Ibuprofen (Motrin IB) Tablet

"Participants evaluated the time to meaningful relief by stopping a second stopwatch labeled 'meaningful relief' at the moment the participant first began to experience meaningful relief. It was also considered achieved if the participant stated meaningful relief at the time the first stopwatch was depressed. Stopwatch was active up to 3 hours after dosing or until stopped by the participant, or rescue medication was administered." (NCT01077973)
Timeframe: 0 to 3 hours

InterventionMinutes (Median)
Ibuprofen Sodium50.3
Ibuprofen (Motrin IB)55.5

Time to Onset of Meaningful Relief: Remaining Comparisons

"Participants evaluated the time to meaningful relief by stopping a second stopwatch labeled 'meaningful relief' at the moment the participant first began to experience meaningful relief. It was also considered achieved if the participant stated meaningful relief at the time the first stopwatch was depressed. Stopwatch was active up to 3 hours after dosing or until stopped by the participant, or rescue medication was administered." (NCT01077973)
Timeframe: 0 to 3 hours

InterventionMinutes (Median)
Placebo48.2
Ibuprofen Sodium50.3
Ibuprofen (Motrin IB)55.5

Time-weighted Sum of Pain Relief Rating and Pain Intensity Difference From 0-3 Hours (SPRID 0-3) for Ibuprofen Sodium Versus Placebo Tablet

SPRID:time-weighted sum of pain relief rating combined with pain intensity difference (PRID) over 3 hours. SPRID score range:-3 (worst) to 21 (best) for SPRID 0-3. PRID: sum of pain intensity differences (PID) and pain relief rating(PRR) at each time point. PRID score range: -1=worst to 7=best. PID: baseline pain severity score minus pain severity score at a given time point (score range 0=none to 3=severe; baseline score range 2=moderately severe to 3=severe). Total score range for PID: -1(worst) to 3 (best). PRR:assessed on 5-point pain relief rating scale (0=No relief to 4=Complete relief). (NCT01077973)
Timeframe: 0 to 3 hours

InterventionUnits on a scale (Mean)
Placebo11.2
Ibuprofen Sodium10.8

Cumulative Percentage of Participants With Complete Relief

Complete relief was defined as a PRR of 4. PRR was assessed on a 5-point categorical pain relief rating scale where 0=No relief to 4=Complete relief. (NCT01077973)
Timeframe: 1, 2, 3 hours

,,
InterventionPercentage of participants (Number)
1 hour2 hours3 hours
Ibuprofen (Motrin IB)1.315.035.0
Ibuprofen Sodium6.321.540.5
Placebo2.417.141.5

Cumulative Percentage of Participants With Confirmed First Perceptible Relief

"Percentage of participants with first perceptible relief evaluated by stopping a stopwatch labeled 'first perceptible relief' at the moment the participant first began to experience any relief. Stopwatch was active up to 3 hours after dosing or until stopped by the participant, or rescue medication was administered. First perceptible relief was considered confirmed by meaningful relief if the participant achieved both first perceptible and meaningful relief by either depressing the second stopwatch or by indicating that his/her first perceptible relief was also meaningful." (NCT01077973)
Timeframe: 0.5, 1, 2, 3 hours

,,
InterventionPercentage of participants (Number)
0.5 hours1 hour2 hours3 hours
Ibuprofen (Motrin IB)28.872.582.582.5
Ibuprofen Sodium30.467.181.081.0
Placebo24.480.585.485.4

Cumulative Percentage of Participants With Meaningful Relief

"Percentage of participants with meaningful relief evaluated by stopping a second stopwatch labeled 'meaningful relief' at the moment the participant first began to experience meaningful relief. It was also considered achieved if the participant stated meaningful relief at the time the first stopwatch was depressed. Stopwatch was active up to 3 hours after dosing or until stopped by the participant, or rescue medication was administered." (NCT01077973)
Timeframe: 0.5, 1, 2, 3 hours

,,
InterventionPercentage of participants (Number)
0.5 hours1 hour2 hours3 hours
Ibuprofen (Motrin IB)10.060.081.382.5
Ibuprofen Sodium17.758.279.781.0
Placebo14.665.985.485.4

Pain Intensity Difference (PID)

PID was derived by subtracting the pain severity score at a given post-dosing time point [pain severity score range 0 (none) to 3 (severe)] from the baseline score [Baseline pain severity score range 2 (moderately severe) to 3 (severe)]. Total possible score range for PID: -1 (worst) to 3 (best). (NCT01077973)
Timeframe: 1, 2, 3 hours

,,
InterventionUnits on a scale (Mean)
1 hour2 hours3 hours
Ibuprofen (Motrin IB)0.81.21.4
Ibuprofen Sodium0.91.31.5
Placebo0.91.31.5

Pain Relief Rating (PRR)

PRR was assessed on a 5-point categorical pain relief rating scale wherein 0=No relief to 4=Complete relief. (NCT01077973)
Timeframe: 1, 2, 3 hours

,,
InterventionUnits on a scale (Mean)
1 hour2 hours3 hours
Ibuprofen (Motrin IB)1.62.42.7
Ibuprofen Sodium1.92.52.8
Placebo1.92.63.0

Sum of Pain Relief Rating and Pain Intensity Difference (PRID)

PRID was sum of PID and PRR at each post-dosing time point. The overall possible score range, for PRID was -1 (worst) to 7 (best). PID was derived by subtracting the pain severity score at a given post-dosing time point [pain severity score range 0 (none) to 3 (severe)] from the baseline score [Baseline pain severity score range 2 (moderately severe) to 3 (severe)]. Total possible score range for PID: -1 (worst) to 3 (best). PRR was assessed on 5-point categorical pain relief rating scale (0=No relief to 4=Complete relief). (NCT01077973)
Timeframe: 1, 2, 3 hours

,,
InterventionUnits on a scale (Mean)
1 hour2 hours3 hours
Ibuprofen (Motrin IB)2.43.64.1
Ibuprofen Sodium2.83.74.3
Placebo2.83.94.5

Time-weighted Sum of Pain Intensity Difference (SPID)

SPID: time-weighted sum of PID over 2 and 3 hours. SPID score range was -2(worst) to 6 (best) for SPID 0-2 and -3 (worst) to 9 (best) for SPID 0-3. PID: baseline pain severity score minus pain severity score at a given time point (score range 0=none to 3=severe; baseline score range 2=moderately severe to 3=severe). Total score range for PID: -1(worst) to 3 (best). (NCT01077973)
Timeframe: 0 to 2, 0 to 3 hours

,,
InterventionUnits on a scale (Mean)
SPID 0-2SPID 0-3
Ibuprofen (Motrin IB)2.03.4
Ibuprofen Sodium2.23.6
Placebo2.23.8

Time-weighted Sum of Pain Relief Rating (TOTPAR)

TOTPAR: time-weighted sum of PRR over 2 and 3 hours. TOTPAR score range was 0 (worst) to 8 (best) for TOTPAR 0-2 and 0 (worst) to 12 (best) for TOTPAR 0-3. PRR was assessed on a 5-point categorical pain relief rating scale wherein 0=No relief to 4=Complete relief. (NCT01077973)
Timeframe: 0 to 2, 0 to 3 hours

,,
InterventionUnits on a scale (Mean)
TOTPAR 0-2TOTPAR 0-3
Ibuprofen (Motrin IB)4.16.8
Ibuprofen Sodium4.47.2
Placebo4.57.5

Time-weighted Sum of Pain Relief Rating and Pain Intensity Difference (SPRID)

SPRID: time-weighted sum of PRID over 2 and 3 hours. SPRID score range was -2(worst) to 14(best) for SPRID 0-2 and -3 (worst) to 21 (best) for SPRID 0-3. PRID: sum of PID and PRR at each time point. Total score range for PRID: -1=worst to 7=best. PID: baseline pain severity score minus pain severity score at a given time point (score range 0=none to 3=severe; baseline score range 2=moderately severe to 3=severe). Total score range for PID: -1(worst) to 3(best), PRR: assessed on 5-point pain relief rating scale (0=No relief to 4=Complete relief). (NCT01077973)
Timeframe: 0 to 2, 0 to 3 hours

,,
InterventionUnits on a scale (Mean)
SPRID 0-2SPRID 0-3
Ibuprofen (Motrin IB)6.110.2
Ibuprofen Sodium6.510.8
Placebo6.711.2

Participant Global Evaluation of Study Medication

Participant global evaluation of study medication was performed at the 6-hour time point or immediately before taking the rescue medication. It was scored on a 6-point categorical scale where 0 = Very poor, 1 = Poor, 2 = Fair, 3 = Good, 4 = Very Good, and 5 = Excellent. (NCT01216163)
Timeframe: 6 hours

Interventionunits on a scale (Mean)
Placebo0.9
Ibuprofen Sodium3.5
Acetaminophen3.0

Time to Confirmed First Perceptible Relief

Participants evaluated the time to first perceptible relief by stopping a stopwatch labeled 'first perceptible relief' at the moment they first began to experience any relief. Stopwatch was active up to 6 hours after dosing or until stopped by the participant, or rescue medication was administered. The first perceptible relief was considered confirmed if the participant also stopped the second stopwatch indicating meaningful relief. (NCT01216163)
Timeframe: 0 to 6 hours

Interventionminutes (Median)
PlaceboNA
Ibuprofen Sodium16.0
Acetaminophen23.7

Time to Onset of Meaningful Relief

Participants evaluated the time to meaningful relief by stopping a second stopwatch labeled 'meaningful relief' at the moment they first began to experience meaningful relief. Stopwatch was active up to 6 hours after dosing or until stopped by the participant, or rescue medication was administered. (NCT01216163)
Timeframe: 0 to 6 hours

Interventionminutes (Median)
PlaceboNA
Ibuprofen Sodium58.0
Acetaminophen53.4

Time to Treatment Failure

Median time of dropping out of the participants from the study due to lack of efficacy or use of rescue medication, whichever comes first. (NCT01216163)
Timeframe: 0 to 6 hours

Interventionhours (Median)
Placebo1.6
Ibuprofen SodiumNA
AcetaminophenNA

Time-weighted Sum of Pain Relief Rating With Pain Intensity Difference From 0 to 6 Hours (SPRID 0-6)

SPRID: time-weighted sum of pain relief rating combined with pain intensity difference (PRID) over 6 hours. Score range: -6(worst) to 42(best) for SPRID 0-6. PRID: sum of pain intensity difference (PID) and pain relief rating (PRR) at each time point. Score range for PRID: -1(worst) to 7(best). PID: baseline pain severity score minus pain severity score at a given time point (score range 0=none to 3=severe; baseline score range 2=moderate to 3=severe). Total score range for PID: -1 (worst) to 3 (best). PRR: assessed on 5-point pain relief rating scale (0=No relief to 4=Complete relief). (NCT01216163)
Timeframe: 0 to 6 hours

Interventionunits on a scale (Mean)
Placebo2.8
Ibuprofen Sodium20.0
Acetaminophen17.1

Cumulative Percentage of Participants With Complete Relief

Complete relief was defined as a PRR of 4. PRR was assessed on a 5-point categorical pain relief rating scale where 0=No relief to 4=Complete relief. (NCT01216163)
Timeframe: 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6 hours

,,
Interventionpercentage of participants (Number)
0.25 hours0.5 hours1 hours1.5 hours2 hours3 hours4 hours5 hours6 hours
Acetaminophen1.24.715.324.729.432.935.335.335.3
Ibuprofen Sodium0.06.823.929.536.442.045.545.546.6
Placebo0.00.00.00.04.44.46.78.98.9

Cumulative Percentage of Participants With Confirmed First Perceptible Relief

Percentage of participants with first perceptible relief evaluated by stopping the stopwatch labeled 'first perceptible relief' at the moment participant first began to experience any relief. First perceptible relief was considered confirmed if the participant also stopped the second stopwatch indicating meaningful relief. Stopwatch was active up to 6 hours after dosing or until stopped by the participant, or rescue medication was administered. (NCT01216163)
Timeframe: 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6 hours

,,
Interventionpercentage of participants (Number)
0.25 hours0.5 hours1 hour1.5 hours2 hours3 hours4 hours5 hours6 hours
Acetaminophen24.762.472.974.174.174.174.174.174.1
Ibuprofen Sodium28.464.878.479.579.579.579.579.579.5
Placebo2.24.411.111.113.313.313.313.313.3

Cumulative Percentage of Participants With Meaningful Relief

Percentage of participants with meaningful relief evaluated by stopping the stopwatch labeled 'meaningful relief' at the moment participant first began to experience meaningful relief. Stopwatch was active up to 6 hours after dosing or until stopped by the participant, or rescue medication was administered. (NCT01216163)
Timeframe: 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6 hours

,,
Interventionpercentage of participants (Number)
0.25 hours0.5 hours1 hour1.5 hours2 hours3 hours4 hours5 hours6 hours
Acetaminophen0.020.056.564.770.671.874.174.174.1
Ibuprofen Sodium0.021.653.472.775.077.378.479.579.5
Placebo0.00.00.02.28.911.113.313.313.3

Cumulative Percentage of Participants With Treatment Failure

Percentage of participants who withdrew from the study due to lack of efficacy or received rescue medication. (NCT01216163)
Timeframe: 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6 hours

,,
Interventionpercentage of participants (Number)
0.25 hours0.5 hours1 hour1.5 hours2 hours3 hours4 hours5 hours6 hours
Acetaminophen0.00.00.02.412.921.227.132.935.3
Ibuprofen Sodium0.00.00.02.35.711.415.925.029.5
Placebo0.00.00.042.268.982.282.282.282.2

Pain Intensity Difference (PID)

PID was derived by subtracting the pain severity score at a given post-dosing time point (pain severity score range 0 [none] to 3 [severe]) from the baseline score (Baseline pain severity score range 2 [moderate] to 3 [severe]). Total possible score range for PID: -1 (worst) to 3 (best). (NCT01216163)
Timeframe: 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6 hours

,,
Interventionunits on a scale (Mean)
0.25 hours0.5 hours1 hour1.5 hours2 hours3 hours4 hours5 hours6 hours
Acetaminophen0.20.51.01.11.10.90.90.80.6
Ibuprofen Sodium0.30.81.31.31.31.21.10.90.9
Placebo-0.1-0.10.0-0.0-0.0-0.0-0.00.0-0.0

Pain Relief Rating (PRR)

PRR was evaluated at different time points during the study up to 6 hours after taking the study medication, and immediately before rescue medication was taken (if necessary). PRR was assessed on a 5-point categorical pain relief rating scale where 0=No relief to 4=Complete relief. (NCT01216163)
Timeframe: 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6 hours

,,
Interventionunits on a scale (Mean)
0.25 hours0.5 hours1 hour1.5 hours2 hours3 hours4 hours5 hours6 hours
Acetaminophen0.41.52.42.52.52.22.11.91.7
Ibuprofen Sodium0.71.82.62.82.82.52.42.02.0
Placebo0.10.30.60.50.50.50.50.50.5

Sum of Pain Relief Rating and Pain Intensity Difference (PRID)

PRID was sum of PID and PRR at each post-dosing time point. The overall possible score range, for PRID was -1 (worst) to 7 (best). PID was derived by subtracting the pain severity score at a given post-dosing time point (pain severity score range 0 [none] to 3 [severe]) from the baseline score (Baseline pain severity score range 2 [moderate] to 3 [severe]). Total possible score range for PID: -1 (worst) to 3 (best). PRR was assessed on 5-point categorical pain relief rating scale (0=No relief to 4=Complete relief). (NCT01216163)
Timeframe: 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6 hours

,,
Interventionunits on a scale (Mean)
0.25 hours0.5 hours1 hour1.5 hours2 hours3 hours4 hours5 hours6 hours
Acetaminophen0.62.03.43.73.63.13.02.72.3
Ibuprofen Sodium0.92.53.94.14.13.73.62.92.8
Placebo0.10.20.60.50.50.40.50.50.5

Time-weighted Sum of Pain Intensity Difference (SPID)

SPID: time-weighted sum of PID over 2, 3 and 6 hours. Total score range: -2 (worst) to 6 (best) for SPID 0-2, -3 (worst) to 9 (best) for SPID 0-3, and -6 (worst) to 18 (best) for SPID 0-6. PID: baseline pain severity score minus pain severity score at a given time point (score range 0=none to 3=severe; baseline score range 2=moderate to 3=severe). Total score range for PID: -1 (worst) to 3 (best). (NCT01216163)
Timeframe: 0 to 2, 0 to 3, 0 to 6 hours

,,
Interventionunits on a scale (Mean)
SPID 0-2SPID 0-3SPID 0-6
Acetaminophen1.82.85.1
Ibuprofen Sodium2.23.46.3
Placebo-0.1-0.1-0.1

Time-weighted Sum of Pain Relief Rating (TOTPAR)

TOTPAR: time-weighted sum of PRR over 2, 3, and 6 hours. Total score range: 0 (worst) to 8 (best) for TOTPAR 0-2, 0 (worst) to 12 (best) for TOTPAR 0-3, and 0 (worst) to 24 (best) for TOTPAR 0-6. PRR was evaluated at different time points during the study up to 6 hours, and immediately after taking rescue medication (if necessary). PRR was assessed on a 5-point categorical pain relief rating scale where 0=No relief to 4=Complete relief. (NCT01216163)
Timeframe: 0 to 2, 0 to 3, 0 to 6 hours

,,
Interventionunits on a scale (Mean)
TOTPAR 0-2TOTPAR 0-3TOTPAR 0-6
Acetaminophen4.26.412.0
Ibuprofen Sodium4.77.213.6
Placebo0.91.42.9

Time-weighted Sum of Pain Relief Rating and Pain Intensity Difference (SPRID)

SPRID: time-weighted sum of PRID over 2 and 3 hours. Total score range: -2 (worst) to 14 (best) for SPRID 0-2, and -3 (worst) to 21 (best) for SPRID 0-3. PRID: sum of PID and PRR at each time point. Total score range for PRID: -1=worst to 7=best. PID: baseline pain severity score minus pain severity score at a given time point (score range 0=none to 3=severe; baseline score range 2=moderate to 3=severe). Total score range for PID: -1 (worst) to 3 (best). PRR: assessed on 5-point pain relief rating scale (0=No relief to 4=Complete relief). (NCT01216163)
Timeframe: 0 to 2, 0 to 3 hours

,,
Interventionunits on a scale (Mean)
SPRID 0-2SPRID 0-3
Acetaminophen6.09.1
Ibuprofen Sodium6.910.6
Placebo0.91.3

Cumulative Percentage of Participants With Treatment Failure

Percentage of participants who withdrew from the study due to lack of efficacy or received rescue medication. (NCT01362491)
Timeframe: 1, 2, 3 hours post-dose

Interventionpercentage of participants (Number)
Ibuprofen Sodium0
Ibuprofen (Motrin IB)0
Placebo0

Time to Confirmed First Perceptible Relief

"Participants evaluated the time to first perceptible relief by stopping a stopwatch labeled 'first perceptible relief' at the moment the participant first began to experience any relief. Stopwatch was active up to 3 hours after dosing or until stopped by the participant, or rescue medication was administered. First perceptible relief was considered confirmed by meaningful relief if the participant achieved both first perceptible and meaningful relief by either depressing the second stopwatch or by indicating that his/her first perceptible relief was also meaningful." (NCT01362491)
Timeframe: 0 to 3 hours

Interventionminutes (Median)
Ibuprofen Sodium36.9
Ibuprofen (Motrin IB)43.6
PlaceboNA

Time to Onset of Meaningful Relief for Ibuprofen Sodium Versus Ibuprofen (Motrin IB) Tablet

"Participants evaluated the time to meaningful relief by stopping a second stopwatch labeled 'meaningful relief' at the moment the participant first began to experience meaningful relief. It was also considered achieved if the participant stated meaningful relief at the time the first stopwatch was depressed. Stopwatch was active up to 3 hours after dosing or until stopped by the participant, or rescue medication was administered." (NCT01362491)
Timeframe: 0 to 3 hours

Interventionminutes (Median)
Ibuprofen Sodium40.6
Ibuprofen (Motrin IB)48.5

Time to Onset of Meaningful Relief: Remaining Comparisons

"Participants evaluated the time to meaningful relief by stopping a second stopwatch labeled 'meaningful relief' at the moment the participant first began to experience meaningful relief. It was also considered achieved if the participant stated meaningful relief at the time the first stopwatch was depressed. Stopwatch was active up to 3 hours after dosing or until stopped by the participant, or rescue medication was administered." (NCT01362491)
Timeframe: 0 to 3 hours

Interventionminutes (Median)
Ibuprofen Sodium40.6
Ibuprofen (Motrin IB)48.5
PlaceboNA

Time-weighted Sum of Pain Relief Rating and Pain Intensity Difference From 0-3 Hours (SPRID 0-3) for Ibuprofen Sodium Versus Placebo Tablet

SPRID:time-weighted sum of pain relief rating combined with pain intensity difference (PRID) over 3 hours. SPRID score range:-3 (worst) to 21 (best) for SPRID 0-3. PRID: sum of pain intensity differences (PID) and pain relief rating(PRR) at each time point. PRID score range: -1=worst to 7=best. PID: baseline pain severity score minus pain severity score at a given time point (score range 0=none to 3=severe; baseline score range 2=moderately severe to 3=severe). Total score range for PID: -1(worst) to 3 (best). PRR:assessed on 5-point pain relief rating scale (0=No relief to 4=Complete relief). (NCT01362491)
Timeframe: 0-3 Hours

Interventionunits on scale (Mean)
Ibuprofen Sodium9.6
Placebo3.5

Cumulative Percentage of Participants With Complete Relief

Complete relief was defined as a PRR of 4. PRR was assessed on a 5-point categorical pain relief rating scale where 0=No relief to 4=Complete relief (NCT01362491)
Timeframe: 1, 2, & 3 hours post-dose

,,
Interventionpercentage of participants (Number)
1 hour2 hours3 hours
Ibuprofen (Motrin IB)04.538.2
Ibuprofen Sodium05.537.4
Placebo02.28.7

Cumulative Percentage of Participants With First Perceptible Relief

"Percentage of participants with first perceptible relief evaluated by stopping a stopwatch labeled 'first perceptible relief' at the moment the participant first began to experience any relief. Stopwatch was active up to 3 hours after dosing or until stopped by the participant, or rescue medication was administered. First perceptible relief was considered confirmed by meaningful relief if the participant achieved both first perceptible and meaningful relief by either depressing the second stopwatch or by indicating that his/her first perceptible relief was also meaningful." (NCT01362491)
Timeframe: 0.5, 1, 2, 3 hours

,,
Interventionpercentage of participants (Number)
0.5 hours1 hour2 hours3 hours
Ibuprofen (Motrin IB)7.974.286.586.5
Ibuprofen Sodium18.776.985.785.7
Placebo015.245.745.7

Cumulative Percentage of Participants With Meaningful Relief

"Percentage of participants with meaningful relief evaluated by stopping a second stopwatch labeled 'meaningful relief' at the moment the participant first began to experience meaningful relief. It was also considered achieved if the participant stated meaningful relief at the time the first stopwatch was depressed. Stopwatch was active up to 3 hours after dosing or until stopped by the participant, or rescue medication was administered." (NCT01362491)
Timeframe: 0.5, 1, 2, 3 hours

,,
Interventionpercentage of participants (Number)
0.5 hours1 hour2 hours3 hours
Ibuprofen (Motrin IB)4.565.286.586.5
Ibuprofen Sodium12.171.485.785.7
Placebo01339.145.7

Pain Intensity Difference (PID)

PID was derived by subtracting the pain severity score at a given post-dosing time point [pain severity score range 0 (none) to 3 (severe)] from the baseline score [Baseline pain severity score range 2 (moderately severe) to 3 (severe)]. Total possible score range for PID: -1 (worst) to 3 (best). (NCT01362491)
Timeframe: 1, 2 & 3 hours post-dose

,,
Interventionunits on scale (Mean)
1 hour2 hours3 hours
Ibuprofen (Motrin IB)0.71.01.4
Ibuprofen Sodium0.71.01.3
Placebo0.20.40.5

Pain Relief Rating (PRR)

PRR was assessed on a 5-point categorical pain relief rating scale wherein 0=No relief to 4=Complete relief. (NCT01362491)
Timeframe: 1, 2 & 3 hours post-dose

,,
Interventionunits on scale (Mean)
1 hour2 hours3 hours
Ibuprofen (Motrin IB)1.62.22.9
Ibuprofen Sodium1.52.32.8
Placebo0.31.01.2

Sum of Pain Relief Rating and Pain Intensity Difference (PRID)

PRID was sum of PID and PRR at each post-dosing time point. The overall possible score range, for PRID was -1 (worst) to 7 (best). PID was derived by subtracting the pain severity score at a given post-dosing time point [pain severity score range 0 (none) to 3 (severe)] from the baseline score [Baseline pain severity score range 2 (moderately severe) to 3 (severe)]. Total possible score range for PID: -1 (worst) to 3 (best). PRR was assessed on 5-point categorical pain relief rating scale (0=No relief to 4=Complete relief). (NCT01362491)
Timeframe: 1, 2 & 3 hours post-dose

,,
Interventionunits on scale (Mean)
1 hour2 hours3 hours
Ibuprofen (Motrin IB)2.23.24.3
Ibuprofen Sodium2.33.24.1
Placebo0.51.41.7

Time-weighted Sum of Pain Intensity Difference (SPID)

SPID: time-weighted sum of PID over 2 and 3 hours. SPID score range was -2(worst) to 6 (best) for SPID 0-2 and -3 (worst) to 9 (best) for SPID 0-3. PID: baseline pain severity score minus pain severity score at a given time point (score range 0=none to 3=severe; baseline score range 2=moderately severe to 3=severe). Total score range for PID: -1(worst) to 3 (best). (NCT01362491)
Timeframe: 0 to 2, 0 to 3 hours

,,
Interventionunits on scale (Mean)
SPID 0-2SPID 0-3
Ibuprofen (Motrin IB)1.73.1
Ibuprofen Sodium1.73.0
Placebo0.51.0

Time-weighted Sum of Pain Relief Rating (TOTPAR)

TOTPAR: time-weighted sum of PRR over 2 and 3 hours. TOTPAR score range was 0 (worst) to 8 (best) for TOTPAR 0-2 and 0 (worst) to 12 (best) for TOTPAR 0-3. PRR was assessed on a 5-point categorical pain relief rating scale wherein 0=No relief to 4=Complete relief. (NCT01362491)
Timeframe: 0 to 2, 0 to 3 hours

,,
Interventionunits on scale (Mean)
TOTPAR 0-2TOTPAR 0-3
Ibuprofen (Motrin IB)3.86.6
Ibuprofen Sodium3.86.6
Placebo1.32.5

Time-weighted Sum of Pain Relief Rating and Pain Intensity Difference (SPRID)

SPRID: time-weighted sum of PRID over 2 and 3 hours. SPRID score range was -2(worst) to 14(best) for SPRID 0-2 and -3 (worst) to 21 (best) for SPRID 0-3. PRID: sum of PID and PRR at each time point. Total score range for PRID: -1=worst to 7=best. PID: baseline pain severity score minus pain severity score at a given time point (score range 0=none to 3=severe; baseline score range 2=moderately severe to 3=severe). Total score range for PID: -1(worst) to 3(best), PRR: assessed on 5-point pain relief rating scale (0=No relief to 4=Complete relief). (NCT01362491)
Timeframe: 0 to 2, 0 to 3 hours

,,
Interventionunits on scale (Mean)
SPRID 0-2SPRID 0-3
Ibuprofen (Motrin IB)5.59.8
Ibuprofen Sodium5.59.6
Placebo1.83.5

Global Assessment of Study Medication as an Antipyretic

Global assessment of study medication was performed at the 8-hours time point or immediately before taking rescue medication (if necessary). It was scored on a 5-point categorical scale where 0=poor, 1=fair, 2=good, 3=very good, and 4=excellent. (NCT01035346)
Timeframe: 8 hours

Interventionunits on a scale (Mean)
Placebo1.8
Ibuprofen Sodium2.5

Rating of Study Medication Relative to Usual Medication

Rating of study medication was performed at the 8-hours time point or immediately before taking rescue medication (if necessary). It was scored on a 5-point categorical scale where 0=poor, 1=fair, 2=good, 3=very good, and 4=excellent. (NCT01035346)
Timeframe: 8 hours

Interventionunits on a scale (Mean)
Placebo1.5
Ibuprofen Sodium2.4

Time to Treatment Failure

Median time of dropping out of the participants from the study due to lack of efficacy or use of rescue medication, whichever comes first. (NCT01035346)
Timeframe: 0 to 8 hours

Interventionhours (Median)
PlaceboNA
Ibuprofen SodiumNA

Time-weighted Sum of The Temperature Differences From Baseline Through Hour 6 (STEMPD 0-6)

STEMPD 0-6 was defined as time-weighted sum of temperature differences over 6 hours, weighted by the time elapsed between each 2 consecutive time points. Temperature difference was defined as baseline temperature minus post-baseline temperature at each time point, where positive value indicated improvement in body temperature. (NCT01035346)
Timeframe: 0 to 6 hours

InterventionDegrees Fahrenheit (Mean)
Placebo3.0
Ibuprofen Sodium10.8

Change From Baseline in Temperature at Hours 0.25, 0.5, 1, 2, 4, 6 and 8

Change from baseline in temperature was calculated as baseline temperature minus post-baseline temperature at each time point, where positive value indicated improvement in body temperature. (NCT01035346)
Timeframe: Baseline, 0.25, 0.5, 1, 2, 4, 6, 8 hours

,
InterventionDegrees Fahrenheit (Mean)
0.25 hours0.5 hours1 hour2 hours4 hours6 hours8 hours
Ibuprofen Sodium0.40.71.21.92.02.11.3
Placebo0.40.50.30.80.30.71.3

Cumulative Percentage of Participants With Treatment Failure

Percentage of participants who withdrew from the study due to lack of efficacy or received rescue medication. (NCT01035346)
Timeframe: 0.25, 0.5, 1, 2, 4, 6, 8 hours

,
Interventionpercentage of participants (Number)
0.25 hours0.5 hours1 hour2 hours4 hours6 hours8 hours
Ibuprofen Sodium0.00.00.00.00.00.011.1
Placebo0.00.00.00.00.00.00.0

Time-weighted Sum of The Temperature Differences From Baseline Through Hour 4 and Hour 8 (STEMPD 0-4 and STEMPD 0-8)

STEMPD 0-4 and STEMPD 0-8 were defined as the time-weighted sum of temperature differences over 4 hours and 8 hours, weighted by the time elapsed between each 2 consecutive time points. Temperature difference was defined as baseline temperature minus post-baseline temperature at each time point, where positive value indicated improvement in body temperature. (NCT01035346)
Timeframe: 0 to 4, 0 to 8 hours

,
InterventionDegrees Fahrenheit (Mean)
STEMPD 0-4STEMPD 0-8
Ibuprofen Sodium6.713.4
Placebo1.75.7

Asthma Control Days

proportion of study days on which asthma was controlled, measured by electronic diary (NCT01606319)
Timeframe: last 46 weeks of 48 week treatment period

Interventionproportion of days (Mean)
Acetaminophen.86
Ibuprofen.87

Asthma Rescue Medication Use

average albuterol rescue use per week, measured by electronic diary (NCT01606319)
Timeframe: last 46 weeks of 48 week treatment period

Interventioninhalations per week (Mean)
Acetaminophen2.8
Ibuprofen3

Exacerbation Frequency

the number of asthma exacerbations requiring systemic corticosteroids (NCT01606319)
Timeframe: last 46 weeks of 48 week treatment period

Interventionasthma exacerbations per 46 weeks (Mean)
Acetaminophen0.81
Ibuprofen.87

Health Care Utilization

frequency of unscheduled physician visits, emergency department visits or hospitalizations for asthma (NCT01606319)
Timeframe: last 46 weeks of 48 week treatment period

Interventionunscheduled health visits per 46 weeks (Mean)
Acetaminophen.75
Ibuprofen.76

Antibody Concentrations Against Hepatitis B Surface Antigen (HBs)

Antibody concentrations assessed were presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL). The seroprotection cut-off for the assay was an antibody concentration ≥ 10 mIU/mL. (NCT01235949)
Timeframe: One month after primary immunization (Month 3)

InterventionmIU/mL (Geometric Mean)
IIBU Group911.85
DIBU Group1139.1
NIBU Group1245.07
IPARA Group934.65
DPARA Group674.25
NPARA Group1027.79

Antibody Concentrations Against Polyribosyl-ribitol-phosphate (PRP)

Antibody concentrations assessed were presented as geometric mean concentrations (GMCs) and expressed in micrograms per milliliter (µg/mL). The seroprotection cut-off for the assay was an antibody concentration ≥ 0.15 µg/mL. (NCT01235949)
Timeframe: One month after primary immunization (Month 3)

Interventionµg/mL (Geometric Mean)
IIBU Group3.994
DIBU Group3.66
NIBU Group4.51
IPARA Group3.29
DPARA Group4.23
NPARA Group5.007

Antibody Concentrations Against Protein D (Anti-PD)

Anti-PD antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in ELISA units (EL.U) per milliliter (EL.U/mL). The seropositivity cut-off of the assay was an antibody concentration ≥ 100 EL.U/mL. (NCT01235949)
Timeframe: One month after primary immunization (At Month 3)

InterventionEL.U/mL (Geometric Mean)
IIBU Group1461.3
DIBU Group1353.1
NIBU Group1557.7
IPARA Group1109.6
DPARA Group1348.6
NPARA Group1667.9

Number of Subjects With Any Serious Adverse Events (SAEs)

SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity. (NCT01235949)
Timeframe: During the entire study period (Month 0 to 10)

InterventionParticipants (Count of Participants)
IIBU Group4
DIBU Group4
NIBU Group2
IPARA Group4
DPARA Group1
NPARA Group0

Number of Subjects With Any Unsolicited Adverse Events (AEs)

An unsolicited adverse event is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. (NCT01235949)
Timeframe: Within 31-days (Day 0-30) following booster vaccination

InterventionSubjects (Number)
IIBU-IIBU Group6
IIBU-DIBU Group6
IIBU-NIBU Group2
DIBU-IIBU Group3
DIBU-DIBU Group3
DIBU-NIBU Group4
NIBU-IIBU Group6
NIBU-DIBU Group6
NIBU-NIBU Group3
IPARA-NPARA Group4
DPARA-IPARA Group0
NPARA-IPARA Group2

Number of Subjects With Any Unsolicited Adverse Events (AEs)

An unsolicited adverse event is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. (NCT01235949)
Timeframe: Within 31-days (Day 0-30) following each primary vaccination dose

InterventionParticipants (Count of Participants)
IIBU Group28
DIBU Group33
NIBU Group35
IPARA Group16
DPARA Group4
NPARA Group13

Antibody Concentrations Against Cross-reactive Pneumococcal Serotypes 6A and 19A

Anti-pneumococcal serotype 6A and 19A antibody concentrations have been assessed by 22F-inhibition ELISA, presented as geometric mean concentrations (GMCs) and expressed in micrograms per milliliter (μg/mL). The seropositivity cut-off for the assay was an antibody concentration ≥ 0.05 μg/mL. (NCT01235949)
Timeframe: One month after primary immunization (At Month 3)

,,,,,
Interventionμg/mL (Geometric Mean)
Anti-6AAnti-19A
DIBU Group0.180.2
DPARA Group0.120.17
IIBU Group0.170.23
IPARA Group0.110.15
NIBU Group0.150.16
NPARA Group0.190.25

Antibody Concentrations Against Diphteria (D) and Tetanus (T) Toxoids

Anti-D and anti-T antibody concentrations were presented as geometric mean concentrations (GMCs) and expressed in IU/mL. The seroprotection cut-off for the assay was an antibody concentration ≥ 0.1 IU/mL. (NCT01235949)
Timeframe: Prior to (Month 9) and one month after booster vaccination (Month 10)

,,,,,,,,,,,
InterventionIU/mL (Geometric Mean)
Anti-D, M9Anti-D, M10Anti-T, M9Anti-T, M10
DIBU-DIBU Group0.5815.8310.8687.269
DIBU-IIBU Group0.555.9260.6817.092
DIBU-NIBU Group0.6286.4860.6926.522
DPARA-IPARA Group0.5466.4770.6987.431
IIBU-DIBU Group0.5935.2570.7356.887
IIBU-IIBU Group0.7367.4920.8388.03
IIBU-NIBU Group0.6167.570.667.283
IPARA-NPARA Group0.6657.2380.6666.491
NIBU-DIBU Group0.6277.2260.88310.8
NIBU-IIBU Group0.7147.0590.8437.095
NIBU-NIBU Group0.6568.2060.8589.045
NPARA-IPARA Group0.6426.7490.97.423

Antibody Concentrations Against Diphtheria (D) and Tetanus (T) Toxoids

Anti-D and anti-T antibody concentrations were presented as geometric mean concentrations (GMCs) and expressed in international units per milliliter (IU/mL). The seroprotection cut-off for the assay was an antibody concentration ≥ 0.1 IU/mL. (NCT01235949)
Timeframe: One month after primary immunization (Month 3)

,,,,,
InterventionIU/mL (Geometric Mean)
Anti-DAnti-T
DIBU Group2.9383.373
DPARA Group2.8913.058
IIBU Group3.3263.746
IPARA Group3.0622.943
NIBU Group3.1323.961
NPARA Group3.4573.762

Antibody Concentrations Against Hepatitis B Surface Antigen

Antibody concentrations assessed were presented as geometric mean concentrations (GMCs) and expressed in mIU/mL. The seroprotection cut-off for the assay was an antibody concentration ≥ 10 mIU/mL. (NCT01235949)
Timeframe: Prior to (Month 9) and one month after booster vaccination (Month 10)

,,,,,,,,,,,
InterventionmIU/mL (Geometric Mean)
Anti-HBs, M9Anti-HBs, M10
DIBU-DIBU Group225.012492.42
DIBU-IIBU Group136.531685.87
DIBU-NIBU Group194.512107.75
DPARA-IPARA Group199.572003.09
IIBU-DIBU Group210.321898.54
IIBU-IIBU Group197.461949.42
IIBU-NIBU Group164.331970.6
IPARA-NPARA Group128.122078.63
NIBU-DIBU Group244.522579.59
NIBU-IIBU Group226.11851.22
NIBU-NIBU Group159.793244.33
NPARA-IPARA Group209.272218.23

Antibody Concentrations Against Pertussis Toxoid (Anti-PT), Filamentous Haemagglutinin (Anti-FHA) and Pertactin (Anti-PRN)

Antibody concentrations assessed were presented as geometric mean concentrations (GMCs) and expressed in ELISA units per milliliter (EL.U/mL). The seropositivity cut-off for the assay was an antibody concentration ≥ 5 EL.U/mL. (NCT01235949)
Timeframe: One month after primary immunization (Month 3)

,,,,,
InterventionEL.U/mL (Geometric Mean)
Anti-PTAnti-FHAAnti-PRN
DIBU Group64.2171.6114.3
DPARA Group63.1196.5106.2
IIBU Group59.1163.1103.9
IPARA Group60.417197.1
NIBU Group65191.1118.1
NPARA Group61.5168.9114

Antibody Concentrations Against Pertussis Toxoid (Anti-PT), Filamentous Haemagglutinin (Anti-FHA) and Pertactin (Anti-PRN)

Antibody concentrations assessed were presented as geometric mean concentrations (GMCs) and expressed in ELISA units per milliliter (EL.U/mL). The seropositivity cut-off for the assay was an antibody concentration ≥ 5 EL.U/mL. (NCT01235949)
Timeframe: Prior to (Month 9) and one month after booster vaccination (Month 10)

,,,,,,,,,,,
InterventionEL.U/mL (Geometric Mean)
Anti-PT, M9Anti-PT, M10Anti-FHA, M9Anti-FHA, M10Anti-PRN, M9Anti-PRN, M10
DIBU-DIBU Group14.275.559.3322.925.1246.2
DIBU-IIBU Group14.772.353.8359.822.4262.9
DIBU-NIBU Group13.674.857.7332.716184.3
DPARA-IPARA Group10.866.848.5332.919.7214.2
IIBU-DIBU Group12.864.442.6252.716173.5
IIBU-IIBU Group13.373.846.1308.815.7218.6
IIBU-NIBU Group10.556.642.6327.218.3225.9
IPARA-NPARA Group1359.450.832120.1205.1
NIBU-DIBU Group1274.945.7338.618.8255.7
NIBU-IIBU Group12.863.457.9312.319.4226.7
NIBU-NIBU Group15.297.659.1442.827.3330.4
NPARA-IPARA Group14.25752.9294.220.3213.6

Antibody Concentrations Against Polyribosyl-ribitol-phosphate (PRP)

Antibody concentrations assessed were presented as geometric mean concentrations (GMCs) and expressed in µg/mL. The seroprotection cut-off for the assay was an antibody concentration ≥ 0.15 µg/mL. (NCT01235949)
Timeframe: Prior to (Month 9) and one month after booster vaccination (Month 10)

,,,,,,,,,,,
Interventionµg/mL (Geometric Mean)
Anti-PRP, M9Anti-PRP, M10
DIBU-DIBU Group0.84718.987
DIBU-IIBU Group0.82420.28
DIBU-NIBU Group0.76317.544
DPARA-IPARA Group0.65121.602
IIBU-DIBU Group0.68417.484
IIBU-IIBU Group0.87821.964
IIBU-NIBU Group0.67821.277
IPARA-NPARA Group0.69616.682
NIBU-DIBU Group0.7233.45
NIBU-IIBU Group0.79820.659
NIBU-NIBU Group1.01322.083
NPARA-IPARA Group0.95323.277

Antibody Concentrations Against Protein D (Anti-PD)

Anti-PD antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in ELISA units per milliliter (EL.U//mL). The seroprotection cut-off for the assay was an antibody concentration ≥ 100 EL.U/mL. (NCT01235949)
Timeframe: Prior to (Month 9) and one month after booster vaccination (Month 10)

,,,,,,,,,,,
InterventionEL.U/mL (Geometric Mean)
Anti-PD, M9Anti-PD M10
DIBU-DIBU Group5901664.8
DIBU-IIBU Group622.91888.7
DIBU-NIBU Group5021540.7
DPARA-IPARA Group525.41517.3
IIBU-DIBU Group660.41980.1
IIBU-IIBU Group661.62069
IIBU-NIBU Group588.31907.5
IPARA-NPARA Group446.11482.7
NIBU-DIBU Group555.11953.1
NIBU-IIBU Group752.12319.7
NIBU-NIBU Group777.22285.5
NPARA-IPARA Group691.32082.5

Antibody Concentrations Against Vaccine Pneumococcal Serotypes

Anti- pneumococcal serotypes 1, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F antibody concentrations have been assessed by 22F-inhibition ELISA, presented as geometric mean concentrations (GMCs) and expressed in micrograms per milliliter (μg/mL). The seropositivity cut-off for the assay was an antibody concentration greater than or equal to (≥) 0.05 μg/mL. (NCT01235949)
Timeframe: Prior to (Month 9) and one month after booster vaccination (Month 10)

,,,,,,,,,,,
Interventionμg/mL (Geometric Mean)
Anti-1, M9Anti-1, M10Anti-4, M9Anti-4, M10Anti-5, M9Anti-5, M10Anti-6B, M9Anti-6B M10Anti-7F, M9Anti-7F M10Anti-9V, M9Anti-9V M10Anti-14, M9Anti-14 M10Anti-18C M9Anti-18C M10Anti-19F M9Anti-19F M10Anti-23F M9Anti-23F M10Anti-6A, M9Anti-6A M10Anti-19A M9Anti-19A M10
IIBU-NIBU Group0.272.390.553.220.764.110.542.430.894.20.833.941.065.160.967.781.726.910.412.590.251.140.221.05
IPARA-NPARA Group0.311.760.523.270.592.620.431.740.843.890.743.111.184.720.916.181.565.940.472.50.190.810.210.74
NIBU-DIBU Group0.383.040.734.080.843.920.582.321.315.550.923.881.936.561.3911.291.77.260.693.170.280.990.20.93
NIBU-IIBU Group0.442.840.724.040.834.210.562.161.075.431.094.071.66.031.127.151.255.240.613.120.261.030.150.67
NIBU-NIBU Group0.432.840.624.070.964.480.672.511.114.931.094.051.956.31.238.681.97.340.583.330.341.40.280.97
NPARA-IPARA Group0.452.840.844.280.854.330.612.290.974.520.973.91.865.621.318.171.726.660.523.150.240.980.241.11
DIBU-DIBU Group0.422.440.723.630.763.330.622.181.14.361.033.161.75.081.17.161.545.270.52.160.321.090.20.66
DIBU-IIBU Group0.382.690.634.050.783.420.552.131.084.961.033.471.314.541.088.231.585.350.552.930.260.890.240.75
DIBU-NIBU Group0.341.870.643.410.73.370.61.521.093.930.933.071.734.611.037.11.385.570.652.740.320.740.240.95
DPARA-IPARA Group0.32.140.63.310.723.580.431.840.984.630.933.491.535.521.148.661.515.540.432.530.220.870.190.63
IIBU-DIBU Group0.362.230.633.650.833.90.441.970.964.20.833.31.745.621.038.061.666.640.643.080.180.860.231.1
IIBU-IIBU Group0.412.870.714.090.984.50.632.751.335.751.074.461.766.021.139.351.946.90.653.720.311.360.281.11

Antibody Concentrations Against Vaccine Pneumococcal Serotypes

Anti-pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F antibody concentrations have been assessed by 22F-inhibition ELISA, presented as geometric mean concentrations (GMCs) and expressed in micrograms per milliliter (μg/mL). The seropositivity cut-off for the assay was an antibody concentration ≥ 0.05 μg/mL. (NCT01235949)
Timeframe: One month after primary immunization (At Month 3)

,,,,,
Interventionµg/mL (Geometric Mean)
Anti-1Anti-4Anti-5Anti-6BAnti-7FAnti-9VAnti-14Anti-18CAnti-19FAnti-23F
DIBU Group1.712.212.390.762.832.014.523.85.040.92
DPARA Group1.381.952.360.422.451.824.124.085.20.74
IIBU Group1.822.252.930.672.872.14.763.856.111.04
IPARA Group1.321.571.950.492.181.673.443.084.950.77
NIBU Group1.92.212.770.62.772.184.774.344.961.07
NPARA Group1.952.593.050.722.952.45.174.966.981

Antibody Titers Against Poliovirus Type 1, 2 and 3

Antibody titers assessed were presented as geometric mean titers (GMTs). The seroprotection cut-off for the assay was a titer ≥ the value of 8. (NCT01235949)
Timeframe: One month after primary immunization (Month 3)

,,,,,
InterventionTiters (Geometric Mean)
Anti-Polio 1Anti-Polio 2Anti-Polio 3
DIBU Group252.5327.4351.3
DPARA Group166394.8394.8
IIBU Group283.4362423.2
IPARA Group225.6240.7284
NIBU Group337378624.1
NPARA Group449.3335.2438.6

Antibody Titers Against Poliovirus Type 1, 2 and 3

Antibody titers assessed were presented as geometric mean titers (GMTs). The seroprotection cut-off for the assay was a titer ≥ the value of 8. (NCT01235949)
Timeframe: Prior to (Month 9) and one month after booster vaccination (Month 10)

,,,,,,,,,,,
InterventionTiters (Geometric Mean)
Anti-Polio 1, M9Anti-Polio 1, M10Anti-Polio 2, M9Anti-Polio 2, M10Anti-Polio 3, M9Anti-Polio 3, M10
DIBU-DIBU Group45.438841.7512.545.3588.1
DIBU-IIBU Group145.71824.5292.12151.9205.43649.1
DIBU-NIBU Group32.1543.98542.445.21152.5
DPARA-IPARA Group128.31448.1139.61625.4108.11625.4
IIBU-DIBU Group85.9790.760.81217.7861724.5
IIBU-IIBU Group561378.2120.8194972861
IIBU-NIBU Group80.9429.948.3548.7127.8359.5
IPARA-NPARA Group53.81290.129.72047.996.52195
NIBU-DIBU Group53.74119.6434.1139.6724.1
NIBU-IIBU Group67.11217.7134.81217.770558.3
NIBU-NIBU Group141.21075.9156.11393.41282233.3
NPARA-IPARA Group117.4861.1168.91116.669.72048

Number of Subjects With Antibody Concentrations Against Vaccine Pneumococcal Serotypes Greater Than or Equal to (≥) the Cut-off

Antibodies against the vaccine pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (Anti-1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F) have been assessed by 22F-inhibition enzyme-linked immunosorbent assay (ELISA). The cut-off value of the assay was an antibody concentration greater than or equal to (≥) 0.2 micrograms per milliliter (μg/mL). (NCT01235949)
Timeframe: One month after primary immunization (At Month 3)

,,,,,
InterventionParticipants (Count of Participants)
Anti-1Anti-4Anti-5Anti-6BAnti-7FAnti-9VAnti-14Anti-18CAnti-19FAnti-23F
DIBU Group155155154135157153153153152141
DPARA Group50515037555050505043
IIBU Group144145143121153144144143145136
IPARA Group52535342555353525347
NIBU Group160158156133164155154155157149
NPARA Group55565448565353545450

Number of Subjects With Any and Grade 3 Solicited Local Symptoms

Solicited local symptoms assessed were pain, redness and swelling. Any = incidence of any local symptom regardless of intensity grade. Grade 3 pain = cried when limb was moved/spontaneously painful. Grade 3 redness/swelling = redness/swelling above 30 millimeters (mm). (NCT01235949)
Timeframe: Within the 4-day (Days 0-3) period following booster vaccination

,,,,,,,,,,,
InterventionParticipants (Count of Participants)
Any PainGrade 3 PainAny RednessGrade 3 RednessAny SwellingGrade 3 Swelling
DIBU-DIBU Group16115161
DIBU-IIBU Group222230160
DIBU-NIBU Group252220110
DPARA-IPARA Group244230120
IIBU-DIBU Group223251160
IIBU-IIBU Group250270160
IIBU-NIBU Group15017090
IPARA-NPARA Group234230170
NIBU-DIBU Group321255182
NIBU-IIBU Group284233160
NIBU-NIBU Group284230150
NPARA-IPARA Group241232160

Number of Subjects With Any and Grade 3 Solicited Local Symptoms

Solicited local symptoms assessed were pain, redness and swelling. Any = incidence of any local symptom regardless of intensity grade. Grade 3 pain = cried when limb was moved/spontaneously painful. Grade 3 redness/swelling = redness/swelling above 30 millimeters (mm). (NCT01235949)
Timeframe: Within the 4-day (Days 0-3) post-primary vaccination period following each dose and across doses

,,,,,
InterventionParticipants (Count of Participants)
Any Pain, Dose 1Grade 3 Pain, Dose 1Any Redness, Dose 1Grade 3 Redness, Dose 1Any Swelling, Dose 1Grade 3 Swelling, Dose 1Any Pain, Dose 2Grade 3 Pain, Dose 2Any Redness, Dose 2Grade 3 Redness, Dose 2Any Swelling, Dose 2Grade 3 Swelling, Dose 2Any Pain, Dose 3Grade 3 Pain, Dose 3Any Redness, Dose 3Grade 3 Redness, Dose 3Any Swelling, Dose 3Grade 3 Swelling, Dose 3Any Pain, Across dosesGrade 3 Pain, Across dosesAny Redness, Across dosesGrade 3 Redness, Across dosesAny Swelling, Across dosesGrade 3 Swelling, Across doses
DIBU Group482520220492590330483630320767890510
DPARA Group28219071220230111211252120373352171
IIBU Group4437412916017313115027023619251084613
IPARA Group212240100192240101181280160305360201
NIBU Group788771280676720310524560300107151051570
NPARA Group337320110251312122221272132447462192

Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms

Solicited general symptoms included drowsiness, irritability, loss of appetite and fever [rectally, greater than or equal to (≥) 38 degrees Celsius (°C)]. Any= incidence of any symptom regardless of intensity grade or relationship to vaccination. Grade 3 drowsiness = drowsiness that interfered with normal activity. Grade 3 irritability = crying that could not be comforted/ prevented normal activity. Grade 3 loss of appetite = not eating at all. Grade 3 fever = fever above (>) 40.0°C. Related = symptom assessed by the investigator as related to the vaccination. (NCT01235949)
Timeframe: Within the 4-day (Days 0-3) period following booster vaccination

,,,,,,,,,,,
InterventionParticipants (Count of Participants)
Any DrowsinessGrade 3 DrowsinessRelated DrowsinessAny IrritabilityGrade 3 IrritabilityRelated IrritabilityAny Loss of appetiteGrade 3 Loss of appetiteRelated Loss of appetiteAny FeverGrade 3 FeverRelated Fever
DIBU-DIBU Group909260201511519118
DIBU-IIBU Group1911322313121919017
DIBU-NIBU Group21017273231901720018
DPARA-IPARA Group1601322320101614013
IIBU-DIBU Group18113273181601121017
IIBU-IIBU Group18115331221401122020
IIBU-NIBU Group170132311390415012
IPARA-NPARA Group121102621890821018
NIBU-DIBU Group24018330262401923019
NIBU-IIBU Group22017363272131920018
NIBU-NIBU Group24221323271411228024
NPARA-IPARA Group19016270161701318016

Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms

Solicited general symptoms included drowsiness, irritability, loss of appetite and fever [rectally, greater than or equal to (≥) 38 degrees Celsius (°C)]. Any= incidence of any symptom regardless of intensity grade or relationship to vaccination. Grade 3 drowsiness = drowsiness that interfered with normal activity. Grade 3 irritability = crying that could not be comforted/ prevented normal activity. Grade 3 loss of appetite = not eating at all. Grade 3 fever = fever above (>) 40.0°C. Related = symptom assessed by the investigator as related to the vaccination. (NCT01235949)
Timeframe: Within the 4-day (Days 0-3) post-primary vaccination period following each dose and across doses

,,,,,
InterventionParticipants (Count of Participants)
Any Drowsiness, Dose 1Grade 3 Drowsiness, Dose 1Related Drowsiness, Dose 1Any Irritability, Dose 1Grade 3 Irritability, Dose 1Related Irritability, Dose 1Any Loss appetite, Dose 1Grade 3 Loss appetite, Dose 1Related Loss appetite, Dose 1Any Fever, Dose 1Grade 3 Fever, Dose 1Related Fever, Dose 1Any Drowsiness, Dose 2Grade 3 Drowsiness, Dose 2Related Drowsiness, Dose 2Any Irritability, Dose 2Grade 3 Irritability, Dose 2Related Irritability, Dose 2Any Loss appetite, Dose 2Grade 3 Loss appetite, Dose 2Related Loss appetite, Dose 2Any Fever, Dose 2Grade 3 Fever, Dose 2Related Fever, Dose 2Any Drowsiness, Dose 3Grade 3 Drowsiness, Dose 3Related Drowsiness, Dose 3Any Irritability, Dose 3Grade 3 Irritability, Dose 3Related Irritability, Dose 3Any Loss appetite, Dose 3Grade 3 Loss appetite, Dose 3Related Loss appetite, Dose 3Any Fever, Dose 3Grade 3 Fever, Dose 3Related Fever, Dose 3Any Drowsiness, Across dosesGrade 3 Drowsiness, Across dosesRelated Drowsiness, Across dosesAny Irritability, Across dosesGrade 3 Irritability, Across dosesRelated Irritability, Across dosesAny Loss appetite, Across dosesGrade 3 Loss appetite, Across dosesRelated Loss appetite, Across dosesAny Fever, Across dosesGrade 3 Fever, Across dosesRelated Fever, Across doses
DIBU Group783478334954035730566604188558550415504950035685484113031027111372121128298168101084
DPARA Group280173411619111110815012311221108150108052121290770533022434282411627018
IIBU Group713429146151032810586424079356520377606162140743484202646038115677120108684056121090
IPARA Group3312027318110880628016301201207140111801217110905120740126404282401623018
NIBU Group10136510967671043850686324389564471286905545030772574232642035123487138121041003641220101
NPARA Group36124433273212030023251153712522014241191601129017161121401245232594404223040131

Opsonophagocytic Activity (OPA) Titers Against Vaccine Pneumococcal Serotypes

"OPA titers against pneumococcal serotypes (Opsono-1, -4, -5, -6A, -6B, -7F, -9V, -14, -18C, -19A, -19F and -23F) were presented as geometric mean titers (GMTs). The seropositivity cut-off for the assay was ≥ 8. When the number of subjects in a group for a specific category equals (=) 1, the lower limit and upper limit of the confidence interval that can't be calculated, are filled in with the GMT value (due to system constraint). Placeholder value 99999.9 has been entered when value to be entered in the system was greater than (>) 1.0 E10." (NCT01235949)
Timeframe: Prior to (Month 9) and one month after booster vaccination (Month 10)

,,,,,,,,,,,
InterventionTiters (Geometric Mean)
OPSONO-1, M9OPSONO-1, M10OPSONO-4, M9OPSONO-4, M10OPSONO-5, M9OPSONO-5, M10OPSONO-6B, M9OPSONO-6B, M10OPSONO-7F, M9OPSONO-7F, M10OPSONO-9V, M9OPSONO-9V, M10OPSONO-14, M9OPSONO-14, M10OPSONO-18C, M9OPSONO-18C, M10OPSONO-19F, M9OPSONO-19F, M10OPSONO-23F, M9OPSONO-23F, M10OPSONO-6A, M9OPSONO-6A, M10OPSONO-19A, M9OPSONO-19A, M10
IPARA-NPARA Group6120.625.9548.35.742.2127.7431.51290.911414.1567.4856.698.3557.56.5149.911163.389.429746.7154444.3
NIBU-DIBU Group40.2546.252.41149.812.7128.913.7173.111523565.8282.12919.8255.9935.39.4707.924.2273.930.53682.734.1106.94253
NIBU-IIBU Group7.3388.298.11953.47.699.516.4237.6256314362.41075.24218.92951498.131.9428.615572.7499.74249.123.398.14125.7
NIBU-NIBU Group10.762715.21414.19.8184.6182.51047.81263.55829.11571.38601.7382.638175.5481.353.2250.615.61464.158.3120412.8
NPARA-IPARA Group15.7887.6161.8854.422.2149.7239376.51744.77567.3738.71340.1195.4587.514242.748.451137.7875.224.578.54541.6
IIBU-NIBU Group4316.442213.48.2241.784.3769.11762.512162.6649.44756.147.24426.642394.788.52575.222.22792.913.4318.4421.2
DIBU-DIBU Group50.6248407.61037.517.5114.1289.4553.15343.29941.81423.63772.9791.7200221.9650.617.71040.71342096.1224.874.57.429.8
DIBU-IIBU Group50.315892096.7197913.3694.21729.9117411302.74190.8737.11507.611.5397.39.7637.129.72977.7239.5581.1428
DIBU-NIBU Group9.9344.474.21096.710.8165.8208.91021.63522.85744.51081.94970.9539.21312.410.9298.167.81575396.63530.199169.24325.4
DPARA-IPARA Group12.2736.356.31885.97.4125.3105.6904.32256.221670480.97262.2260.7228819.1888.942.31215.3274.51436.284159.19.1416.5
IIBU-DIBU Group4296.380.2865.89.293.3237.2606.21777.34591.41283.87041.7255.1671.47.2207.332.1330.5132.42381.545.1125.444
IIBU-IIBU Group5.8346.234928.112.9131.896.1745.6207616259.98304969149.21592.97.2912.9631112.927.958139.8183.74363.7

Opsonophagocytic Activity (OPA) Titers Against Vaccine Pneumococcal Serotypes

OPA titers against pneumococcal serotypes 1, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F (Opsono-1, -4, -5, -6A, -6B, -7F, -9V, -14, -18C, -19A, -19F and -23F) were presented as geometric mean titers (GMTs). The seropositivity cut-off for the assay was an antibody titer ≥ 8. (NCT01235949)
Timeframe: One month after primary immunization (Month 3)

,,,,,
InterventionTiters (Geometric Mean)
OPSONO-1OPSONO-4OPSONO-5OPSONO-6BOPSONO-7FOPSONO-9VOPSONO-14OPSONO-18COPSONO-19FOPSONO-23FOPSONO-6AOPSONO-19A
DIBU Group67.91172.352.4882.44977.94040.41219.7167.6514.81105.5151.146.1
DPARA Group941712.470.7140.37306.43777.11780.5382.7254.272334.239.7
IIBU Group69.4131186.67238827.73429.21346.3186.9536.2989.87916.6
IPARA Group23684.838.7739.98362.75520.1591.591.6501.11188.4100.711.2
NIBU Group75.91027.774.3361.36444.82744.21417.9135.9267.9129626.420.4
NPARA Group64.4777.280.8237.16286.12273.21460.1106272.1838.444.511.4

Change From Baseline in Temperature After the First 30 Minutes of Treatment

Change in temperature in patients receiving intravenous ibuprofen and acetaminophen (APAP) after the first 30 minutes of treatment. (NCT01002573)
Timeframe: 30 minutes following treatment

InterventionCelsius (Mean)
Ibuprofen-0.5
Acetaminophen-0.3

Change From Baseline in Temperature After the First 60 Minutes of Treatment

Change in temperature in patients receiving intravenous ibuprofen and APAP after the first 60 minutes of treatment. (NCT01002573)
Timeframe: 60 minutes following treatment

InterventionCelsius (Mean)
Ibuprofen-0.9
Acetaminophen-0.5

Change From Baseline in Temperature After the First Four Hours of Treatment

Change in temperature during the first 4 hours of treatment by assessing the area under the change in temperature versus time curve during the first four hours of treatment (AUC0-4) (NCT01002573)
Timeframe: 0 to 4 hours post-dose

Interventiondegree Celsius*Time (Mean)
Ibuprofen-4.4
Acetaminophen-2.6

Change in Temperature

Change in temperature in patients receiving intravenous ibuprofen and APAP after the first 4 hours of treatment. (NCT01002573)
Timeframe: 4 hours following treatment

InterventionCelsius (Mean)
Ibuprofen-1.5
Acetaminophen-0.9

Fever Reduction

Treatment of fever as measured by the area under the change in temperature versus time curve during the first two hours of treatment (AUC0-2) (NCT01002573)
Timeframe: 0 to 2 hours post-dose

Interventiondegree Celsius*Time (Mean)
Ibuprofen-1.5
Acetaminophen-0.9

Time to Afebrility (in Hours)

Tme to afebrility (temperature less than 100.4 ºF [38 ºC]) in patients receiving intravenous ibuprofen and APAP. (NCT01002573)
Timeframe: 4 Hour post treatment

InterventionHours (Mean)
Ibuprofen2.2
Acetaminophen3.3

Number of Afebrile and Febrile Subject at 4 Hours Post-Dose

Number of Afebrile and Febrile Subject at 4 Hours Following Treatment (NCT01002573)
Timeframe: 4 Hours Post-Dose

,
Interventionparticipants (Number)
Afebrile Subjects at 4 hoursFebrile at 4 Hours
Acetaminophen4011
Ibuprofen433

Geometric Mean Concentration (GMC) for Antigen-specific Haemophilus Influenzae Type b (Hib) Polyribosylribitol Phosphate (PRP) Antibody 1 Month After the Infant Series

Geometric LS mean concentrations (GMCs) and corresponding 2-sided 95% CIs were evaluated for Hib PRP antibody. (NCT01392378)
Timeframe: 1 month after the infant series

Interventionmcg/mL (Geometric Mean)
13vPnC + INFANRIX Hexa + Paracetamol Twice Daily0.54
13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily0.59
13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily0.49
13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily0.51
13vPnC + INFANRIX Hexa0.58

Geometric Mean Concentration (GMC) for Antigen-specific Haemophilus Influenzae Type b (Hib) Polyribosylribitol Phosphate (PRP) Antibody 1 Month After the Toddler Dose

Geometric LS mean concentration (GMCs) were measured in mcg/mL and corresponding 2-sided 95% CIs were evaluated for Hib PRP antibody. (NCT01392378)
Timeframe: 1 month after the toddler dose

Interventionmcg/mL (Geometric Mean)
13vPnC + INFANRIX Hexa + Paracetamol Twice Daily9.65
13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily9.35
13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily8.25
13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily7.84
13vPnC + INFANRIX Hexa8.96

Geometric Mean Concentration (GMC) for Antigen-specific Hepatitis B Virus (HBV) Antibody 1 Month After the Infant Series

Geometric LS mean concentration (GMCs) were measured in milli international units/mL (mIU/mL) and corresponding 2-sided 95% CIs were evaluated for hepatitis B virus (HBV) antibody. (NCT01392378)
Timeframe: 1 month after the infant series

InterventionmIU/mL (Geometric Mean)
13vPnC + INFANRIX Hexa + Paracetamol Twice Daily756.42
13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily770.93
13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily689.34
13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily599.12
13vPnC + INFANRIX Hexa733.29

Geometric Mean Concentration (GMC) for Antigen-specific Hepatitis B Virus (HBV) Antibody 1 Month After the Toddler Dose

Geometric LS mean concentration (GMCs) were measured in mIU/mL and corresponding 2-sided 95% CIs were evaluated for hepatitis B virus (HBV) antibody. (NCT01392378)
Timeframe: 1 month after the toddler dose

InterventionmIU/mL (Geometric Mean)
13vPnC + INFANRIX Hexa + Paracetamol Twice Daily4868.61
13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily4148.04
13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily4250.41
13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily4263.28
13vPnC + INFANRIX Hexa3866.37

Geometric Mean Concentration (GMC) for Antigen-specific Pertussis Toxin (PT), Filamentous Hemagglutinin (FHA) and Pertactin (PRN) Antibodies 1 Month After the Toddler Dose

Geometric LS mean concentration (GMCs) were measured in EU/mL and corresponding 2-sided 95% CIs were evaluated for pertussis (pertussis toxin [PT], filamentous hemagglutinin [FHA] and pertactin [PRN]) antibodies. (NCT01392378)
Timeframe: 1 month after the toddler dose

,,,,
InterventionEU/mL (Geometric Mean)
Pertussis PTPertussis FHAPertussis PRN
13vPnC + INFANRIX Hexa74.01117.01172.80
13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily73.38108.11158.71
13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily76.93117.87156.98
13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily73.72123.56160.96
13vPnC + INFANRIX Hexa + Paracetamol Twice Daily77.43115.55158.28

Geometric Mean Concentration (GMC) for Antigen-specific Pertussis Toxin (PT), Filamentous Hemagglutinin (FHA) and Pertactin (PRN) Antibody 1 Month After the Infant Series

Geometric LS mean concentration (GMCs) were measured in Enzyme-linked Immunosorbent Assay (ELISA) units/mL (EU/mL) and corresponding 2-sided 95% CIs were evaluated for pertussis (pertussis toxin [PT], filamentous hemagglutinin [FHA] and pertactin [PRN]) antibodies. (NCT01392378)
Timeframe: 1 month after the infant series

,,,,
InterventionEU/mL (Geometric Mean)
Pertussis PTPertussis FHAPertussis PRN
13vPnC + INFANRIX Hexa44.8548.4284.57
13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily39.2635.5568.53
13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily43.5140.6571.26
13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily40.2741.3265.82
13vPnC + INFANRIX Hexa + Paracetamol Twice Daily40.8646.2972.90

Geometric Mean Concentration (GMC) for Antigen-specific Tetanus and Diphtheria Antibodies 1 Month After the Toddler Dose

Geometric LS mean concentration (GMCs) were measured in IU/mL and corresponding 2-sided 95% CIs were evaluated for tetanus and diphtheria antibodies. (NCT01392378)
Timeframe: 1 month after the toddler dose

,,,,
InterventionIU/mL (Geometric Mean)
TetanusDiphtheria
13vPnC + INFANRIX Hexa2.661.90
13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily2.291.87
13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily2.501.94
13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily2.601.69
13vPnC + INFANRIX Hexa + Paracetamol Twice Daily2.541.64

Geometric Mean Concentration (GMC) for Antigen-specific Tetanus and Diphtheria Antibody 1 Month After the Infant Series

Geometric LS mean concentration (GMCs) were measured in International Units/mL (IU/mL) and corresponding 2-sided 95% CIs were evaluated for tetanus and diphtheria antibodies. (NCT01392378)
Timeframe: 1 month after the infant series

,,,,
InterventionIU/mL (Geometric Mean)
TetanusDiphtheria
13vPnC + INFANRIX Hexa0.820.65
13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily0.600.65
13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily0.700.68
13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily0.690.61
13vPnC + INFANRIX Hexa + Paracetamol Twice Daily0.730.62

Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After the Infant Series

Antibody geometric least squares (LS) mean concentrations (GMCs) for 13 pneumococcal serotypes (4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95 percent (%) confidence interval (CI) were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw. Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies participants with a determinate IgG concentration to the given serotype for each arm, respectively. (NCT01392378)
Timeframe: 1 month after the infant series

,,,,
Interventionmicrogram per milliliter (mcg/mL) (Geometric Mean)
4 (n = 137, 155, 148, 146, 210)6B (n = 136, 155, 148, 146, 210)9V (n = 138, 155, 148, 147, 210)14 (n = 138, 155, 148, 147, 210)18C (n = 138, 155, 148, 147, 210)19F (n = 138, 155, 148, 147, 210)23F (n= 137, 155, 148, 146, 210)1 (n = 138, 155, 148, 147, 210)3 (n = 138, 155, 148, 147, 210)5 (n = 137, 155, 148, 146, 210)6A (n = 138, 155, 148, 146, 210)7F (n = 138, 155, 148, 146, 210)19A (n = 137, 155, 148, 146, 210)
13vPnC + INFANRIX Hexa2.020.811.315.381.541.991.041.250.880.811.102.153.02
13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily2.070.901.405.261.752.041.071.290.840.901.222.283.14
13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily1.990.911.454.731.732.301.191.500.830.981.252.223.39
13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily1.480.561.174.751.251.590.731.020.570.630.851.832.53
13vPnC + INFANRIX Hexa + Paracetamol Twice Daily1.640.681.134.451.471.780.851.120.710.790.971.942.70

Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After the Toddler Dose

Antibody geometric LS mean concentrations (GMCs) for 13 pneumococcal serotypes (4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% CI were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw. Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies participants with a determinate IgG concentration to the given serotype for each arm respectively. (NCT01392378)
Timeframe: 1 month after the toddler dose

,,,,
Interventionmcg/mL (Geometric Mean)
4 (n = 130, 144, 143, 139, 206)6B (n = 130, 144, 143, 139, 206)9V (n = 130, 144, 143, 139, 206)14 (n = 130, 144, 143, 139, 206)18C (n = 130, 144, 143, 139, 206)19F (n = 130, 144, 143, 139, 206)23F (n = 130, 144, 142, 139, 206)1 (n = 130, 144, 143, 139, 206)3 (n = 129, 144, 143, 138, 203)5 (n = 130, 144, 143, 139, 206)6A (n = 130, 144, 143, 139, 206)7F (n = 130, 144, 142, 139, 206)19A (n = 129, 144, 142, 139, 206)
13vPnC + INFANRIX Hexa3.107.082.169.101.597.952.753.040.542.845.523.987.71
13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily3.437.302.129.121.638.022.863.120.492.625.363.977.35
13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily3.438.012.238.401.688.992.963.220.542.755.733.897.99
13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily2.976.382.177.951.367.532.372.660.462.405.273.567.31
13vPnC + INFANRIX Hexa + Paracetamol Twice Daily3.076.702.158.101.358.412.342.800.462.335.123.797.11

Geometric Mean Titer (GMT) for Antigen-specific Poliomyelitis Type 1, 2 and 3 Antibodies 1 Month After the Infant Series

Geometric LS mean concentrations (GMCs) were measured as titers and corresponding 2-sided 95% CIs were evaluated for poliomyelitis type 1, 2 and 3 antibodies. (NCT01392378)
Timeframe: 1 month after the infant series

,,,,
Interventiontiter (Geometric Mean)
Poliomyelitis Type 1Poliomyelitis Type 2Poliomyelitis Type 3
13vPnC + INFANRIX Hexa72.0267.37231.02
13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily70.6655.17218.85
13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily66.5973.52184.03
13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily67.4362.12257.92
13vPnC + INFANRIX Hexa + Paracetamol Twice Daily68.1179.60246.22

Geometric Mean Titer (GMT) for Antigen-specific Poliomyelitis Type 1, 2 and 3 Antibodies 1 Month After the Toddler Dose

Geometric LS mean concentration (GMCs) were measured as titers and corresponding 2-sided 95% CIs were evaluated for poliomyelitis type 1, 2 and 3 antibodies. (NCT01392378)
Timeframe: 1 month after the toddler dose

,,,,
Interventiontiter (Geometric Mean)
Poliomyelitis Type 1Poliomyelitis Type 2Poliomyelitis Type 3
13vPnC + INFANRIX Hexa406.37621.071237.86
13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily415.45605.781187.11
13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily426.63586.301045.57
13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily443.97587.561210.29
13vPnC + INFANRIX Hexa + Paracetamol Twice Daily399.56613.181205.80

Geometric Mean Titer (GMT) for Serotype-specific Pneumococcal Opsonophagocytic Activity (OPA) 1 Month After the Infant Series

Antibody-mediated serum OPA against the 13 pneumococcal serotypes (4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F and 19A) was measured centrally using a pneumococcal OPA assay. Results were expressed as OPA titers. OPA titers were logarithmically transformed for analysis; geometric means calculated and expressed as geometric mean titers (GMTs). (NCT01392378)
Timeframe: 1 month after the infant series

,,,,
Interventiontiter (Geometric Mean)
4 (n = 37, 46, 42, 41, 61)6B (n = 36, 45, 43, 40, 62)9V (n = 37, 48, 42, 41, 65)14 (n = 38, 48, 41, 41, 64)18C (n = 37, 47, 41, 41, 62)19F (n = 37, 46, 41, 42, 63)23F (n = 38, 45, 42, 42, 63)1 (n = 42, 42, 43, 44, 74)3 (n = 41, 41, 39, 39, 69)5 (n = 42, 43, 44, 42, 73)6A (n = 46, 42, 39, 39, 76)7F (n = 46, 42, 40, 39, 76)19A (n = 42, 44, 41, 42, 74)
13vPnC + INFANRIX Hexa1086748241951109227936612877614622125240
13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily136166328599110312943218629912811584159
13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily113565516662285322144111769616811907257
13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily1240470936508771653328565412281747163
13vPnC + INFANRIX Hexa + Paracetamol Twice Daily1269794120435109434634212728610601766185

Number of Participants With Non-Serious Adverse Events (AEs) and Serious Adverse Events (SAEs): After the Infant Series

An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. SAE: an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent events after the infant series were events between 1 month (28 to 42 days) after infant series to toddler dose that were absent before treatment or that worsened relative to pre-treatment state. Reported non-SAEs included AEs other than SAEs spontaneously collected on case report form (non-systematic assessment). (NCT01392378)
Timeframe: 1 Month (28 to 42 days) after infant series Dose 3 up to toddler dose

,,,,
Interventionparticipants (Number)
Non-SAEsSAEs
13vPnC + INFANRIX Hexa89
13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily411
13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily614
13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily310
13vPnC + INFANRIX Hexa + Paracetamol Twice Daily36

Number of Participants With Non-Serious Adverse Events (AEs) and Serious Adverse Events (SAEs): Infant Series

An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. SAE: an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent events for infant series were events between infant series Dose 1 and up to 1 month (28 to 42 days) after infant series that were absent before treatment or that worsened relative to pre-treatment state. Reported non-SAEs included AEs other than SAEs collected using electronic diary (fever, systematic assessment) and events spontaneously collected on case report form at each visit (non-systematic assessment). (NCT01392378)
Timeframe: Baseline up to 1 Month (28 to 42 days) after infant series

,,,,
Interventionparticipants (Number)
Non-SAEsSAEs
13vPnC + INFANRIX Hexa8010
13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily728
13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily713
13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily6711
13vPnC + INFANRIX Hexa + Paracetamol Twice Daily577

Number of Participants With Non-Serious Adverse Events (AEs) and Serious Adverse Events (SAEs): Toddler Dose

An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. SAE: an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent events for toddler dose were events between toddler dose and up to 1 month (28 to 42 days) after toddler dose that were absent before treatment or that worsened relative to pre-treatment state. Reported non-SAEs included AEs other than SAEs collected using electronic diary (fever, systematic assessment) and events spontaneously collected on case report form at each visit (non-systematic assessment). (NCT01392378)
Timeframe: Toddler dose up to 1 Month (28 to 42 days) after toddler dose

,,,,
Interventionparticipants (Number)
Non-SAEsSAEs
13vPnC + INFANRIX Hexa501
13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily761
13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily572
13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily521
13vPnC + INFANRIX Hexa + Paracetamol Twice Daily473

Percentage of Participants Achieving Pre-specified Criteria for the Concomitant Antigens Contained in INFANRIX Hexa 1 Month After the Infant Series

Percentage of participants achieving pre-specified criteria for concomitant antigens contained in INFANRIX hexa (Hib polyribosylribitol phosphate [PRP] >=0.15 mcg/mL; Hib PRP >=1 mcg/mL; Pertussis PT >=14.6 EU/mL, FHA >=16.1 EU/mL, PRN >=24.0 EU/mL; Tetanus >=0.1 IU/mL; Diphtheria >=0.1 IU/mL; HBV >=10 mIU/mL; Poliomyelitis Type 1, 2, 3 >=1:8 titer) along with the corresponding 95% CIs were presented. Exact 2-sided CI based on the observed proportion of participants. Pre-specified criteria for pertussis was the level that 95% of the participants achieved in 13vPnC + INFANRIX hexa group. (NCT01392378)
Timeframe: 1 month after the infant series

,,,,
Interventionpercentage of participants (Number)
Hib PRP >=0.15 mcg/mL (n= 136, 146, 144, 139, 198)Hib PRP >=1 mcg/mL (n = 136, 146, 144, 139, 198)Pertussis PT >=14.6 EU/mL (n= 132,143,141,131,193)Pertussis FHA >=16.1 EU/mL (n=132,143,141,131,193)Pertussis PRN >=24.0 EU/mL (n=132,143,141,131,193)Tetanus >=0.1 IU/mL (n = 132,143,141,131,193)Diphtheria >=0.1 IU/mL (n = 132,143,141,131,193)HBV >= 10mIU/mL (n = 105,116,120,112,156)PoliomyelitisType1 >=1:8titer (n=89,105,93,84,135)PoliomyelitisType2 >=1:8titer (n=89,105,93,84,135)PoliomyelitisType3 >=1:8titer (n=89,105,93,84,135)
13vPnC + INFANRIX Hexa87.933.895.395.395.399.599.598.799.395.699.3
13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily85.628.190.888.589.398.597.799.1100.096.498.8
13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily84.237.097.292.387.4100.098.699.198.198.1100.0
13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily86.127.191.593.688.7100.099.399.297.895.798.9
13vPnC + INFANRIX Hexa + Paracetamol Twice Daily87.533.893.296.290.9100.0100.0100.097.895.5100.0

Percentage of Participants Achieving Pre-specified Criteria for the Concomitant Antigens Contained in INFANRIX Hexa 1 Month After the Toddler Dose

Percentage of participants achieving pre-specified criteria for concomitant antigens contained in INFANRIX hexa (Hib polyribosylribitol phosphate [PRP] >=0.15 mcg/mL; Hib PRP >=1 mcg/mL; Pertussis PT >=14.8 EU/mL, FHA >=46.5 EU/mL, PRN >=43.5 EU/mL; Tetanus >=0.1 IU/mL; Diphtheria >=0.1 IU/mL; HBV >=10 mIU/mL; Poliomyelitis Type 1, 2, 3 >=1:8 titer) along with the corresponding 95% CIs were presented. Exact 2-sided CI based on the observed proportion of participants. Pre-specified criteria for pertussis was the level that 95% of the participants achieved in 13vPnC + INFANRIX hexa group. (NCT01392378)
Timeframe: 1 month after the toddler dose

,,,,
Interventionpercentage of participants (Number)
Hib PRP >=0.15 mcg/mL (n= 126, 135, 141, 138, 202)Hib PRP >=1 mcg/mL (n = 126, 135, 141, 138, 202)Pertussis PT >=14.8 EU/mL (n= 123,137,141,136,199)Pertussis FHA >=46.5 EU/mL (n=123,137,141,136,199)Pertussis PRN >=43.5 EU/mL (n=123,137,141,136,199)Tetanus >=0.1 IU/mL (n = 123,137,141,136,199)Diphtheria >=0.1 IU/mL (n = 123,137,141,136,199)HBV >= 10 mIU/mL (n = 119,131,133,133,191)Poliomyelitis 1 >=1:8titer (n=123,133,141,136,201)Poliomyelitis 2 >=1:8titer (n=123,133,141,136,201)Poliomyelitis 3 >=1:8titer (n=123,133,141,136,201)
13vPnC + INFANRIX Hexa100.095.095.595.595.5100.0100.099.599.5100.0100.0
13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily100.095.7100.092.694.1100.0100.0100.0100.0100.0100.0
13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily99.396.399.394.994.9100.0100.098.5100.0100.0100.0
13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily100.095.798.693.694.3100.0100.0100.0100.0100.0100.0
13vPnC + INFANRIX Hexa + Paracetamol Twice Daily100.095.297.691.191.9100.0100.0100.099.2100.0100.0

Percentage of Participants Achieving Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Level Greater Than or Equal to (>=)0.35 Microgram Per Milliliter (Mcg/mL) 1 Month After the Infant Series

Percentage of participants achieving predefined antibody threshold >=0.35 mcg/mL along with the corresponding 95% confidence interval (CI) for 13 pneumococcal serotypes (4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants. (NCT01392378)
Timeframe: 1 month after the infant series

,,,,
Interventionpercentage of participants (Number)
4 (n = 137, 155, 148, 146, 210)6B (n = 136, 155, 148, 146, 210)9V (n = 138, 155, 148, 147, 210)14 (n = 138, 155, 148, 147, 210)18C (n = 138, 155, 148, 147, 210)19F (n = 138, 155, 148, 147, 210)23F (n = 137, 155, 148, 146, 210)1 (n = 138, 155, 148, 147, 210)3 (n = 138, 155, 148, 147, 210)5 (n = 137, 155, 148, 146, 210)6A (n = 138, 155, 148, 146, 210)7F (n = 138, 155, 148, 146, 210)19A (n = 137, 155, 148, 146, 210)
13vPnC + INFANRIX Hexa98.177.696.299.596.797.688.194.391.084.391.999.5100.0
13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily97.379.595.998.695.996.688.494.688.489.791.8100.099.3
13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily97.480.099.498.797.499.490.397.489.791.092.399.499.4
13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily96.661.595.999.395.395.374.390.581.176.483.197.398.0
13vPnC + INFANRIX Hexa + Paracetamol Twice Daily96.472.894.2100.096.497.186.194.283.384.786.2100.098.5

Percentage of Participants Achieving Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Titers Greater Than or Equal to (>=) Lower Limit of Quantitation (LLOQ) 1 Month After the Infant Series

Percentage of participants achieving serotype-specific pneumococcal OPA titer >= LLOQ, along with the corresponding 95% CIs for 13 pneumococcal serotypes (4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants. The OPA LLOQ in titers for each serotype: 1 = 1:18; 3 = 1:12; 4 = 1:21; 5 = 1:29; 6A = 1:37; 6B = 1:43; 7F = 1:210; 9V = 1:345; 14 = 1:35; 18C = 1:31; 19A = 1:18; 19F = 1:48; 23F = 1:13. (NCT01392378)
Timeframe: 1 month after the infant series

,,,,
Interventionpercentage of participants (Number)
4 (n = 37, 46, 42, 41, 61)6B (n = 36, 45, 43, 40, 62)9V (n = 37, 48, 42, 41, 65)14 (n = 38, 48, 41, 41, 64)18C (n = 37, 47, 41, 41, 62)19F (n = 37, 46, 41, 42, 63)23F (n = 38, 45, 42, 42, 63)1 (n = 42, 42, 43, 44, 74)3 (n = 41, 41, 39, 39, 69)5 (n = 42, 43, 44, 42, 73)6A (n = 46, 42, 39, 39, 76)7F (n = 46, 42, 40, 39, 76)19A (n = 42, 44, 41, 42, 74)
13vPnC + INFANRIX Hexa100.096.875.496.9100.095.293.745.9100.086.398.7100.097.3
13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily100.092.580.597.697.692.990.529.594.992.9100.097.488.1
13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily100.088.966.797.995.787.097.842.997.690.7100.0100.0100.0
13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily100.088.459.5100.0100.090.292.930.297.486.4100.0100.090.2
13vPnC + INFANRIX Hexa + Paracetamol Twice Daily100.094.462.289.5100.097.392.147.697.692.993.5100.092.9

Percentage of Participants Reporting Fever Within 4 Days: Infant Series Dose 1

Participants' core (rectal) temperature was collected for 4 days after each vaccination using an electronic diary. Participants' temperature was collected at 6 to 8 hours after vaccination, 6 to 8 hours following that and coincidentally with antipyretic administration for groups receiving antipyretics. Temperature was recorded at bedtime daily for 3 following days (Day 2 to Day 4) and at any time during the 3 days when fever was suspected. The highest temperature for each day was recorded in the e-diary. Incidences of fever were presented in following categories: >=38 but <=39 degree Celsius (degree C), greater than (>) 39 but <=40 degree C and >40 degree C. (NCT01392378)
Timeframe: Within 4 days after infant series Dose 1

,,,,
Interventionpercentage of participants (Number)
Fever >=38, <=39 degree C (n= 149,157,147,155,187)Fever >39, <=40 degree C (n = 138,145,137,146,170)Fever >40 degree C (n = 138,145,137,146,170)
13vPnC + INFANRIX Hexa41.71.20.0
13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily34.20.70.0
13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily45.21.40.0
13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily18.40.70.0
13vPnC + INFANRIX Hexa + Paracetamol Twice Daily32.91.40.0

Percentage of Participants Reporting Fever Within 4 Days: Infant Series Dose 2

Participants' rectal temperature was collected for 4 days after each vaccination using an electronic diary. Participants' temperature was collected at 6 to 8 hours after vaccination, 6 to 8 hours following that and coincidentally with antipyretic administration for groups receiving antipyretics. Temperature was recorded at bedtime daily for 3 following days (Day 2 to Day 4) and at any time during the 3 days when fever was suspected. The highest temperature for each day was recorded in the e-diary. Incidences of fever were presented in following categories: >=38 but <=39 degree C, >39 but <=40 degree C and >40 degree C. (NCT01392378)
Timeframe: Within 4 days after infant series Dose 2

,,,,
Interventionpercentage of participants (Number)
Fever >=38, <=39 degree C (n= 141,152,140,159,181)Fever >39, <=40 degree C (n = 133,140,134,145,164)Fever >40 degree C (n = 131,140,133,144,164)
13vPnC + INFANRIX Hexa39.83.70.0
13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily44.01.40.0
13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily42.80.70.0
13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily21.41.50.0
13vPnC + INFANRIX Hexa + Paracetamol Twice Daily26.21.50.0

Percentage of Participants Reporting Fever Within 4 Days: Infant Series Dose 3

Participants' rectal temperature was collected for 4 days after each vaccination using an electronic diary. Participants' temperature was collected at 6 to 8 hours after vaccination, 6 to 8 hours following that and coincidentally with antipyretic administration for groups receiving antipyretics. Temperature was recorded at bedtime daily for 3 following days (Day 2 to Day 4) and at any time during the 3 days when fever was suspected. The highest temperature for each day was recorded in the e-diary. Incidences of fever were presented in following categories: >=38 but <=39 degree C, >39 but <=40 degree C and >40 degree C. Report of fever >40 degrees C after 13vPnC Infant Series Dose 3 was confirmed as data entry error. (NCT01392378)
Timeframe: Within 4 days after infant series Dose 3

,,,,
Interventionpercentage of participants (Number)
Fever >=38, <=39 degree C (n= 136,146,135,141,175)Fever >39, <=40 degree C (n = 129,137,125,136,167)Fever >40 degree C (n = 128,136,126,135,166)
13vPnC + INFANRIX Hexa29.71.80.0
13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily33.31.50.0
13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily30.82.90.0
13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily17.00.80.8
13vPnC + INFANRIX Hexa + Paracetamol Twice Daily22.11.60.0

Percentage of Participants Reporting Fever Within 4 Days: Toddler Dose

Participants' rectal temperature was collected for 4 days after each vaccination using an electronic diary. Participants' temperature was collected at 6 to 8 hours after vaccination, 6 to 8 hours following that and coincidentally with antipyretic administration for groups receiving antipyretics. Temperature was recorded at bedtime daily for 3 following days (Day 2 to Day 4) and at any time during the 3 days when fever was suspected. The highest temperature for each day was recorded in the e-diary. Incidences of fever were presented in following categories: >=38 but <=39 degree C, >39 but <=40 degree C and >40 degree C. (NCT01392378)
Timeframe: Within 4 days after toddler dose

,,,,
Interventionpercentage of participants (Number)
Fever >=38, <=39 degree C (n= 133,140,134,144,162)Fever >39, <=40 degree C (n = 128,127,118,123,150)Fever >40 degree C (n = 123,125,117,122,150)
13vPnC + INFANRIX Hexa30.22.00.0
13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily50.05.70.0
13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily37.17.10.0
13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily37.34.20.0
13vPnC + INFANRIX Hexa + Paracetamol Twice Daily31.65.50.0

Pain Score 120 Minutes After Study Medication Administration

Pain is measured on a visual analog scale 0=no pain and 10=worst pain imaginable. (NCT02268955)
Timeframe: 120 minutes post medication administration

Interventionscore on a scale (Median)
Control Group: Adults Age 18-55 Years3.0
IV Ibuprofen: Adults Age 18-55 Years0.3

Child Temperature (Degrees C)Over 6 Hours

Temperature was measured hourly using a temporal thermometer to monitor the child's temperature in degrees C. Temperature of 38 degrees C or higher was considered febrile. (NCT00267293)
Timeframe: 6 hours

Interventiondegrees Celcius (Mean)
Group A: Ibuprofen Alone38.5
Group B: Ibuprofen and Acetaminophen37.2
Group C: Ibuprofen Then Acetaminophen36.9

Temperature Burden

Mean total body temperature burden above 37°C over 48 hours during which patient receives either control or intervention medication. (NCT03496545)
Timeframe: over 48 hours

InterventionTemperature in degrees Celsius (Mean)
Acetaminophen37.8
Bromocriptine and Acetaminophen37.7

Total Time That Temperature is ≥ 38.3ºC

Time in minutes where the temperature is ≥ 38.3ºC during the 48 hours of control versus intervention administration. (NCT03496545)
Timeframe: 48 hours

InterventionMinutes (Mean)
Acetaminophen216
Bromocriptine and Acetaminophen300

Total Time to First Temperature < 37.5ºC

Time in minutes it took after medication administration for the temperature to reach < 37.5ºC. (NCT03496545)
Timeframe: 48 hours

InterventionMinutes (Mean)
Acetaminophen253.5
Bromocriptine and Acetaminophen556

Incidence of Adverse Events - Symptomatic Hypotension, Nausea and Headache

Episodes of symptomatic hypotension, including decrease in supine systolic and diastolic pressures of greater than 20mm and 10mm Hg respectively with patient reported accompanying symptoms of light headedness or dizziness and incidence of nausea and headache. (NCT03496545)
Timeframe: Nursing assessment at every shift during 48 hour study period after first drug administration

,
InterventionParticipants (Count of Participants)
Decrease in blood pressureNauseaHeadache
Acetaminophen1228
Bromocriptine and Acetaminophen17312

Number of Participants With Level 3 Postoperative Hemorrhage

Postoperative hemorrhage is defined as any history of bleeding occurring within the 14 day postoperative period. Hemorrhage will be stratified into 3 levels of severity. Level 1: includes children with a history of postoperative bleeding evaluated and/or treated by a physician in the emergency room, inpatient unit or operating room; Level 2: children requiring inpatient admission for postoperative bleeding regardless of the need for operative intervention; Level 3: children requiring inpatient admission and return to the operating room for control of post-tonsillectomy hemorrhage. (NCT01605903)
Timeframe: Data about post-tonsillectomy bleeding will be obtained after the end of a 14-day postoperative period.

InterventionParticipants (Count of Participants)
Treatment With Ibuprofen10
Treatment With Acetaminophen4

Faces Pain Score

Using the Faces Pain Scale, the pediatric patient will indicate his/her pain level at scheduled intervals (7 times per day) for 14 days post-surgery.The Faces Pain Scale Revised is a dimensionless 10 point likert scale used to assess self-reported pain intensity on a scale from 0 (no pain) to 10 (most pain you can imagine). Greater pain scores are indicative of more severe pain. For this analysis, participant pain scores were summed and the mean per group was calculated. Total summed scores could range from 0 to 980. (NCT02296840)
Timeframe: 2 weeks after surgery

Interventionunits on a scale (Mean)
Ibuprofen158.95
Hydrocodone-acetaminophen219.94

Number of Participants With Post-operative Bleeding

The occurrence of post-operative bleeding at the surgical site for each participant will be assessed by review of the participant's study records and clinical records and by questioning the caregiver in follow-up. If postoperative bleeding has occurred, details of the episode of bleeding will also be obtained (requirement for surgical intervention, observation at home, or observation at the hospital). (NCT02296840)
Timeframe: 2 weeks after surgery

InterventionParticipants (Count of Participants)
Ibuprofen2
Hydrocodone-acetaminophen0

Reviews

56 reviews available for ibuprofen and Fever

ArticleYear
Comparison between Ibuprofen and Acetaminophen in the Treatment of Infectious Fever in Children: A Meta-Analysis.
    Journal of healthcare engineering, 2022, Volume: 2022

    Topics: Acetaminophen; Child; Fever; Humans; Ibuprofen; Odds Ratio; Retrospective Studies

2022
Clinical management of fever in children in Brazil: practical recommendations from an expert panel.
    Einstein (Sao Paulo, Brazil), 2022, Volume: 20

    Topics: Acetaminophen; Antipyretics; Brazil; Child; Fever; Humans; Ibuprofen

2022
Common Selfcare Indications of Pain Medications in Children.
    Paediatric drugs, 2023, Volume: 25, Issue:3

    Topics: Acetaminophen; Adolescent; Analgesics, Non-Narcotic; Child; COVID-19; Fever; Humans; Ibuprofen; Pain

2023
Intravenous ibuprofen in postoperative pain and fever management in adults: A systematic review and meta-analysis of randomized controlled trials.
    Pharmacology research & perspectives, 2023, Volume: 11, Issue:4

    Topics: Acetaminophen; Adult; Antipyretics; Fever; Humans; Ibuprofen; Pain, Postoperative; Randomized Contro

2023
Paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs, alone or combined, for pain relief in acute otitis media in children.
    The Cochrane database of systematic reviews, 2023, 08-18, Volume: 8

    Topics: Acetaminophen; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Child; Fever; Humans;

2023
Comparison of Acetaminophen (Paracetamol) With Ibuprofen for Treatment of Fever or Pain in Children Younger Than 2 Years: A Systematic Review and Meta-analysis.
    JAMA network open, 2020, 10-01, Volume: 3, Issue:10

    Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Child, Preschool; Female; Fever; Humans; Ibu

2020
Ibuprofen Better than Acetaminophen for Reducing Fever, Pain in Young Children.
    The American journal of nursing, 2021, 02-01, Volume: 121, Issue:2

    Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Fever; Humans; Ibuprofen; Incidence; Pediatr

2021
Ibuprofen vs. Acetaminophen for Fever or Pain in Children Younger Than Two Years.
    American family physician, 2021, 05-01, Volume: 103, Issue:9

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Fever; Humans; Ibuprofen; Infant; Pain; Patient Selection;

2021
Acetaminophen and ibuprofen in the treatment of pediatric fever: a narrative review.
    Current medical research and opinion, 2021, Volume: 37, Issue:8

    Topics: Acetaminophen; Administration, Intravenous; Analgesics, Non-Narcotic; Antipyretics; Child; Fever; Hu

2021
[Revision of the Dutch College of General Practitioners practice guideline 'Children with fever'].
    Nederlands tijdschrift voor geneeskunde, 2017, Volume: 161

    Topics: Acetaminophen; Child; Family Practice; Fever; General Practitioners; Humans; Ibuprofen; Netherlands;

2017
Effectiveness of paracetamol versus ibuprofen administration in febrile children: A systematic literature review.
    Journal of paediatrics and child health, 2017, Volume: 53, Issue:8

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Antipyretics; Child; Child, Preschool; Fever; Humans; Ibupr

2017
Efficacy and Safety of Ibuprofen in Infants Aged Between 3 and 6 Months.
    Paediatric drugs, 2017, Volume: 19, Issue:4

    Topics: Analgesia; Anti-Inflammatory Agents, Non-Steroidal; Fever; Humans; Ibuprofen; Infant; Pain; Pain Man

2017
Working Towards an Appropriate Use of Ibuprofen in Children: An Evidence-Based Appraisal.
    Drugs, 2017, Volume: 77, Issue:12

    Topics: Abnormalities, Multiple; Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Cerebellar Di

2017
Symptomatic treatment of dengue: should the NSAID contraindication be reconsidered?
    Postgraduate medicine, 2019, Volume: 131, Issue:2

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Contraindications, Drug; Dengue; Fever; Hemorrhage; Humans;

2019
Does combination treatment with ibuprofen and acetaminophen improve fever control?
    Annals of emergency medicine, 2013, Volume: 61, Issue:5

    Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Antipyretics; Child; Child, Preschool; Drug

2013
Combined and alternating paracetamol and ibuprofen therapy for febrile children.
    The Cochrane database of systematic reviews, 2013, Oct-30, Issue:10

    Topics: Acetaminophen; Antipyretics; Body Temperature; Child; Combined Modality Therapy; Fever; Humans; Ibup

2013
A practical approach to the treatment of low-risk childhood fever.
    Drugs in R&D, 2014, Volume: 14, Issue:2

    Topics: Acetaminophen; Child; Fever; Humans; Ibuprofen

2014
A practical approach to the treatment of low-risk childhood fever.
    Drugs in R&D, 2014, Volume: 14, Issue:2

    Topics: Acetaminophen; Child; Fever; Humans; Ibuprofen

2014
A practical approach to the treatment of low-risk childhood fever.
    Drugs in R&D, 2014, Volume: 14, Issue:2

    Topics: Acetaminophen; Child; Fever; Humans; Ibuprofen

2014
A practical approach to the treatment of low-risk childhood fever.
    Drugs in R&D, 2014, Volume: 14, Issue:2

    Topics: Acetaminophen; Child; Fever; Humans; Ibuprofen

2014
A practical approach to the treatment of low-risk childhood fever.
    Drugs in R&D, 2014, Volume: 14, Issue:2

    Topics: Acetaminophen; Child; Fever; Humans; Ibuprofen

2014
A practical approach to the treatment of low-risk childhood fever.
    Drugs in R&D, 2014, Volume: 14, Issue:2

    Topics: Acetaminophen; Child; Fever; Humans; Ibuprofen

2014
A practical approach to the treatment of low-risk childhood fever.
    Drugs in R&D, 2014, Volume: 14, Issue:2

    Topics: Acetaminophen; Child; Fever; Humans; Ibuprofen

2014
A practical approach to the treatment of low-risk childhood fever.
    Drugs in R&D, 2014, Volume: 14, Issue:2

    Topics: Acetaminophen; Child; Fever; Humans; Ibuprofen

2014
A practical approach to the treatment of low-risk childhood fever.
    Drugs in R&D, 2014, Volume: 14, Issue:2

    Topics: Acetaminophen; Child; Fever; Humans; Ibuprofen

2014
Combined and alternating paracetamol and ibuprofen therapy for febrile children.
    Evidence-based child health : a Cochrane review journal, 2014, Volume: 9, Issue:3

    Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Antipyretics; Child; Child, Preschool; Drug

2014
Safety of a novel formulation of ibuprofen sodium compared with standard ibuprofen and placebo.
    Postgraduate medicine, 2015, Volume: 127, Issue:1

    Topics: Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Chemistry, Pharmaceutical; Child; Double-Blind Me

2015
Safety of a novel formulation of ibuprofen sodium compared with standard ibuprofen and placebo.
    Postgraduate medicine, 2015, Volume: 127, Issue:1

    Topics: Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Chemistry, Pharmaceutical; Child; Double-Blind Me

2015
Safety of a novel formulation of ibuprofen sodium compared with standard ibuprofen and placebo.
    Postgraduate medicine, 2015, Volume: 127, Issue:1

    Topics: Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Chemistry, Pharmaceutical; Child; Double-Blind Me

2015
Safety of a novel formulation of ibuprofen sodium compared with standard ibuprofen and placebo.
    Postgraduate medicine, 2015, Volume: 127, Issue:1

    Topics: Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Chemistry, Pharmaceutical; Child; Double-Blind Me

2015
Safety of a novel formulation of ibuprofen sodium compared with standard ibuprofen and placebo.
    Postgraduate medicine, 2015, Volume: 127, Issue:1

    Topics: Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Chemistry, Pharmaceutical; Child; Double-Blind Me

2015
Safety of a novel formulation of ibuprofen sodium compared with standard ibuprofen and placebo.
    Postgraduate medicine, 2015, Volume: 127, Issue:1

    Topics: Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Chemistry, Pharmaceutical; Child; Double-Blind Me

2015
Safety of a novel formulation of ibuprofen sodium compared with standard ibuprofen and placebo.
    Postgraduate medicine, 2015, Volume: 127, Issue:1

    Topics: Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Chemistry, Pharmaceutical; Child; Double-Blind Me

2015
Safety of a novel formulation of ibuprofen sodium compared with standard ibuprofen and placebo.
    Postgraduate medicine, 2015, Volume: 127, Issue:1

    Topics: Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Chemistry, Pharmaceutical; Child; Double-Blind Me

2015
Safety of a novel formulation of ibuprofen sodium compared with standard ibuprofen and placebo.
    Postgraduate medicine, 2015, Volume: 127, Issue:1

    Topics: Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Chemistry, Pharmaceutical; Child; Double-Blind Me

2015
Safety of a novel formulation of ibuprofen sodium compared with standard ibuprofen and placebo.
    Postgraduate medicine, 2015, Volume: 127, Issue:1

    Topics: Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Chemistry, Pharmaceutical; Child; Double-Blind Me

2015
Safety of a novel formulation of ibuprofen sodium compared with standard ibuprofen and placebo.
    Postgraduate medicine, 2015, Volume: 127, Issue:1

    Topics: Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Chemistry, Pharmaceutical; Child; Double-Blind Me

2015
Safety of a novel formulation of ibuprofen sodium compared with standard ibuprofen and placebo.
    Postgraduate medicine, 2015, Volume: 127, Issue:1

    Topics: Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Chemistry, Pharmaceutical; Child; Double-Blind Me

2015
Safety of a novel formulation of ibuprofen sodium compared with standard ibuprofen and placebo.
    Postgraduate medicine, 2015, Volume: 127, Issue:1

    Topics: Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Chemistry, Pharmaceutical; Child; Double-Blind Me

2015
Safety of a novel formulation of ibuprofen sodium compared with standard ibuprofen and placebo.
    Postgraduate medicine, 2015, Volume: 127, Issue:1

    Topics: Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Chemistry, Pharmaceutical; Child; Double-Blind Me

2015
Safety of a novel formulation of ibuprofen sodium compared with standard ibuprofen and placebo.
    Postgraduate medicine, 2015, Volume: 127, Issue:1

    Topics: Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Chemistry, Pharmaceutical; Child; Double-Blind Me

2015
Safety of a novel formulation of ibuprofen sodium compared with standard ibuprofen and placebo.
    Postgraduate medicine, 2015, Volume: 127, Issue:1

    Topics: Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Chemistry, Pharmaceutical; Child; Double-Blind Me

2015
Safety of a novel formulation of ibuprofen sodium compared with standard ibuprofen and placebo.
    Postgraduate medicine, 2015, Volume: 127, Issue:1

    Topics: Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Chemistry, Pharmaceutical; Child; Double-Blind Me

2015
Safety of a novel formulation of ibuprofen sodium compared with standard ibuprofen and placebo.
    Postgraduate medicine, 2015, Volume: 127, Issue:1

    Topics: Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Chemistry, Pharmaceutical; Child; Double-Blind Me

2015
Safety of a novel formulation of ibuprofen sodium compared with standard ibuprofen and placebo.
    Postgraduate medicine, 2015, Volume: 127, Issue:1

    Topics: Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Chemistry, Pharmaceutical; Child; Double-Blind Me

2015
Safety of a novel formulation of ibuprofen sodium compared with standard ibuprofen and placebo.
    Postgraduate medicine, 2015, Volume: 127, Issue:1

    Topics: Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Chemistry, Pharmaceutical; Child; Double-Blind Me

2015
Safety of a novel formulation of ibuprofen sodium compared with standard ibuprofen and placebo.
    Postgraduate medicine, 2015, Volume: 127, Issue:1

    Topics: Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Chemistry, Pharmaceutical; Child; Double-Blind Me

2015
Safety of a novel formulation of ibuprofen sodium compared with standard ibuprofen and placebo.
    Postgraduate medicine, 2015, Volume: 127, Issue:1

    Topics: Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Chemistry, Pharmaceutical; Child; Double-Blind Me

2015
Safety of a novel formulation of ibuprofen sodium compared with standard ibuprofen and placebo.
    Postgraduate medicine, 2015, Volume: 127, Issue:1

    Topics: Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Chemistry, Pharmaceutical; Child; Double-Blind Me

2015
Safety of a novel formulation of ibuprofen sodium compared with standard ibuprofen and placebo.
    Postgraduate medicine, 2015, Volume: 127, Issue:1

    Topics: Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Chemistry, Pharmaceutical; Child; Double-Blind Me

2015
Safety of a novel formulation of ibuprofen sodium compared with standard ibuprofen and placebo.
    Postgraduate medicine, 2015, Volume: 127, Issue:1

    Topics: Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Chemistry, Pharmaceutical; Child; Double-Blind Me

2015
Paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs, alone or combined, for pain relief in acute otitis media in children.
    The Cochrane database of systematic reviews, 2016, 12-15, Volume: 12

    Topics: Acetaminophen; Acute Disease; Analgesics, Non-Narcotic; Anti-Bacterial Agents; Anti-Inflammatory Age

2016
A clinical and safety review of paracetamol and ibuprofen in children.
    Inflammopharmacology, 2017, Volume: 25, Issue:1

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Child; Drug Overdo

2017
[Research advance on pediatric antipyretic].
    Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, 2008, Volume: 10, Issue:6

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Aspirin; Fever; Humans; Ibuprofen; Sulfonamides

2008
Systematic review and meta-analysis of the clinical safety and tolerability of ibuprofen compared with paracetamol in paediatric pain and fever.
    Current medical research and opinion, 2009, Volume: 25, Issue:9

    Topics: Acetaminophen; Algorithms; Analgesics, Non-Narcotic; Anaphylaxis; Child; Fever; Gastrointestinal Hem

2009
Is combining or alternating antipyretic therapy more beneficial than monotherapy for febrile children?
    BMJ (Clinical research ed.), 2009, Oct-01, Volume: 339

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Child; Combined Modality Therapy; Fever; Humans; Ibuprofen

2009
Clinical safety and tolerability of ibuprofen compared with paracetamol in pediatric pain and fever. A systematic review.
    Minerva pediatrica, 2009, Volume: 61, Issue:6

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Child; Fever; Humans; Ibuprofen; Pain

2009
Ibuprofen: pharmacology, efficacy and safety.
    Inflammopharmacology, 2009, Volume: 17, Issue:6

    Topics: Adult; Animals; Anti-Inflammatory Agents, Non-Steroidal; Child; Dose-Response Relationship, Drug; Fe

2009
Efficacy and safety of ibuprofen and acetaminophen in children and adults: a meta-analysis and qualitative review.
    The Annals of pharmacotherapy, 2010, Volume: 44, Issue:3

    Topics: Acetaminophen; Adult; Age Factors; Analgesics, Non-Narcotic; Child; Female; Fever; Humans; Ibuprofen

2010
Fever management: evaluating the use of ibuprofen and paracetamol.
    Paediatric nursing, 2010, Volume: 22, Issue:3

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Child; Drug Administration Schedule; Emergency Nursing; Fem

2010
Clinical inquiries. Does lowering a fever >101 degrees F in children improve clinical outcomes?
    The Journal of family practice, 2010, Volume: 59, Issue:6

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Chickenpox; Cryotherapy; Fasciitis, Necrotizing; Fever; Hum

2010
Fever without a localizing source.
    Pediatric annals, 2011, Volume: 40, Issue:1

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Antipyretics; Bacteremia; Child, Preschool; Female; Fever;

2011
[Efficacy and safety of ibuprofen and paracetamol in fever among children].
    Journal de pharmacie de Belgique, 2011, Issue:2

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Child; Drug Combin

2011
Systematic review of studies comparing combined treatment with paracetamol and ibuprofen, with either drug alone.
    Archives of disease in childhood, 2011, Volume: 96, Issue:12

    Topics: Acetaminophen; Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Antipyretics; Child; Child, Pres

2011
Short-term acetylsalicylic acid (aspirin) use for pain, fever, or colds - gastrointestinal adverse effects: a meta-analysis of randomized clinical trials.
    Drugs in R&D, 2011, Sep-01, Volume: 11, Issue:3

    Topics: Acetaminophen; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Common Cold; Double-Blind Me

2011
Pharmacokinetics of intravenous ibuprofen: implications of time of infusion in the treatment of pain and fever.
    Drugs, 2012, Feb-12, Volume: 72, Issue:3

    Topics: Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Biological Availability; Dose-Res

2012
Acetaminophen and Ibuprofen overdosage.
    Pediatrics in review, 2012, Volume: 33, Issue:4

    Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Antipyretics; Chemical and Drug Induced Live

2012
Efficacy and gastrointestinal risk of aspirin used for the treatment of pain and cold.
    Best practice & research. Clinical gastroenterology, 2012, Volume: 26, Issue:2

    Topics: Acetaminophen; Aspirin; Common Cold; Dyspepsia; Fever; Gastrointestinal Tract; Humans; Ibuprofen; No

2012
Alternating antipyretics in the treatment of fever in children: a systematic review of randomized clinical trials.
    Jornal de pediatria, 2012, Volume: 88, Issue:4

    Topics: Acetaminophen; Antipyretics; Child; Drug Substitution; Drug Therapy, Combination; Fever; Humans; Ibu

2012
Optimising the management of fever and pain in children.
    International journal of clinical practice. Supplement, 2013, Issue:178

    Topics: Acetaminophen; Analgesics; Child; Comparative Effectiveness Research; Dose-Response Relationship, Dr

2013
A general overview of the use of ibuprofen in paediatrics.
    International journal of clinical practice. Supplement, 2003, Issue:135

    Topics: Acute Disease; Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Juvenile; Child; Chil

2003
The safety of ibuprofen suspension in children.
    International journal of clinical practice. Supplement, 2003, Issue:135

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Child; Fev

2003
Antipyretic efficacy and safety of ibuprofen and acetaminophen in children.
    The Annals of pharmacotherapy, 2004, Volume: 38, Issue:1

    Topics: Acetaminophen; Child; Child, Preschool; Drug Administration Schedule; Fever; Humans; Ibuprofen; Infa

2004
Efficacy and safety of acetaminophen vs ibuprofen for treating children's pain or fever: a meta-analysis.
    Archives of pediatrics & adolescent medicine, 2004, Volume: 158, Issue:6

    Topics: Acetaminophen; Adolescent; Analgesics, Non-Narcotic; Child; Child, Preschool; Fever; Humans; Ibuprof

2004
How safe is ibuprofen in febrile asthmatic children?
    Archives of disease in childhood, 2004, Volume: 89, Issue:9

    Topics: Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Child, Preschool; Contrai

2004
Best evidence topic report. Non-steroidal anti-inflammatory drugs and exacerbations of asthma in children.
    Emergency medicine journal : EMJ, 2004, Volume: 21, Issue:6

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Asthma; Child; Emergencies; Fever; Humans; Ibuprofen; Male

2004
Efficacy and safety of over-the-counter analgesics in the treatment of common cold and flu.
    Journal of clinical pharmacy and therapeutics, 2006, Volume: 31, Issue:4

    Topics: Acetaminophen; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Child; Child, Preschool; Com

2006
[Answers to the questions on application of ibuprofen and acetaminophen in children with fever].
    Zhonghua er ke za zhi = Chinese journal of pediatrics, 2007, Volume: 45, Issue:9

    Topics: Acetaminophen; Child; Fever; Humans; Ibuprofen; Neonatology

2007
A review of ibuprofen and acetaminophen use in febrile children and the occurrence of asthma-related symptoms.
    Clinical therapeutics, 2007, Volume: 29, Issue:12

    Topics: Acetaminophen; Algorithms; Analgesics, Non-Narcotic; Asthma; Child; Fever; Hospitalization; Humans;

2007
Use of ibuprofen in paediatric populations.
    Journal of the Royal Society of Medicine, 2007, Volume: 100 Suppl 48

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Chickenpox; Child; Fever; Humans; Ibuprofen; Infant, Newbor

2007
[Using evidence-based nursing to explore the management of child fever].
    Hu li za zhi The journal of nursing, 2008, Volume: 55, Issue:2

    Topics: Acetaminophen; Child; Evidence-Based Medicine; Fever; Humans; Ibuprofen

2008
Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. Paracetamol or ibuprofen in febrile children.
    Journal of accident & emergency medicine, 1999, Volume: 16, Issue:2

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Child, Preschool; Emergency Medicine; Evidence-Based Medici

1999
The effects of ibuprofen on eicosanoid synthesis in sepsis.
    Critical care medicine, 1999, Volume: 27, Issue:4

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Cytokines; Disease Models, Anima

1999
Childhood fever revisited.
    Hong Kong medical journal = Xianggang yi xue za zhi, 2002, Volume: 8, Issue:1

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Body Temperature; Child; Fever; Humans; Ibuprofen; Thermome

2002
Antipyretics in children.
    Indian journal of pediatrics, 2002, Volume: 69, Issue:1

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Aspirin; Child; Cyclooxygenase Inhibitors; Fever; Humans; I

2002
Treating fever in children: paracetamol or ibuprofen?
    British journal of community nursing, 2002, Volume: 7, Issue:6

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Child; Effect Modifier, Epidemiologic; Evidence-Based Medic

2002
Antipyretic therapy in the febrile child.
    Clinical pharmacy, 1992, Volume: 11, Issue:12

    Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Child, Preschool; Drug Therapy, Com

1992
Update on ibuprofen: review article.
    The Journal of international medical research, 1986, Volume: 14, Issue:2

    Topics: Analgesia; Arthritis; Arthritis, Rheumatoid; Clinical Trials as Topic; Connective Tissue Diseases; D

1986

Trials

87 trials available for ibuprofen and Fever

ArticleYear
Panic or peace - prioritising infant welfare when medicating feverish infants: a grounded theory study of adherence in a paediatric clinical trial.
    BMC pediatrics, 2022, 04-11, Volume: 22, Issue:1

    Topics: Acetaminophen; Asthma; Fever; Grounded Theory; Humans; Ibuprofen; Infant; Infant Welfare

2022
Aggressive antipyretics in central nervous system malaria: Study protocol of a randomized-controlled trial assessing antipyretic efficacy and parasite clearance effects (Malaria FEVER study).
    PloS one, 2022, Volume: 17, Issue:10

    Topics: Acetaminophen; Animals; Antipyretics; Central Nervous System; Child; Fever; Histidine; Humans; Ibupr

2022
Comparing the effect of body wash with marshmallow plant and lukewarm water on reducing the temperature of febrile children: a randomized clinical trial.
    BMC complementary medicine and therapies, 2022, Nov-12, Volume: 22, Issue:1

    Topics: Acetaminophen; Child; Fever; Humans; Ibuprofen; Iran; Temperature; Water

2022
A Multi-Center Evaluation of the Pharmacokinetics and Safety of Intravenous Ibuprofen in Infants 1-6 Months of Age.
    Paediatric drugs, 2023, Volume: 25, Issue:5

    Topics: Administration, Intravenous; Aged; Child; Female; Fever; Humans; Ibuprofen; Infant; Infant, Newborn;

2023
Ibuprofen does not prevent postbronchoscopy fever in children undergoing broncho-alveolar lavage.
    Pediatric pulmonology, 2020, Volume: 55, Issue:10

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Bronchoalveolar Lavage; Bronchoscopy; Child; Child, Prescho

2020
Ibuprofen versus paracetamol for treating fever in preschool children in Nigeria: a randomized clinical trial of effectiveness and safety.
    The Pan African medical journal, 2020, Volume: 36

    Topics: Acetaminophen; Antipyretics; Body Temperature; Child, Preschool; Female; Fever; Hospitals, Teaching;

2020
Comparison of intravenous ibuprofen and paracetamol in the treatment of fever: A randomized double-blind study.
    The American journal of emergency medicine, 2021, Volume: 46

    Topics: Acetaminophen; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antipyretics; Double-Blind Method; Em

2021
Alternating Acetaminophen and Ibuprofen versus Monotherapies in Improvements of Distress and Reducing Refractory Fever in Febrile Children: A Randomized Controlled Trial.
    Paediatric drugs, 2017, Volume: 19, Issue:5

    Topics: Acetaminophen; Antipyretics; Child; Child, Preschool; Drug Administration Schedule; Drug Therapy, Co

2017
The antipyretic efficacy and safety of propacetamol compared with dexibuprofen in febrile children: a multicenter, randomized, double-blind, comparative, phase 3 clinical trial.
    BMC pediatrics, 2018, 06-23, Volume: 18, Issue:1

    Topics: Acetaminophen; Administration, Oral; Adolescent; Antipyretics; Child; Child, Preschool; Double-Blind

2018
[In process].
    Medizinische Monatsschrift fur Pharmazeuten, 2016, Volume: 39, Issue:10

    Topics: Acetaminophen; Asthma; Child, Preschool; Disease Progression; Fever; Humans; Ibuprofen; Pain; Prospe

2016
Dexibuprofen for fever in children with upper respiratory tract infection.
    Pediatrics international : official journal of the Japan Pediatric Society, 2013, Volume: 55, Issue:4

    Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Body Temperature; Child; Child, Preschool; Dose

2013
The shortened infusion time of intravenous ibuprofen part 1: a multicenter, open-label, surveillance trial to evaluate safety and efficacy.
    Clinical therapeutics, 2015, Feb-01, Volume: 37, Issue:2

    Topics: Adult; Aged; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Double-Blin

2015
Acetaminophen versus Ibuprofen in Young Children with Mild Persistent Asthma.
    The New England journal of medicine, 2016, Aug-18, Volume: 375, Issue:7

    Topics: Acetaminophen; Asthma; Child, Preschool; Double-Blind Method; Female; Fever; Humans; Ibuprofen; Inci

2016
Effects of prophylactic ibuprofen and paracetamol administration on the immunogenicity and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugated vaccine (PHiD-CV) co-administered with DTPa-combined vaccines
    Human vaccines & immunotherapeutics, 2017, 03-04, Volume: 13, Issue:3

    Topics: Acetaminophen; Antibodies, Bacterial; Antipyretics; Diphtheria-Tetanus-acellular Pertussis Vaccines;

2017
Antipyretic Efficacy and Safety of Ibuprofen Versus Acetaminophen Suspension in Febrile Children: Results of 2 Randomized, Double-Blind, Single-Dose Studies.
    Clinical pediatrics, 2017, Volume: 56, Issue:12

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Antipyretics; Chil

2017
A multicenter, randomized, open-label, active-comparator trial to determine the efficacy, safety, and pharmacokinetics of intravenous ibuprofen for treatment of fever in hospitalized pediatric patients.
    BMC pediatrics, 2017, 02-01, Volume: 17, Issue:1

    Topics: Acetaminophen; Administration, Oral; Adolescent; Antipyretics; Area Under Curve; Child; Child, Presc

2017
A randomized study of fever prophylaxis and the immunogenicity of routine pediatric vaccinations.
    Vaccine, 2017, 04-04, Volume: 35, Issue:15

    Topics: Acetaminophen; Antibodies, Bacterial; Antipyretics; Chemoprevention; Diphtheria-Tetanus-Pertussis Va

2017
Alternating antipyretics: antipyretic efficacy of acetaminophen versus acetaminophen alternated with ibuprofen in children.
    Clinical pediatrics, 2008, Volume: 47, Issue:9

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Child; Child, Preschool; Double-Blind Method; Female; Fever

2008
Paracetamol plus ibuprofen for the treatment of fever in children (PITCH): randomised controlled trial.
    BMJ (Clinical research ed.), 2008, Sep-02, Volume: 337

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Body Temperature; Child; Child, Preschool; Drug Therapy, Co

2008
Paracetamol plus ibuprofen for the treatment of fever in children (PITCH): economic evaluation of a randomised controlled trial.
    BMJ (Clinical research ed.), 2008, Sep-09, Volume: 337

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Child; Child, Preschool; Cost-Benefit Analysis; Drug Therap

2008
The effects and safety of dexibuprofen compared with ibuprofen in febrile children caused by upper respiratory tract infection.
    British journal of clinical pharmacology, 2008, Volume: 66, Issue:6

    Topics: Administration, Oral; Adolescent; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Chi

2008
Antipyretic effect of ketoprofen.
    Indian journal of pediatrics, 2009, Volume: 76, Issue:3

    Topics: Acetaminophen; Adolescent; Analgesics, Non-Narcotic; Analysis of Variance; Anti-Inflammatory Agents,

2009
Paracetamol and ibuprofen for the treatment of fever in children: the PITCH randomised controlled trial.
    Health technology assessment (Winchester, England), 2009, Volume: 13, Issue:27

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Child; Child, Preschool; Cost-Benefit Analysis; Double-Blin

2009
Antibiotic prophylaxis in third molar surgery: A randomized double-blind placebo-controlled clinical trial using split-mouth technique.
    International journal of oral and maxillofacial surgery, 2010, Volume: 39, Issue:2

    Topics: Acetaminophen; Adult; Amoxicillin; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Bacterial Agen

2010
Ketoprofen versus paracetamol (acetaminophen) or ibuprofen in the management of fever: results of two randomized, double-blind, double-dummy, parallel-group, repeated-dose, multicentre, phase III studies in children.
    Clinical drug investigation, 2010, Volume: 30, Issue:6

    Topics: Acetaminophen; Administration, Oral; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroid

2010
A multi-center, randomized, double-blind, parallel, placebo-controlled trial to evaluate the efficacy, safety, and pharmacokinetics of intravenous ibuprofen for the treatment of fever in critically ill and non-critically ill adults.
    Critical care (London, England), 2010, Volume: 14, Issue:3

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Critical Illness; Double-Blind Method; Drug-Related

2010
A multi-center, randomized, double-blind, parallel, placebo-controlled trial to evaluate the efficacy, safety, and pharmacokinetics of intravenous ibuprofen for the treatment of fever in critically ill and non-critically ill adults.
    Critical care (London, England), 2010, Volume: 14, Issue:3

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Critical Illness; Double-Blind Method; Drug-Related

2010
A multi-center, randomized, double-blind, parallel, placebo-controlled trial to evaluate the efficacy, safety, and pharmacokinetics of intravenous ibuprofen for the treatment of fever in critically ill and non-critically ill adults.
    Critical care (London, England), 2010, Volume: 14, Issue:3

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Critical Illness; Double-Blind Method; Drug-Related

2010
A multi-center, randomized, double-blind, parallel, placebo-controlled trial to evaluate the efficacy, safety, and pharmacokinetics of intravenous ibuprofen for the treatment of fever in critically ill and non-critically ill adults.
    Critical care (London, England), 2010, Volume: 14, Issue:3

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Critical Illness; Double-Blind Method; Drug-Related

2010
A multi-center, randomized, double-blind, parallel, placebo-controlled trial to evaluate the efficacy, safety, and pharmacokinetics of intravenous ibuprofen for the treatment of fever in critically ill and non-critically ill adults.
    Critical care (London, England), 2010, Volume: 14, Issue:3

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Critical Illness; Double-Blind Method; Drug-Related

2010
A multi-center, randomized, double-blind, parallel, placebo-controlled trial to evaluate the efficacy, safety, and pharmacokinetics of intravenous ibuprofen for the treatment of fever in critically ill and non-critically ill adults.
    Critical care (London, England), 2010, Volume: 14, Issue:3

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Critical Illness; Double-Blind Method; Drug-Related

2010
A multi-center, randomized, double-blind, parallel, placebo-controlled trial to evaluate the efficacy, safety, and pharmacokinetics of intravenous ibuprofen for the treatment of fever in critically ill and non-critically ill adults.
    Critical care (London, England), 2010, Volume: 14, Issue:3

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Critical Illness; Double-Blind Method; Drug-Related

2010
A multi-center, randomized, double-blind, parallel, placebo-controlled trial to evaluate the efficacy, safety, and pharmacokinetics of intravenous ibuprofen for the treatment of fever in critically ill and non-critically ill adults.
    Critical care (London, England), 2010, Volume: 14, Issue:3

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Critical Illness; Double-Blind Method; Drug-Related

2010
A multi-center, randomized, double-blind, parallel, placebo-controlled trial to evaluate the efficacy, safety, and pharmacokinetics of intravenous ibuprofen for the treatment of fever in critically ill and non-critically ill adults.
    Critical care (London, England), 2010, Volume: 14, Issue:3

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Critical Illness; Double-Blind Method; Drug-Related

2010
Intravenous ibuprofen (IV-ibuprofen) controls fever effectively in adults with acute uncomplicated Plasmodium falciparum malaria but prolongs parasitemia.
    The American journal of tropical medicine and hygiene, 2010, Volume: 83, Issue:1

    Topics: Acute Disease; Adult; Animals; Antimalarials; Artemisinins; Artesunate; Double-Blind Method; Drug Th

2010
Treatment with acetaminophen/paracetamol or ibuprofen alleviates post-dose symptoms related to intravenous infusion with zoledronic acid 5 mg.
    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2012, Volume: 23, Issue:2

    Topics: Acetaminophen; Aged; Arthralgia; Body Temperature; Bone Density Conservation Agents; Diphosphonates;

2012
Efficacy of standard doses of Ibuprofen alone, alternating, and combined with acetaminophen for the treatment of febrile children.
    Clinical therapeutics, 2010, Volume: 32, Issue:14

    Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Antipyretics; Child; Child, Preschool; Dose-

2010
Efficacy of standard doses of Ibuprofen alone, alternating, and combined with acetaminophen for the treatment of febrile children.
    Clinical therapeutics, 2010, Volume: 32, Issue:14

    Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Antipyretics; Child; Child, Preschool; Dose-

2010
Efficacy of standard doses of Ibuprofen alone, alternating, and combined with acetaminophen for the treatment of febrile children.
    Clinical therapeutics, 2010, Volume: 32, Issue:14

    Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Antipyretics; Child; Child, Preschool; Dose-

2010
Efficacy of standard doses of Ibuprofen alone, alternating, and combined with acetaminophen for the treatment of febrile children.
    Clinical therapeutics, 2010, Volume: 32, Issue:14

    Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Antipyretics; Child; Child, Preschool; Dose-

2010
A prospective randomized study to evaluate the antipyretic effect of the combination of acetaminophen and ibuprofen in neurological ICU patients.
    Neurocritical care, 2011, Volume: 15, Issue:3

    Topics: Academic Medical Centers; Acetaminophen; Antipyretics; Body Temperature; Drug Therapy, Combination;

2011
A prospective randomized study to evaluate the antipyretic effect of the combination of acetaminophen and ibuprofen in neurological ICU patients.
    Neurocritical care, 2011, Volume: 15, Issue:3

    Topics: Academic Medical Centers; Acetaminophen; Antipyretics; Body Temperature; Drug Therapy, Combination;

2011
A prospective randomized study to evaluate the antipyretic effect of the combination of acetaminophen and ibuprofen in neurological ICU patients.
    Neurocritical care, 2011, Volume: 15, Issue:3

    Topics: Academic Medical Centers; Acetaminophen; Antipyretics; Body Temperature; Drug Therapy, Combination;

2011
A prospective randomized study to evaluate the antipyretic effect of the combination of acetaminophen and ibuprofen in neurological ICU patients.
    Neurocritical care, 2011, Volume: 15, Issue:3

    Topics: Academic Medical Centers; Acetaminophen; Antipyretics; Body Temperature; Drug Therapy, Combination;

2011
Effect of paracetamol (acetaminophen) and ibuprofen on body temperature in acute ischemic stroke PISA, a phase II double-blind, randomized, placebo-controlled trial [ISRCTN98608690].
    BMC cardiovascular disorders, 2003, Feb-06, Volume: 3

    Topics: Acetaminophen; Acute Disease; Aged; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroida

2003
A multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled, parallel-group comparison of diclofenac-K and ibuprofen for the treatment of adults with influenza-like symptoms.
    Clinical therapeutics, 2003, Volume: 25, Issue:2

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Double-Blind Method; Drug Administration

2003
The antipyretic effect of ibuprofen and acetaminophen in children.
    Pharmacotherapy, 2004, Volume: 24, Issue:2

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Body Temperature; Child; Child, Preschool; Fever; Half-Life

2004
Corticosteroids, ibuprofen, and acetaminophen for IFNbeta-1a flu symptoms in MS: a randomized trial.
    Neurology, 2004, Aug-10, Volume: 63, Issue:3

    Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Asthenia; Chills; Double-Blind Method; Drug Administ

2004
[Antipyretic effectiveness of ibuprofen and paracetamol].
    Anales de pediatria (Barcelona, Spain : 2003), 2005, Volume: 62, Issue:2

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Child; Child, Preschool; Female; Fever; Humans; Ibuprofen;

2005
[Randomized controlled study of S (+) -ismer of ibuprofen supporsitory].
    Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2004, Volume: 29, Issue:4

    Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Female; Fever; Humans; Ibuprofen;

2004
Antipyretic treatment in young children with fever: acetaminophen, ibuprofen, or both alternating in a randomized, double-blind study.
    Archives of pediatrics & adolescent medicine, 2006, Volume: 160, Issue:2

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Child, Preschool; Double-Blind Method; Drug Therapy, Combin

2006
Randomised controlled trial of combined paracetamol and ibuprofen for fever.
    Archives of disease in childhood, 2006, Volume: 91, Issue:5

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Child; Child, Preschool; Drug Therapy, Combination; Emergen

2006
Alternating ibuprofen and acetaminophen in the treatment of febrile children: a pilot study [ISRCTN30487061].
    BMC medicine, 2006, Mar-04, Volume: 4

    Topics: Acetaminophen; Administration, Oral; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroid

2006
Antipyretic efficacy and tolerability of oral ibuprofen, oral dipyrone and intramuscular dipyrone in children: a randomized controlled trial.
    Sao Paulo medical journal = Revista paulista de medicina, 2006, May-04, Volume: 124, Issue:3

    Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Child; Child, Preschool; Dipyrone; Fe

2006
Ibuprofen versus paracetamol in pediatric fever: objective and subjective findings from a randomized, blinded study.
    Current medical research and opinion, 2007, Volume: 23, Issue:9

    Topics: Acetaminophen; Child; Child, Preschool; Double-Blind Method; Female; Fever; Humans; Ibuprofen; Infan

2007
Comparative evaluation of antipyretic activity of ibuprofen and aspirin in children with pyrexia of varied aetiology.
    The Journal of international medical research, 1984, Volume: 12, Issue:5

    Topics: Aspirin; Child, Preschool; Female; Fever; Humans; Ibuprofen; Male; Respiratory Tract Infections; Tim

1984
[A clinical study on the effect of K-708 (acemetacin)--a double blind comparative study with ibuprofen in upper respiratory tract inflammation with fever (author's transl)].
    Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases, 1981, Volume: 55, Issue:9

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Double-Blind Method; Femal

1981
Comparative efficacy and tolerance of ibuprofen syrup and acetaminophen syrup in children with pyrexia associated with infectious diseases and treated with antibiotics.
    European journal of clinical pharmacology, 1994, Volume: 46, Issue:3

    Topics: Acetaminophen; Anti-Bacterial Agents; Child, Preschool; Double-Blind Method; Female; Fever; Humans;

1994
Comparing efficacy and tolerability of ibuprofen and paracetamol in fever.
    Archives of disease in childhood, 1996, Volume: 74, Issue:2

    Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Body Temperature; Child; Child, Preschool; D

1996
Choice of antipyretic in children.
    The Journal of the Association of Physicians of India, 1995, Volume: 43, Issue:9

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Child; Child, Pres

1995
Phase II trial of intravenous endotoxin in patients with colorectal and non-small cell lung cancer.
    European journal of cancer (Oxford, England : 1990), 1996, Volume: 32A, Issue:10

    Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Bacterial Toxins; Carcinoma, Non-Small-Cell Lu

1996
Evaluation of ibuprofen versus aspirin and paracetamol on efficacy and comfort in children with fever.
    European journal of clinical pharmacology, 1997, Volume: 51, Issue:5

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Body Temp

1997
The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group.
    The New England journal of medicine, 1997, Mar-27, Volume: 336, Issue:13

    Topics: Acidosis, Lactic; Double-Blind Method; Epoprostenol; Female; Fever; Hemodynamics; Humans; Ibuprofen;

1997
The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group.
    The New England journal of medicine, 1997, Mar-27, Volume: 336, Issue:13

    Topics: Acidosis, Lactic; Double-Blind Method; Epoprostenol; Female; Fever; Hemodynamics; Humans; Ibuprofen;

1997
The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group.
    The New England journal of medicine, 1997, Mar-27, Volume: 336, Issue:13

    Topics: Acidosis, Lactic; Double-Blind Method; Epoprostenol; Female; Fever; Hemodynamics; Humans; Ibuprofen;

1997
The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group.
    The New England journal of medicine, 1997, Mar-27, Volume: 336, Issue:13

    Topics: Acidosis, Lactic; Double-Blind Method; Epoprostenol; Female; Fever; Hemodynamics; Humans; Ibuprofen;

1997
The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group.
    The New England journal of medicine, 1997, Mar-27, Volume: 336, Issue:13

    Topics: Acidosis, Lactic; Double-Blind Method; Epoprostenol; Female; Fever; Hemodynamics; Humans; Ibuprofen;

1997
The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group.
    The New England journal of medicine, 1997, Mar-27, Volume: 336, Issue:13

    Topics: Acidosis, Lactic; Double-Blind Method; Epoprostenol; Female; Fever; Hemodynamics; Humans; Ibuprofen;

1997
The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group.
    The New England journal of medicine, 1997, Mar-27, Volume: 336, Issue:13

    Topics: Acidosis, Lactic; Double-Blind Method; Epoprostenol; Female; Fever; Hemodynamics; Humans; Ibuprofen;

1997
The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group.
    The New England journal of medicine, 1997, Mar-27, Volume: 336, Issue:13

    Topics: Acidosis, Lactic; Double-Blind Method; Epoprostenol; Female; Fever; Hemodynamics; Humans; Ibuprofen;

1997
The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group.
    The New England journal of medicine, 1997, Mar-27, Volume: 336, Issue:13

    Topics: Acidosis, Lactic; Double-Blind Method; Epoprostenol; Female; Fever; Hemodynamics; Humans; Ibuprofen;

1997
The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group.
    The New England journal of medicine, 1997, Mar-27, Volume: 336, Issue:13

    Topics: Acidosis, Lactic; Double-Blind Method; Epoprostenol; Female; Fever; Hemodynamics; Humans; Ibuprofen;

1997
The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group.
    The New England journal of medicine, 1997, Mar-27, Volume: 336, Issue:13

    Topics: Acidosis, Lactic; Double-Blind Method; Epoprostenol; Female; Fever; Hemodynamics; Humans; Ibuprofen;

1997
The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group.
    The New England journal of medicine, 1997, Mar-27, Volume: 336, Issue:13

    Topics: Acidosis, Lactic; Double-Blind Method; Epoprostenol; Female; Fever; Hemodynamics; Humans; Ibuprofen;

1997
The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group.
    The New England journal of medicine, 1997, Mar-27, Volume: 336, Issue:13

    Topics: Acidosis, Lactic; Double-Blind Method; Epoprostenol; Female; Fever; Hemodynamics; Humans; Ibuprofen;

1997
The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group.
    The New England journal of medicine, 1997, Mar-27, Volume: 336, Issue:13

    Topics: Acidosis, Lactic; Double-Blind Method; Epoprostenol; Female; Fever; Hemodynamics; Humans; Ibuprofen;

1997
The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group.
    The New England journal of medicine, 1997, Mar-27, Volume: 336, Issue:13

    Topics: Acidosis, Lactic; Double-Blind Method; Epoprostenol; Female; Fever; Hemodynamics; Humans; Ibuprofen;

1997
The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group.
    The New England journal of medicine, 1997, Mar-27, Volume: 336, Issue:13

    Topics: Acidosis, Lactic; Double-Blind Method; Epoprostenol; Female; Fever; Hemodynamics; Humans; Ibuprofen;

1997
The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group.
    The New England journal of medicine, 1997, Mar-27, Volume: 336, Issue:13

    Topics: Acidosis, Lactic; Double-Blind Method; Epoprostenol; Female; Fever; Hemodynamics; Humans; Ibuprofen;

1997
The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group.
    The New England journal of medicine, 1997, Mar-27, Volume: 336, Issue:13

    Topics: Acidosis, Lactic; Double-Blind Method; Epoprostenol; Female; Fever; Hemodynamics; Humans; Ibuprofen;

1997
The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group.
    The New England journal of medicine, 1997, Mar-27, Volume: 336, Issue:13

    Topics: Acidosis, Lactic; Double-Blind Method; Epoprostenol; Female; Fever; Hemodynamics; Humans; Ibuprofen;

1997
The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group.
    The New England journal of medicine, 1997, Mar-27, Volume: 336, Issue:13

    Topics: Acidosis, Lactic; Double-Blind Method; Epoprostenol; Female; Fever; Hemodynamics; Humans; Ibuprofen;

1997
The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group.
    The New England journal of medicine, 1997, Mar-27, Volume: 336, Issue:13

    Topics: Acidosis, Lactic; Double-Blind Method; Epoprostenol; Female; Fever; Hemodynamics; Humans; Ibuprofen;

1997
The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group.
    The New England journal of medicine, 1997, Mar-27, Volume: 336, Issue:13

    Topics: Acidosis, Lactic; Double-Blind Method; Epoprostenol; Female; Fever; Hemodynamics; Humans; Ibuprofen;

1997
The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group.
    The New England journal of medicine, 1997, Mar-27, Volume: 336, Issue:13

    Topics: Acidosis, Lactic; Double-Blind Method; Epoprostenol; Female; Fever; Hemodynamics; Humans; Ibuprofen;

1997
The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group.
    The New England journal of medicine, 1997, Mar-27, Volume: 336, Issue:13

    Topics: Acidosis, Lactic; Double-Blind Method; Epoprostenol; Female; Fever; Hemodynamics; Humans; Ibuprofen;

1997
The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group.
    The New England journal of medicine, 1997, Mar-27, Volume: 336, Issue:13

    Topics: Acidosis, Lactic; Double-Blind Method; Epoprostenol; Female; Fever; Hemodynamics; Humans; Ibuprofen;

1997
Evaluation of sponging and antipyretic medication to reduce body temperature in febrile children.
    Acta paediatrica Japonica : Overseas edition, 1997, Volume: 39, Issue:2

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Aspirin; Baths; Child, Preschool; Female; Fever; Humans; Ib

1997
A comparison of ibuprofen versus acetaminophen with codeine in the young tonsillectomy patient.
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 1997, Volume: 117, Issue:1

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal

1997
A comparison of ibuprofen versus acetaminophen with codeine in the young tonsillectomy patient.
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 1997, Volume: 117, Issue:1

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal

1997
A comparison of ibuprofen versus acetaminophen with codeine in the young tonsillectomy patient.
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 1997, Volume: 117, Issue:1

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal

1997
A comparison of ibuprofen versus acetaminophen with codeine in the young tonsillectomy patient.
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 1997, Volume: 117, Issue:1

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal

1997
A comparison of ibuprofen versus acetaminophen with codeine in the young tonsillectomy patient.
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 1997, Volume: 117, Issue:1

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal

1997
A comparison of ibuprofen versus acetaminophen with codeine in the young tonsillectomy patient.
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 1997, Volume: 117, Issue:1

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal

1997
A comparison of ibuprofen versus acetaminophen with codeine in the young tonsillectomy patient.
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 1997, Volume: 117, Issue:1

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal

1997
A comparison of ibuprofen versus acetaminophen with codeine in the young tonsillectomy patient.
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 1997, Volume: 117, Issue:1

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal

1997
A comparison of ibuprofen versus acetaminophen with codeine in the young tonsillectomy patient.
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 1997, Volume: 117, Issue:1

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal

1997
Renal function after short-term ibuprofen use in infants and children.
    Pediatrics, 1997, Volume: 100, Issue:6

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Blood Urea Nitroge

1997
Equivalent antipyretic activity of ibuprofen and paracetamol in febrile children.
    The Journal of pediatrics, 1997, Volume: 131, Issue:5

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Child; Child, Pres

1997
Randomized, controlled trial of ibuprofen syrup administered during febrile illnesses to prevent febrile seizure recurrences.
    Pediatrics, 1998, Volume: 102, Issue:5

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Child, Preschool; Double-Blind Method; Female; Fever; Human

1998
Effects of ibuprofen on the physiology and survival of hypothermic sepsis. Ibuprofen in Sepsis Study Group.
    Critical care medicine, 1999, Volume: 27, Issue:4

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Epoprostenol; Female; Fever; Humans; Hypothermia; Ibuprofen

1999
Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans.
    Clinical pharmacology and therapeutics, 1999, Volume: 65, Issue:6

    Topics: Administration, Oral; Analysis of Variance; Animals; Body Temperature; Cyclooxygenase 2; Cyclooxygen

1999
Parents' fear regarding fever and febrile seizures.
    Acta paediatrica (Oslo, Norway : 1992), 1999, Volume: 88, Issue:6

    Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Attitude to Health; Body Temperature; Child, P

1999
The safety of acetaminophen and ibuprofen among children younger than two years old.
    Pediatrics, 1999, Volume: 104, Issue:4

    Topics: Acetaminophen; Acute Disease; Analgesics, Non-Narcotic; Asthma; Bronchiolitis; Double-Blind Method;

1999
Assessment of the efficacy and safety of paracetamol, ibuprofen and nimesulide in children with upper respiratory tract infections.
    European journal of clinical pharmacology, 1999, Volume: 55, Issue:9

    Topics: Acetaminophen; Acute Disease; Adolescent; Analgesics, Non-Narcotic; Analysis of Variance; Anti-Infla

1999
Pharmacokinetic-Pharmacodynamic Modelling of the antipyretic effect of two oral formulations of ibuprofen.
    Clinical pharmacokinetics, 2000, Volume: 38, Issue:6

    Topics: Adolescent; Adult; Algorithms; Analgesics, Non-Narcotic; Analysis of Variance; Body Temperature; Chi

2000
[Evaluation of the antipyretic safety and accuracy of two pediatric ibuprofen formulations].
    Anales espanoles de pediatria, 2000, Volume: 53, Issue:5

    Topics: Adolescent; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Body Temperature; Bod

2000
Antipyretic effects of nimesulide, paracetamol and ibuprofen-paracetamol.
    Indian journal of pediatrics, 2000, Volume: 67, Issue:12

    Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Child, Preschool; Double-Blind Method; Drug

2000
Effect of endotoxin on ventilation and breath variability: role of cyclooxygenase pathway.
    American journal of respiratory and critical care medicine, 2001, Aug-15, Volume: 164, Issue:4

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Gas Analysis; Carbon Dioxide; Dyspnea; Endotox

2001
Antipyretic effects of dipyrone versus ibuprofen versus acetaminophen in children: results of a multinational, randomized, modified double-blind study.
    Clinical pediatrics, 2001, Volume: 40, Issue:6

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroid

2001
Asthma morbidity after the short-term use of ibuprofen in children.
    Pediatrics, 2002, Volume: 109, Issue:2

    Topics: Acetaminophen; Age Factors; Ambulatory Care; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non

2002
Both paracetamol and ibuprofen are equally effective in managing flu-like symptoms in relapsing-remitting multiple sclerosis patients during interferon beta-1a (AVONEX) therapy.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2002, Volume: 8, Issue:1

    Topics: Acetaminophen; Adult; Chills; Female; Fever; Headache; Humans; Ibuprofen; Interferon beta-1a; Interf

2002
Effectiveness and tolerability of ibuprofen-arginine versus paracetamol in children with fever of likely infectious origin.
    Acta paediatrica (Oslo, Norway : 1992), 2002, Volume: 91, Issue:4

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Arginine; Child; Child, Preschool; Double-Blind Method; Dru

2002
Pharmacokinetics and pharmacodynamics of ibuprofen isomers and acetaminophen in febrile children.
    Clinical pharmacology and therapeutics, 1992, Volume: 52, Issue:2

    Topics: Acetaminophen; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Fever; Humans; Ibu

1992
Efficacy of ibuprofen in pediatric patients with fever.
    International journal of clinical pharmacology, therapy, and toxicology, 1992, Volume: 30, Issue:3

    Topics: Body Temperature; Child; Child, Preschool; Double-Blind Method; Female; Fever; Heart Rate; Humans; I

1992
Antipyretic efficacy of ibuprofen vs acetaminophen.
    American journal of diseases of children (1960), 1992, Volume: 146, Issue:5

    Topics: Acetaminophen; Body Temperature; Child; Child, Preschool; Double-Blind Method; Female; Fever; Humans

1992
Comparison of multidose ibuprofen and acetaminophen therapy in febrile children.
    American journal of diseases of children (1960), 1992, Volume: 146, Issue:5

    Topics: Acetaminophen; Body Temperature; Child; Child, Preschool; Double-Blind Method; Drug Administration S

1992
A dose ranging study of ibuprofen suspension as an antipyretic.
    Archives of disease in childhood, 1991, Volume: 66, Issue:9

    Topics: Child, Preschool; Double-Blind Method; Drug Administration Schedule; Female; Fever; Humans; Ibuprofe

1991
Single-dose, placebo-controlled comparative study of ibuprofen and acetaminophen antipyresis in children.
    The Journal of pediatrics, 1991, Volume: 119, Issue:5

    Topics: Acetaminophen; Administration, Oral; Anti-Bacterial Agents; Body Temperature; Body Weight; Child; Ch

1991
Detection of interleukin 8 and tumor necrosis factor in normal humans after intravenous endotoxin: the effect of antiinflammatory agents.
    The Journal of experimental medicine, 1991, Apr-01, Volume: 173, Issue:4

    Topics: Adult; Endotoxins; Escherichia coli; Female; Fever; Humans; Ibuprofen; Injections, Intravenous; Inte

1991
Ibuprofen versus paracetamol for the treatment of fever in children.
    British journal of clinical practice. Supplement, 1990, Volume: 70

    Topics: Acetaminophen; Child; Child, Preschool; Fever; Humans; Ibuprofen; Infant; Research Design

1990
A double-blind dose-ranging trial with paediatric ibuprofen.
    British journal of clinical practice. Supplement, 1990, Volume: 70

    Topics: Body Temperature; Child, Preschool; Double-Blind Method; Drug Administration Schedule; Female; Fever

1990
A double-blind comparison of ibuprofen and paracetamol in juvenile pyrexia.
    British journal of clinical practice. Supplement, 1990, Volume: 70

    Topics: Acetaminophen; Body Temperature; Child; Child, Preschool; Double-Blind Method; Drug Administration S

1990
Adverse effects of aspirin, acetaminophen, and ibuprofen on immune function, viral shedding, and clinical status in rhinovirus-infected volunteers.
    The Journal of infectious diseases, 1990, Volume: 162, Issue:6

    Topics: Acetaminophen; Adult; Antibodies, Viral; Aspirin; Common Cold; Double-Blind Method; Female; Fever; H

1990
Comparative evaluation of the antipyretic efficacy of ibuprofen and paracetamol.
    Indian pediatrics, 1990, Volume: 27, Issue:8

    Topics: Acetaminophen; Child; Child, Preschool; Female; Fever; Humans; Ibuprofen; Infant; Male

1990
Comparison of nonsteroidal anti-inflammatory drugs, ibuprofen and flurbiprofen, with methylprednisolone and placebo for acute pain, swelling, and trismus.
    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 1990, Volume: 48, Issue:9

    Topics: Adult; Double-Blind Method; Evaluation Studies as Topic; Female; Fever; Flurbiprofen; Humans; Ibupro

1990
Comparison of nonsteroidal anti-inflammatory drugs, ibuprofen and flurbiprofen, with methylprednisolone and placebo for acute pain, swelling, and trismus.
    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 1990, Volume: 48, Issue:9

    Topics: Adult; Double-Blind Method; Evaluation Studies as Topic; Female; Fever; Flurbiprofen; Humans; Ibupro

1990
Comparison of nonsteroidal anti-inflammatory drugs, ibuprofen and flurbiprofen, with methylprednisolone and placebo for acute pain, swelling, and trismus.
    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 1990, Volume: 48, Issue:9

    Topics: Adult; Double-Blind Method; Evaluation Studies as Topic; Female; Fever; Flurbiprofen; Humans; Ibupro

1990
Comparison of nonsteroidal anti-inflammatory drugs, ibuprofen and flurbiprofen, with methylprednisolone and placebo for acute pain, swelling, and trismus.
    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 1990, Volume: 48, Issue:9

    Topics: Adult; Double-Blind Method; Evaluation Studies as Topic; Female; Fever; Flurbiprofen; Humans; Ibupro

1990
Ibuprofen, acetaminophen, and placebo treatment of febrile children.
    Clinical pharmacology and therapeutics, 1989, Volume: 46, Issue:1

    Topics: Acetaminophen; Administration, Oral; Adolescent; Child; Child, Preschool; Clinical Trials as Topic;

1989
A single-blind parallel group study investigating the antipyretic properties of ibuprofen syrup versus acetylsalicylic acid syrup in febrile children.
    The British journal of clinical practice, 1988, Volume: 42, Issue:6

    Topics: Aspirin; Child; Child, Preschool; Clinical Trials as Topic; Female; Fever; Humans; Ibuprofen; Infant

1988
Induction of prostaglandin synthesis as the mechanism responsible for the chills and fever produced by infusing amphotericin B.
    The Journal of infectious diseases, 1987, Volume: 156, Issue:5

    Topics: Adolescent; Adult; Amphotericin B; Animals; Child; Child, Preschool; Clinical Trials as Topic; Dinop

1987
Update on ibuprofen: review article.
    The Journal of international medical research, 1986, Volume: 14, Issue:2

    Topics: Analgesia; Arthritis; Arthritis, Rheumatoid; Clinical Trials as Topic; Connective Tissue Diseases; D

1986
A comparative study of two dosage levels of ibuprofen syrup in children with pyrexia.
    The Journal of international medical research, 1985, Volume: 13, Issue:2

    Topics: Child; Child, Preschool; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Fever;

1985
Antipyretic activity of ibuprofen and paracetamol in children with pyrexia.
    The British journal of clinical practice, 1985, Volume: 39, Issue:4

    Topics: Acetaminophen; Child; Child, Preschool; Clinical Trials as Topic; Female; Fever; Humans; Ibuprofen;

1985
Antipyretic activity of ibuprofen (Brufen).
    The Journal of the Association of Physicians of India, 1973, Volume: 21, Issue:7

    Topics: Adult; Aspirin; Double-Blind Method; Fever; Humans; Ibuprofen; Male

1973

Other Studies

143 other studies available for ibuprofen and Fever

ArticleYear
Synthesis and antiinflammatory activity of [(cycloalkylmethyl)phenyl]acetic acids and related compounds.
    Journal of medicinal chemistry, 1984, Volume: 27, Issue:2

    Topics: Analgesics; Animals; Chemical Phenomena; Chemistry; Female; Fever; Ibuprofen; Indomethacin; Inflamma

1984
Does immunosuppressive property of non-steroidal anti-inflammatory drugs (NSAIDs) reduce COVID-19 vaccine-induced systemic side effects?
    Drug discoveries & therapeutics, 2021, Nov-21, Volume: 15, Issue:5

    Topics: Acetaminophen; Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; COVID-19 Vaccines; Fati

2021
Acetaminophen Versus Ibuprofen for Fever Reduction in the Pediatric Emergency Department.
    Clinical pediatrics, 2023, Volume: 62, Issue:7

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Child; Drug Therap

2023
Acetaminophen Versus Ibuprofen for Fever Reduction in the Pediatric Emergency Department.
    Clinical pediatrics, 2023, Volume: 62, Issue:7

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Child; Drug Therap

2023
Acetaminophen Versus Ibuprofen for Fever Reduction in the Pediatric Emergency Department.
    Clinical pediatrics, 2023, Volume: 62, Issue:7

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Child; Drug Therap

2023
Acetaminophen Versus Ibuprofen for Fever Reduction in the Pediatric Emergency Department.
    Clinical pediatrics, 2023, Volume: 62, Issue:7

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Child; Drug Therap

2023
Treatment of fever and associated symptoms in the emergency department: which drug to choose?
    European review for medical and pharmacological sciences, 2023, Volume: 27, Issue:15

    Topics: Acetaminophen; Adult; Aged; Bacteriophages; Emergency Service, Hospital; Fever; Humans; Ibuprofen; M

2023
Antipyretic Efficacy of Acetaminophen and Ibuprofen in Critically Ill Pediatric Patients.
    Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies, 2019, Volume: 20, Issue:8

    Topics: Acetaminophen; Antipyretics; Body Temperature; Child; Child, Preschool; Critical Illness; Female; Fe

2019
The use of ibuprofen to treat fever in COVID-19: A possible indirect association with worse outcome?
    Medical hypotheses, 2020, Volume: 144

    Topics: Acetaminophen; Antipyretics; COVID-19 Drug Treatment; Fever; Humans; Ibuprofen; Models, Theoretical;

2020
Ibuprofen use and clinical outcomes in COVID-19 patients.
    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2020, Volume: 26, Issue:9

    Topics: Acetaminophen; Adult; Antipyretics; COVID-19; COVID-19 Drug Treatment; Female; Fever; Humans; Ibupro

2020
Fever response to ibuprofen in viral and bacterial childhood infections.
    The American journal of emergency medicine, 2021, Volume: 46

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antipyretics; Bacterial Infections; Cross-Sectional

2021
Paracetamol or ibuprofen for fever or pain in children under 2 years old.
    Journal of paediatrics and child health, 2021, Volume: 57, Issue:8

    Topics: Acetaminophen; Antipyretics; Child; Fever; Humans; Ibuprofen; Infant; Pain

2021
Assessment of pharmacological activities of Lygodium microphyllum Cav. leaves in the management of pain, inflammation, pyrexia, diarrhea, and helminths: In vivo, in vitro and in silico approaches.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2021, Volume: 139

    Topics: Albendazole; Analgesics; Animals; Anthelmintics; Anti-Inflammatory Agents; Antidiarrheals; Antipyret

2021
Community use of paracetamol and ibuprofen in children with fever.
    Journal of paediatrics and child health, 2021, Volume: 57, Issue:10

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Child; Fever; Humans; Ibuprofen; Prospective Studies

2021
A risk score for pericarditis recurrence.
    European journal of clinical investigation, 2021, Volume: 51, Issue:11

    Topics: Adult; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chest Pain; Colchicine;

2021
Severe polyarthralgia, high-grade fever, diffuse maculopapular rash on trunk and extremities · Dx?
    The Journal of family practice, 2017, Volume: 66, Issue:4

    Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Ankle; Anti-Inflammatory Agents; Arthralgia; Caribbe

2017
Synergistic analgesic, anti-pyretic and anti-inflammatory effects of extra virgin olive oil and ibuprofen in different experimental models of albino mice.
    International journal of rheumatic diseases, 2017, Volume: 20, Issue:10

    Topics: Acetic Acid; Albinism; Analgesics; Animals; Anti-Inflammatory Agents; Antipyretics; Carrageenan; Din

2017
Antipyretic Medication Exposures Among Young Children Reported to US Poison Centers, 2000-2015.
    Clinical pediatrics, 2018, Volume: 57, Issue:3

    Topics: Acetaminophen; Age Distribution; Antipyretics; Child; Child, Preschool; Confidence Intervals; Databa

2018
Ibuprofen and Paracetamol: Acceptably Safe for All?
    Drug safety, 2018, Volume: 41, Issue:11

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Fever; Humans; Ibuprofen

2018
AGEP from a dog bite treated with Ibuprofen.
    The American journal of emergency medicine, 2018, Volume: 36, Issue:10

    Topics: Acute Generalized Exanthematous Pustulosis; Analgesics, Non-Narcotic; Animals; Anti-Bacterial Agents

2018
Antipyretic effect of phytol, possibly via 5KIR-dependent COX-2 inhibition pathway.
    Inflammopharmacology, 2019, Volume: 27, Issue:4

    Topics: Acetaminophen; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antipyretics; Cyclooxygenase 1; Cyc

2019
IBUPROFEN-INDUCED ASEPTIC MENINGITIS: A CASE REPORT.
    Revista paulista de pediatria : orgao oficial da Sociedade de Pediatria de Sao Paulo, 2019, Volume: 37, Issue:3

    Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Diagnosis, Differential; Drug Hypersensitivity;

2019
Effects of Bai-Hu decoction on fever induced by lipopolysaccharide.
    The Kaohsiung journal of medical sciences, 2013, Volume: 29, Issue:3

    Topics: Animals; Antipyretics; Body Temperature; Drugs, Chinese Herbal; Fever; Hypothalamus; Ibuprofen; Inte

2013
Management of children's fever by parents and caregivers: Practical measurement of functional health literacy.
    Journal of child health care : for professionals working with children in the hospital and community, 2014, Volume: 18, Issue:4

    Topics: Acetaminophen; Antipyretics; Australia; Caregivers; Child, Preschool; Female; Fever; Health Literacy

2014
Is fever treated more promptly than pain in the pediatric emergency department?
    The Journal of emergency medicine, 2014, Volume: 46, Issue:3

    Topics: Acetaminophen; Adolescent; Age Factors; Analgesics, Non-Narcotic; Antipyretics; Child; Child, Presch

2014
Adherence among Italian paediatricians to the Italian guidelines for the management of fever in children: a cross sectional survey.
    BMC pediatrics, 2013, Dec-18, Volume: 13

    Topics: Acetaminophen; Administration, Rectal; Antipyretics; Child; Cross-Sectional Studies; Fever; Guidelin

2013
[How to treat pediatric fever in 2013 with little evidence-based?].
    Revue medicale suisse, 2014, Jan-15, Volume: 10, Issue:412-413

    Topics: Acetaminophen; Child; Evidence-Based Practice; Fever; Humans; Ibuprofen; Seizures, Febrile

2014
Cochrane in context: Combined and alternating paracetamol and ibuprofen therapy for febrile children.
    Evidence-based child health : a Cochrane review journal, 2014, Volume: 9, Issue:3

    Topics: Acetaminophen; Antipyretics; Child; Child, Preschool; Drug Therapy, Combination; Fever; Humans; Ibup

2014
Drug-induced liver injury with serious multiform exudative erythema following the use of an over-the-counter medication containing ibuprofen.
    Internal medicine (Tokyo, Japan), 2015, Volume: 54, Issue:4

    Topics: Adult; Asian People; Chemical and Drug Induced Liver Injury; Drug Eruptions; Erythema; Female; Fever

2015
Paracetamol is no more likely to exacerbate asthma in children than ibuprofen, shows study.
    BMJ (Clinical research ed.), 2016, 08-17, Volume: 354

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Child; Fev

2016
Ibuprofen induced DRESS Syndrome in a Child.
    Indian pediatrics, 2016, Aug-08, Volume: 53, Issue:8

    Topics: Child; Drug Hypersensitivity Syndrome; Exanthema; Fever; Humans; Ibuprofen; Male

2016
Hand-Foot and Mouth Dısease and Reactıve Arthritis: An Unusual Paediatric Case.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2016, Volume: 26, Issue:9

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Reactive; Child, Preschool; Coxsackievi

2016
National modulators of symptomatic fever management in children: comparative analysis of survey data.
    Minerva pediatrica, 2018, Volume: 70, Issue:4

    Topics: Acetaminophen; Administration, Rectal; Antipyretics; Female; Fever; Humans; Ibuprofen; Infant; Italy

2018
Association of Acetaminophen and Ibuprofen Use With Wheezing in Children With Acute Febrile Illness.
    The Annals of pharmacotherapy, 2017, Volume: 51, Issue:3

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Antipyretics; Asthma; Child; Child, Preschool; Cross-Sectio

2017
Parental Approach to the Prevention and Management of Fever and Pain Following Childhood Immunizations: A Survey Study.
    Clinical pediatrics, 2017, Volume: 56, Issue:5

    Topics: Acetaminophen; Adult; Analgesics; Antipyretics; Caregivers; Cross-Sectional Studies; Culture; Female

2017
Acetaminophen versus Ibuprofen in Mild Persistent Asthma.
    The New England journal of medicine, 2016, 11-24, Volume: 375, Issue:21

    Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Double-Blind Method; Fever; Humans;

2016
Acetaminophen versus Ibuprofen in Mild Persistent Asthma.
    The New England journal of medicine, 2016, 11-24, Volume: 375, Issue:21

    Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Double-Blind Method; Fever; Humans;

2016
Systemic onset juvenile idiopathic arthritis--its unusual presentation.
    Indian journal of pediatrics, 2008, Volume: 75, Issue:4

    Topics: Arthralgia; Arthritis, Juvenile; Diagnosis, Differential; Drug Therapy, Combination; Exanthema; Feve

2008
Antipyretic treatment for feverish young children in primary care.
    BMJ (Clinical research ed.), 2008, Sep-02, Volume: 337

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Child; Child, Preschool; Fever; Humans; Ibuprofen; Infant;

2008
Combining paracetamol and ibuprofen for fever in children.
    BMJ (Clinical research ed.), 2008, Sep-10, Volume: 337

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Child; Drug Therapy, Combination; Fever; Humans; Ibuprofen

2008
Ibuprofen increases soft tissue infections in children.
    BMJ (Clinical research ed.), 2008, Sep-23, Volume: 337

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Child; Fever; Humans; Ibuprofen; Soft Tissue Infections

2008
Paracetamol with ibuprofen: Ibuprofen is a marker of soft tissue infection.
    BMJ (Clinical research ed.), 2008, Oct-13, Volume: 337

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Chickenpox; Child; Fever; Humans; Ibuprofen; Soft Tissue In

2008
Reduction of nuclear peroxisome proliferator-activated receptor gamma expression in methamphetamine-induced neurotoxicity and neuroprotective effects of ibuprofen.
    Neurochemical research, 2009, Volume: 34, Issue:4

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Body Temperature; Central Nervous System

2009
. . . And which works better on fever--acetaminophen, ibuprofen, or both?
    Child health alert, 2008, Volume: 26

    Topics: Acetaminophen; Age Factors; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Child

2008
Fever: to treat or not to treat?
    World journal of pediatrics : WJP, 2008, Volume: 4, Issue:4

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Drug Therapy, Combination; Fever; Humans; Ibuprofen; Treatm

2008
Acute non-oliguric kidney failure and cholestatic hepatitis induced by ibuprofen and acetaminophen: a case report.
    Acta paediatrica (Oslo, Norway : 1992), 2009, Volume: 98, Issue:5

    Topics: Acetaminophen; Acute Kidney Injury; Analgesics, Non-Narcotic; Chemical and Drug Induced Liver Injury

2009
Characterization and pharmacological evaluation of febrile response on zymosan-induced arthritis in rats.
    American journal of physiology. Regulatory, integrative and comparative physiology, 2009, Volume: 296, Issue:5

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Animals; Arthritis, Experimental; Body Temperature; Celecox

2009
Defunct gadgets and changing times.
    Issues in comprehensive pediatric nursing, 2009, Volume: 32, Issue:1

    Topics: Acquired Immunodeficiency Syndrome; Amoxicillin; Anti-HIV Agents; Anti-Inflammatory Agents, Non-Ster

2009
Ethnic differences in parental perceptions and management of childhood fever.
    Clinical pediatrics, 2010, Volume: 49, Issue:3

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Black or African American; Body Temperature; Child; Child,

2010
Effects of prenatal immune activation on hippocampal neurogenesis in the rat.
    Schizophrenia research, 2009, Volume: 113, Issue:2-3

    Topics: Age Factors; Analysis of Variance; Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-Steroida

2009
A strategy for evaluating antipyretic efficacy of Chinese herbal medicines based on UV spectra fingerprints.
    Journal of ethnopharmacology, 2009, Jul-06, Volume: 124, Issue:1

    Topics: Animals; Bupleurum; Drugs, Chinese Herbal; Evaluation Studies as Topic; Female; Fever; Flowers; Fors

2009
Management of fever in children: summary of the Italian Pediatric Society guidelines.
    Clinical therapeutics, 2009, Volume: 31, Issue:8

    Topics: Acetaminophen; Age Factors; Analgesics, Non-Narcotic; Axilla; Body Temperature; Body Weight; Child;

2009
Intravenous ibuprofen (Caldolor).
    The Medical letter on drugs and therapeutics, 2010, Jan-11, Volume: 52, Issue:1329

    Topics: Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Drug Interactions; Fever; Humans;

2010
Caldolor: old drug, new route.
    South Dakota medicine : the journal of the South Dakota State Medical Association, 2010, Volume: 63, Issue:1

    Topics: Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Fever; Humans; Ibuprofen; Injecti

2010
A 27-year-old Cambodian woman with fever, lymphadenopathy, and arthritis.
    Arthritis care & research, 2010, Volume: 62, Issue:8

    Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Asian

2010
Hot times in the intensive care unit.
    Critical care (London, England), 2010, Volume: 14, Issue:4

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Critical Illness; Fever; Humans; Ibuprofen; Infusions, Intr

2010
Treatment of pediatric fever: Are acetaminophen and ibuprofen equivalent?
    Canadian family physician Medecin de famille canadien, 2010, Volume: 56, Issue:8

    Topics: Acetaminophen; Antipyretics; Child; Child, Preschool; Family Practice; Fever; Humans; Ibuprofen; Inf

2010
Cyclooxygenase-independent mechanism of ibuprofen-induced antipyresis: the role of central vasopressin V₁ receptors.
    Fundamental & clinical pharmacology, 2011, Volume: 25, Issue:6

    Topics: Animals; Antipyretics; Arginine Vasopressin; Dinoprostone; Dose-Response Relationship, Drug; Fever;

2011
Pediatric rash and joint pain: a case review.
    Journal of emergency nursing, 2010, Volume: 36, Issue:6

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Ankle Joint; Anti-Bacterial Agents; Arthralgia; Ceftriaxone

2010
Premarketing surveillance of ibuprofen suppositories in febrile children.
    Clinical pediatrics, 2011, Volume: 50, Issue:3

    Topics: Administration, Rectal; Adult; Antipyretics; Child; Child, Preschool; Drug Administration Schedule;

2011
Ibuprofen transdermal ethosomal gel: characterization and efficiency in animal models.
    Journal of biomedical nanotechnology, 2010, Volume: 6, Issue:5

    Topics: Administration, Cutaneous; Analgesics, Non-Narcotic; Animals; Antipyretics; Disease Models, Animal;

2010
Antipyretic therapy for influenza infection--benefit or harm?
    The New Zealand medical journal, 2011, Jul-08, Volume: 124, Issue:1338

    Topics: Acetaminophen; Adult; Animals; Antipyretics; Child; Fever; Humans; Ibuprofen; Influenza, Human; Mice

2011
Fever control in the NICU: is there still a simpler and cheaper solution?
    Neurocritical care, 2011, Volume: 15, Issue:3

    Topics: Acetaminophen; Antipyretics; Fever; Humans; Ibuprofen; Intensive Care Units; Intracranial Hemorrhage

2011
AAP reports on the use of antipyretics for fever in children.
    American family physician, 2012, Mar-01, Volume: 85, Issue:5

    Topics: Acetaminophen; Antipyretics; Child; Drug Therapy, Combination; Fever; Humans; Ibuprofen; Practice Gu

2012
[Ibuprofen is more effective than paracetamol in lowering the temperature in febrile children].
    Ugeskrift for laeger, 2012, Apr-30, Volume: 174, Issue:18

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Antipyretics; Child; Drug Therapy, Combination; Fever; Huma

2012
Intravenous ibuprofen: in adults for pain and fever.
    Drugs, 2012, May-28, Volume: 72, Issue:8

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Double-Blind Method; Fever; Human

2012
Alternating acetaminophen and ibuprofen for pain in children.
    Canadian family physician Medecin de famille canadien, 2012, Volume: 58, Issue:6

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Child; Child, Pres

2012
Update of the 2009 Italian Pediatric Society Guidelines about management of fever in children.
    Clinical therapeutics, 2012, Volume: 34, Issue:7

    Topics: Acetaminophen; Age Factors; Antipyretics; Axilla; Body Temperature; Child; Child, Preschool; Fever;

2012
Non-prescription medicines for pain and fever--a comparison of recommendations and counseling from staff in pharmacy and general sales stores.
    Health policy (Amsterdam, Netherlands), 2013, Volume: 110, Issue:1

    Topics: Acetaminophen; Analgesics; Antipyretics; Aspirin; Child; Commerce; Contraindications; Counseling; Fe

2013
Fever phobia revisited.
    Archives of disease in childhood, 2004, Volume: 89, Issue:1

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Child, Preschool; Drug Therapy, Combination; Fever; Humans;

2004
Ibuprofen or acetaminophen in children? As the debate continues, the evidence may favor ibuprofen.
    The American journal of nursing, 2004, Volume: 104, Issue:9

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Child; Fever; Huma

2004
Hypothermia following fever.
    Archives of disease in childhood, 2004, Volume: 89, Issue:12

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Female; Fever; Humans; Hypothermia; Ibuprofen; Infant

2004
[Ibuprofen: a febrile rumor].
    Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 2005, Volume: 12, Issue:2

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Chickenpox; Child; Child Welfare; Contraindications; Fever;

2005
[Aspirin, paracetamol, ibuprofen: analgesics in the family medicine cabinet].
    Revue de l'infirmiere, 2005, Issue:110

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Contraind

2005
[Familial use of ibuprofen in febrile children: a prospective study in the emergency room of an hospital in Lille].
    Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 2005, Volume: 12, Issue:8

    Topics: Acetaminophen; Adolescent; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Child;

2005
Immunizations. Can fever-reducers prevent redness from DTP shots?
    Child health alert, 2006, Volume: 24

    Topics: Acetaminophen; Anti-Inflammatory Agents; Child; Diphtheria-Tetanus-Pertussis Vaccine; Drug Eruptions

2006
[Change in habits among the population in the management of childhood fever].
    Anales de pediatria (Barcelona, Spain : 2003), 2006, Volume: 64, Issue:5

    Topics: Acetaminophen; Child; Child, Preschool; Fever; Habits; Humans; Ibuprofen; Infant

2006
Antipyretic drugs for children.
    BMJ (Clinical research ed.), 2006, Jul-01, Volume: 333, Issue:7557

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Child; Drug Combinations; Fever; Humans; Ibuprofen

2006
Alternating acetaminophen and ibuprofen in children may cause parental confusion and is dangerous.
    Archives of pediatrics & adolescent medicine, 2006, Volume: 160, Issue:7

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Child; Child, Preschool; Confusion; Drug Administration Sch

2006
Concerns over alternating acetaminophen and ibuprofen for fever.
    Archives of pediatrics & adolescent medicine, 2006, Volume: 160, Issue:7

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Child; Confusion; Drug Therapy, Combination; Fever; Humans;

2006
Determinants of antipyretic misuse in children up to 5 years of age: a cross-sectional study.
    Clinical therapeutics, 2006, Volume: 28, Issue:5

    Topics: Acetaminophen; Administration, Oral; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroid

2006
Ibuprofen-induced fever in Sjogren's syndrome.
    Journal of investigational allergology & clinical immunology, 2006, Volume: 16, Issue:4

    Topics: Aged; Analgesics, Non-Narcotic; Drug Hypersensitivity; Female; Fever; Humans; Ibuprofen; Meningitis,

2006
Endotoxin fever in granulocytopenic rats: evidence that brain cyclooxygenase-2 is more important than circulating prostaglandin E(2).
    Journal of leukocyte biology, 2006, Volume: 80, Issue:6

    Topics: Animals; Bacterial Infections; Brain; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dinoprostone; Fev

2006
Tramadol infusion for the pain management in sickle cell disease: a case report.
    Paediatric anaesthesia, 2007, Volume: 17, Issue:1

    Topics: Abdominal Pain; Acetaminophen; Analgesics, Non-Narcotic; Analgesics, Opioid; Anemia, Sickle Cell; Ch

2007
57-year-old Asian-American man with Kikuchi's disease.
    Hawaii medical journal, 2006, Volume: 65, Issue:11

    Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Arthralgia; Asian; Biopsy; Diagno

2006
Alternating antipyretics for fever reduction in children: an unfounded practice passed down to parents from pediatricians.
    Clinical pediatrics, 2007, Volume: 46, Issue:2

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Child, Preschool; Drug Administration Schedule; Fever; Heal

2007
Treatment of fever and over-the-counter medicines.
    Archives of disease in childhood, 2007, Volume: 92, Issue:10

    Topics: Adult; Analgesics, Non-Narcotic; Child; Child, Preschool; England; Female; Fever; Health Knowledge,

2007
Antipyretic drug use in children in French office based medical practice.
    Pharmacoepidemiology and drug safety, 2007, Volume: 16, Issue:7

    Topics: Acetaminophen; Age Factors; Analgesics, Non-Narcotic; Aspirin; Child; Child, Preschool; Drug Therapy

2007
Over-the-counter medication use for childhood fever: a cross-sectional study of Australian parents.
    Journal of paediatrics and child health, 2007, Volume: 43, Issue:9

    Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Child, Preschool; Cross-Sectional Studies; Female; F

2007
Alternating acetaminophen with ibuprofen for fever: is this a problem?
    Pediatric annals, 2007, Volume: 36, Issue:7

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Child, Preschool; Drug Therapy, Combination; Fever; Humans;

2007
Question from the clinician: alternating acetaminophen and ibuprofen in the treatment of fever.
    Pediatrics in review, 2007, Volume: 28, Issue:10

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Child; Drug Administration Schedule; Drug Therapy, Combinat

2007
When the child has a fever.
    Drug and therapeutics bulletin, 2008, Volume: 46, Issue:3

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Child; Diagnosis, Differential; Fever; Humans; Ibuprofen; P

2008
Effect of ibuprofen on fever and metabolic changes induced by continuous infusion of leukocytic pyrogen (interleukin 1) or endotoxin.
    Infection and immunity, 1983, Volume: 42, Issue:3

    Topics: Animals; Drug Evaluation, Preclinical; Endotoxins; Fever; Guinea Pigs; Humans; Ibuprofen; Interleuki

1983
Role of arachidonate metabolism in the immunoregulatory function of human leukocytic pyrogen/lymphocyte-activating factor/interleukin 1.
    Journal of immunology (Baltimore, Md. : 1950), 1983, Volume: 130, Issue:2

    Topics: 4,5-Dihydro-1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-amine; 5,8,11,14-Eicosatetraynoic Acid; Anima

1983
Comparative study of the antipyretic effect of ibuprofen (oral suspension) and paracetamol (suppositories) in paediatrics.
    The Journal of international medical research, 1984, Volume: 12, Issue:4

    Topics: Acetaminophen; Administration, Oral; Body Temperature; Child; Child, Preschool; Female; Fever; Human

1984
Ibuprofen: a severe systemic reaction.
    Canadian Medical Association journal, 1983, Oct-15, Volume: 129, Issue:8

    Topics: Amoxicillin; Dopamine; Female; Fever; Gingivitis; Humans; Hypotension; Ibuprofen; Middle Aged; Respi

1983
Demonstration of a circulating suppressor factor of thymocyte proliferation during endotoxin fever in humans.
    Journal of immunology (Baltimore, Md. : 1950), 1981, Volume: 127, Issue:6

    Topics: Adult; Animals; Blood; Cell Division; Endotoxins; Female; Fever; Hot Temperature; Humans; Ibuprofen;

1981
Oral antipyretic therapy evaluation of the propionic acid derivatives ibuprofen, ketoprofen, fenoprofen and naproxen.
    Padiatrie und Padologie, 1980, Volume: 15, Issue:3

    Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Dose-Response Relationship, Drug; Fen

1980
A toxicological and pharmacological study of ibuprofen guaiacol ester (AF 2259) in the rat.
    Toxicology and applied pharmacology, 1980, Jun-30, Volume: 54, Issue:2

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Behavior, Animal; Digestive System; Edema; Female;

1980
Tolmetin-induced aseptic meningitis.
    JAMA, 1981, Jan-02, Volume: 245, Issue:1

    Topics: Adult; Female; Fever; Humans; Ibuprofen; Knee; Lupus Erythematosus, Systemic; Meningitis; Meningitis

1981
Effect of ibuprofen on monocyte activation by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (CGP 19835A): can ibuprofen reduce fever and chills without compromising immune stimulation?
    Cancer immunology, immunotherapy : CII, 1993, Volume: 36, Issue:1

    Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adjuvants, Immunologic; Cytotoxicity Tests, Immunologic; Drug Car

1993
NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions.
    General pharmacology, 1993, Volume: 24, Issue:1

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Carrageenan; Cyclooxygena

1993
Supportive care during aldesleukin therapy for patients infected with human immunodeficiency virus.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 1997, May-15, Volume: 54, Issue:10

    Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Antiemetics; Female; Fever; HIV Infections; Humans;

1997
Suppression of fever and the acute-phase response in a patient with juvenile chronic arthritis treated with monoclonal antibody to tumour necrosis factor-alpha (cA2).
    British journal of rheumatology, 1997, Volume: 36, Issue:5

    Topics: Acute-Phase Reaction; Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; A

1997
Ibuprofen and/or acetaminophen: what price for "euthermia"?
    The Journal of pediatrics, 1997, Volume: 131, Issue:2

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Body Temperature;

1997
Ibuprofen and/or acetaminophen: what price for "euthermia"?
    The Journal of pediatrics, 1997, Volume: 131, Issue:2

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Chemistry, Pharmac

1997
Ibuprofen use in pediatric patients.
    South Dakota journal of medicine, 1998, Volume: 51, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Child; Child, Preschool; Fever; Humans; Ibuprofen; Infant

1998
Acetaminophen: a clarification.
    The Journal of pediatrics, 1998, Volume: 132, Issue:6

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Child; Fever; Huma

1998
Combined antipyretic therapy: another potential source of chronic acetaminophen toxicity.
    The Journal of pediatrics, 1998, Volume: 133, Issue:5

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Child; Chronic Disease; Drug Interactions; Drug Therapy, Co

1998
Detection of macrophage inflammatory protein (MIP)-1alpha and MIP-1beta during experimental endotoxemia and human sepsis.
    The Journal of infectious diseases, 1999, Volume: 179, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antigens, CD; Chemokine CCL3; Chemokine CCL4; Child; Cyc

1999
Adult onset Still's disease associated with Epstein-Barr virus infection in a 66-year-old woman.
    Scandinavian journal of rheumatology, 1998, Volume: 27, Issue:6

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Antinuclear; Antirheumatic Agents; Arthralgia;

1998
Parental guidance suggested. Pediatric fever and pain relief require expert input.
    Advance for nurse practitioners, 1999, Volume: 7, Issue:6

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Child; Child, Preschool; Education; Fever; Humans; Ibuprofe

1999
Ibuprofen treatment versus gradual introduction of interferon beta-1b in patients with MS.
    Neurology, 2000, Apr-25, Volume: 54, Issue:8

    Topics: Acetaminophen; Drug Administration Schedule; Fever; Humans; Hypothalamus; Ibuprofen; Interferon beta

2000
Life-threatening illness in a nontransfusable patient: a health care challenge.
    Nephrology nursing journal : journal of the American Nephrology Nurses' Association, 2000, Volume: 27, Issue:2

    Topics: Abdominal Pain; Adult; Analgesics, Non-Narcotic; Anemia, Iron-Deficiency; Appendicitis; Epoetin Alfa

2000
[Analysis of prognostic factors for the antipyretic response to ibuprofen].
    Anales espanoles de pediatria, 2000, Volume: 53, Issue:5

    Topics: Age Factors; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Body Temperature; Ch

2000
Invasive group A streptococcal infection and nonsteroidal antiinflammatory drug use among children with primary varicella.
    Pediatrics, 2001, Volume: 107, Issue:5

    Topics: Acetaminophen; Adolescent; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Case-C

2001
Toxicity of over-the-counter cough and cold medications.
    Pediatrics, 2001, Volume: 108, Issue:3

    Topics: Acetaminophen; Antitussive Agents; Bradycardia; Brompheniramine; Cardiovascular Diseases; Child, Pre

2001
Alternating antipyretics: is this an alternative?
    Pediatrics, 2001, Volume: 108, Issue:5

    Topics: Acetaminophen; Acute Kidney Injury; Analgesics, Non-Narcotic; Cyclooxygenase Inhibitors; Drug Synerg

2001
Ibuprofen induced acute renal failure in an infant.
    The New Zealand medical journal, 2001, Sep-28, Volume: 114, Issue:1140

    Topics: Acute Kidney Injury; Female; Fever; Follow-Up Studies; Humans; Ibuprofen; Infant; Kidney Function Te

2001
[Use of alternating antipyretics in the treatment of fever in Spain].
    Anales espanoles de pediatria, 2001, Volume: 55, Issue:6

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Child; Child, Preschool; Fever; Humans; Ibuprofen; Infant;

2001
PISA. The effect of paracetamol (acetaminophen) and ibuprofen on body temperature in acute stroke: protocol for a phase II double-blind randomised placebo-controlled trial [ISRCTN98608690].
    BMC cardiovascular disorders, 2002, Mar-27, Volume: 2

    Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Body Temperature; Clinical Trials, Phase II

2002
Acute adverse reactions to ibuprofen in systemic lupus erythematosus.
    JAMA, 1979, Jun-15, Volume: 241, Issue:24

    Topics: Acute Disease; Adult; Arthritis; Drug Hypersensitivity; Female; Fever; Headache; Humans; Hypotension

1979
Oral antipyretic therapy.
    Scandinavian journal of rheumatology, 1976, Volume: 5, Issue:2

    Topics: Acetaminophen; Administration, Oral; Aminopyrine; Aspirin; Child; Child, Preschool; Drug Evaluation;

1976
Letter: Fever from ibuprofen in a patient with lupus erythematosus.
    Annals of internal medicine, 1976, Volume: 85, Issue:2

    Topics: Adult; Female; Fever; Humans; Ibuprofen; Lupus Erythematosus, Systemic; Phenylpropionates

1976
Drugs for childhood fever.
    Lancet (London, England), 1992, Jan-04, Volume: 339, Issue:8784

    Topics: Acetaminophen; Child; Contraindications; Fever; Humans; Ibuprofen

1992
Effect of age on ibuprofen pharmacokinetics and antipyretic response.
    The Journal of pediatrics, 1992, Volume: 121, Issue:6

    Topics: Acute Disease; Aging; Axilla; Body Temperature; Child; Child, Preschool; Drug Evaluation; Female; Fe

1992
Ibuprofen safety.
    Pediatrics, 1992, Volume: 90, Issue:1 Pt 1

    Topics: Aspirin; Child; Fever; Humans; Ibuprofen; Reye Syndrome

1992
Single-dose pharmacokinetics of ibuprofen and acetaminophen in febrile children.
    Journal of clinical pharmacology, 1992, Volume: 32, Issue:3

    Topics: Acetaminophen; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Schedu

1992
Management of childhood fever.
    Lancet (London, England), 1991, Oct-26, Volume: 338, Issue:8774

    Topics: Acetaminophen; Child; Fever; Humans; Ibuprofen

1991
Management of childhood fever.
    Lancet (London, England), 1991, Nov-30, Volume: 338, Issue:8779

    Topics: Acetaminophen; Aspirin; Child; Fever; Humans; Ibuprofen

1991
Ibuprofin safety.
    Pediatrics, 1992, Volume: 89, Issue:1

    Topics: Child; Fever; Humans; Ibuprofen; United Kingdom; United States; United States Food and Drug Administ

1992
Junifen suspension--ibuprofen for febrile children.
    Drug and therapeutics bulletin, 1991, Feb-04, Volume: 29, Issue:3

    Topics: Administration, Oral; Child; Child, Preschool; Fever; Humans; Ibuprofen; Infant; Suspensions

1991
Ibuprofen for fever.
    Pediatrics, 1991, Volume: 87, Issue:1

    Topics: Child, Preschool; Fever; Humans; Ibuprofen; Infant

1991
A case of severe pancytopenia caused by ibuprofen.
    Journal of internal medicine, 1991, Volume: 229, Issue:3

    Topics: Aged; Fever; Hematemesis; Humans; Ibuprofen; Male; Pancytopenia; Time Factors

1991
Pharmacokinetics of ibuprofen in febrile children.
    European journal of clinical pharmacology, 1991, Volume: 40, Issue:4

    Topics: Administration, Oral; Child; Child, Preschool; Chromatography, High Pressure Liquid; Fever; Half-Lif

1991
Paediatric ibuprofen--an overview.
    British journal of clinical practice. Supplement, 1990, Volume: 70

    Topics: Child; Child, Preschool; Consumer Product Safety; Fever; Humans; Ibuprofen; Infant

1990
Acquired Brown's syndrome in systemic lupus erythematosus: another ocular manifestation.
    Clinical rheumatology, 1990, Volume: 9, Issue:3

    Topics: Adult; Diclofenac; Diplopia; Fever; Humans; Hydroxychloroquine; Ibuprofen; Lupus Erythematosus, Syst

1990
Hepatic granulomata. Presenting with prolonged fever. Resolution with anti-inflammatory treatment.
    Clinical pediatrics, 1990, Volume: 29, Issue:6

    Topics: Child; Diagnosis, Differential; Female; Fever; Granuloma; Granulomatous Disease, Chronic; Humans; Ib

1990
Antipyretic effect of central alpha-MSH summates with that of acetaminophen or ibuprofen.
    Brain research bulletin, 1989, Volume: 23, Issue:6

    Topics: Acetaminophen; alpha-MSH; Animals; Anti-Inflammatory Agents, Non-Steroidal; Drug Combinations; Femal

1989
Ibuprofen vs acetaminophen in children.
    The Medical letter on drugs and therapeutics, 1989, Dec-15, Volume: 31, Issue:807

    Topics: Acetaminophen; Child; Drug Overdose; Fever; Humans; Ibuprofen; Pain; Suspensions

1989
Macrophage inflammatory protein-1: a prostaglandin-independent endogenous pyrogen.
    Science (New York, N.Y.), 1989, Feb-24, Volume: 243, Issue:4894 Pt 1

    Topics: Animals; Chemotactic Factors; Dinoprostone; Female; Fever; Heparin; Humans; Ibuprofen; Interleukin-1

1989
Ibuprofen: an alternative for children's fevers.
    The American journal of nursing, 1989, Volume: 89, Issue:11

    Topics: Acetaminophen; Child; Child, Preschool; Fever; Humans; Ibuprofen

1989
Fever. What to do and what not to do.
    Postgraduate medicine, 1988, Volume: 83, Issue:8

    Topics: Acetaminophen; Acute-Phase Reaction; Aspirin; Body Temperature Regulation; Cold Temperature; Fever;

1988
Severe generalized reactions to ibuprofen: report of a case.
    The Journal of rheumatology, 1986, Volume: 13, Issue:3

    Topics: Diagnosis, Differential; Disseminated Intravascular Coagulation; Female; Fever; Humans; Hypotension;

1986
Ibuprofen prevents Pasteurella hemolytica endotoxin-induced changes in plasma prostanoids and serotonin, and fever in sheep.
    Journal of veterinary pharmacology and therapeutics, 1985, Volume: 8, Issue:4

    Topics: 6-Ketoprostaglandin F1 alpha; Animals; Dinoprost; Endotoxins; Female; Fever; Ibuprofen; Pasteurella;

1985
Fever: to treat or not to treat.
    Rational drug therapy, 1985, Volume: 19, Issue:12

    Topics: Acetaminophen; Aspirin; Child; Fever; Humans; Ibuprofen; Interleukin-1; Reye Syndrome

1985